Nerve Growth factor and lower urinary tract dysfunction by Vijaya, Gopalan
	  	  	  	  
1	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
NERVE	  GROWTH	  FACTOR	  AND	  LOWER	  
URINARY	  TRACT	  DYSFUNCTION	  	  	  	  	   	   	   	   	  	   G.VIJAYA	  MBBS,	  MRCOG.	  	   	  Imperial	  College	  London,	  Department	  of	  Surgery	  and	  Cancer	  MD	  (Res)	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  
2	  













“What	  you	  have	  learned	  is	  a	  mere	  handful;	  what	  you	  
haven't	  learned	  is	  the	  size	  of	  the	  world"	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   	   	   	   Avvaiyar,	  13th	  century	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  
3	  
	  
DECLARATION	  	  	  	  The	   studies	   described	   in	   this	   thesis	   were	   conducted	   at	   the	  Department	  of	  Urogynaecology,	  St	  Mary’s	  Hospital,	   Imperial	  College	  Healthcare	   NHS	   Trust.	   Ethical	   approval	   was	   obtained	   from	   local	  research	  ethics	  committee	  (REC	  reference	  number:11/LO/1029)	  .	  	  I	  am	  the	  principal	  investigator	  of	  all	  the	  studies	  and	  was	  involved	  in	  recruiting	   patients	   after	   informed	   consent,	   clinical	   assessment,	  collecting	  data,	  performing	  ELISA	  analysis,	  data	  analysis	  and	  writing	  up	  the	  thesis.	  The	  results	  presented	   in	   this	   thesis	  have	  been	  produced	  entirely	  by	  my	  own	  original	  research	  and	  the	  work	  of	  other	  researchers	  has	  been	  appropriately	  referenced.	  	  The	   copyright	   of	   this	   thesis	   rests	   with	   the	   author	   and	   is	   made	  available	  under	  a	  Creative	  Commons	  Attribution-­‐Non	  Commercial-­‐No	  Derivatives	   licence.	   Researchers	   are	   free	   to	   copy,	   distribute	   or	  transmit	  the	  thesis	  on	  the	  condition	  that	  they	  attribute	  it,	  that	  they	  do	  not	   use	   it	   for	   commercial	   purposes	   and	   that	   they	   do	   not	   alter,	  transform	  or	  build	  upon	  it.	  For	  any	  reuse	  or	  distribution,	  researchers	  must	  make	  clear	  to	  others	  the	  licence	  terms	  of	  this	  work.	  	  	  	   	   	   	   	   	   	   	   G.Vijaya	  MBBS,	  MRCOG.	  	   	   	   	   	   	   	   	   	   April	  2014	  
	  	  	  	  
4	  
ABSTRACT	  
	  	  The	   polypeptide	   nerve	   growth	   factor	   (NGF)	   has	   been	   explored	  extensively	   over	   the	   span	   of	   six	   decades	   since	   its	   detection	   with	  amazing	   discoveries	   from	   its	   neurotrophic	   action	   to	   tissue	   healing	  properties.	   In	   lower	   urinary	   tract	   there	   is	   substantial	   evidence	  linking	  NGF	  and	  lower	  urinary	  tract	  dysfunction	  (LUTD).	  Over	  recent	  years	  the	  role	  of	  urinary	  NGF	  [UrNGF]	  in	  diagnosing	  LUTD	  as	  well	  as	  monitoring	   treatment	   response	   has	   been	   investigated	   extensively.	  However,	   the	   available	   studies	   report	   conflicting	   data	   regarding	   an	  association	   between	   lower	   urinary	   tract	   symptoms	   [LUTS]	   and	  UrNGF,	  and	  there	  is	  limited	  evidence	  for	  the	  validity	  and	  reliability	  of	  urinary	  NGF	  assays.	  	  In	  a	  quest	   to	  explore	   the	  role	  of	  UrNGF	  as	  a	  LUTS	  biomarker,	   levels	  were	  measured	   in	   patients	  with	   LUTD,	   prolapse	   and	   asymptomatic	  controls.	   This	   thesis	   hypotheses	   that	  measurement	   of	   NGF	   is	   of	   no	  value	  in	  LUTD	  and	  prolapse.	  Therefore	  the	  aims	  were	  to	  evaluate	  the	  diagnostic	  and	  discriminant	  ability	  of	  UrNGF	  measurement	   in	  LUTD	  and	   to	   test	   the	   reliability	  of	  NGF	  assays.	  The	  other	  objective	  was	   to	  study	   the	   association	   between	   UrNGF	   levels	   and	   cystoscopic	   and	  histology	  findings	  of	  bladder	  inflammation	  in	  women	  with	  overactive	  bladder	   [OAB]	   to	   explore	   the	   link	   between	   NGF	   and	   inflammation.	  Change	   in	   UrNGF	   levels	   after	   cystocele	   repair	   was	   studied,	   since	  bladder	  wall	  stretching	  has	  been	  postulated	  as	  one	  of	  the	  causes	  for	  increased	  NGF	  levels.	  Finally	  UrNGF	  levels	  before	  and	  after	  antibiotic	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treatment	   for	   refractory	   OAB	   were	   measured	   with	   the	   aim	   to	  evaluate	  its	  role	  to	  assess	  treatment	  response.	  	  On	   test	   retest	   reliability	   analysis	   of	   13	   samples	   there	   was	   almost	  perfect	  reliability	  with	  an	   Intraclass	  correlation	  coefficient	  of	  0.889;	  95%[C.I=0.676-­‐0.965;	   p<0.001]. Urinary	   NGF	   was	   significantly	   but	  non-­‐specifically	   increased	   in	   symptomatic	   patients	   [n=205]	   when	  compared	   to	   controls	   [n=31](13.33	   vs.	   2.05	   ng	   NGF/	   g	   Cr,	   Mann	  Whitney	   test;	  p	   <0.001)	  However	  ROC	   analysis,	   demonstrated	   poor	  discriminant	  ability	  between	  either	  different	  symptomatic	  groups	  or	  urodynamic	  groups.	  Using	  a	  cut	  off	  of	  13.0	  ng	  NGF/	  g	  creatinine	  the	  test	  provides	  a	  sensitivity	  of	  81%,	  but	  a	  specificity	  of	  only	  39	  %	  for	  overactive	  bladder.	  UrNGF	   levels	   were	   not	   associated	   with	   cystoscopic	   or	   histology	  findings	  of	  inflammation	  and	  did	  not	  improve	  after	  anterior	  repair	  in	  women	  who	  had	  an	  improvement	  in	  OAB	  symptoms.	  However	  in	  the	  study	   done	   to	   explore	   the	   role	   of	   urinary	   NGF	   as	   a	   biomarker	   to	  assess	   treatment	   response,	   NGF	   levels	   were	   found	   to	   decrease	  significantly	   after	   six	   weeks	   of	   antibiotic	   therapy	   in	   women	   with	  refractory	   OAB	   symptoms	   [n=35	   patients]	   (Wilcoxon	   Signed	   rank	  test;	   p=0.015).	   This	   was	   associated	   with	   improvement	   in	   OAB	  symptoms.	  	  UrNGF	  does	  not	  appear	   to	  be	  a	  good	  diagnostic	  biomarker	  but	  may	  have	   a	   role	   as	   a	   marker	   of	   treatment	   response,	   hence	   may	   have	  limited	  role	  in	  assessment	  of	  women	  with	  LUTD.	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ABBREVIATIONS	  	  AUC	  	  	  	  	   	   Area	  under	  curve	  BDNF	  	  	   	   Brain	  derived	  neurotrophic	  factor	  BOO	   	   	   Bladder	  outlet	  obstruction	  BP	  	   	   	   Bladder	  pain	  BP/IBS/RBC	   	  Bladder	  pain/Increased	  bladder	  	   	   	   	  	  	  	  	   	   	   sensation/reduced	  bladder	  capacity	  BPS	   	   	   Bladder	  pain	  syndrome	  C	   	   	  	   Control	  	  CGRP	  	   	   calcitonin	  gene	  related	  peptide	  	  CNS	  	  	   	   	   central	  nervous	  system	  	  CP/CPPS	  	   	   Chronic	  prostatitis/Chronic	  pelvic	  pain	  syndrome	  CRP	  	  	   	   	   C	  –reactive	  protein	  CVA	  	   	   	   Cerebrovascular	  accident	  CVD	  	   	   	   Cerebrovascular	  disease	  	  DO	   	   	   Detrusor	  overactivity	  DRG	  	   	   	   dorsal	  root	  ganglia	  	  	  ELISA	   	   Enzyme	  linked	  immunosorbent	  assay	  	  ESSIC	  	  	  	  	   	   European	  Society	  for	  the	  Study	  of	  interstitial	  	  	   	   	   cystitis	  	  FDV	   	   	   First	  desire	  to	  void	  FSF	   	   	   First	  sensation	  of	  filling	  GDNF	  	   	   glial-­‐derived	  neurotrophic	  factor	  	  HRP	  	  	  	   	   horseradish	  peroxidase	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HRQoL	  	  	   	   Health	  related	  quality	  of	  life	  measures	  	  IBS	  	   	   	   Increased	  bladder	  sensation,	  	  IC	   	   	   Interstitial	  cystitis	  IC/BPS	  	  	   	   Interstitial	  cystitis/	  bladder	  pain	  syndrome	  ICC	   	   	   Intraclass	  Correlation	  Coefficient	  	  ICI	  	  	  	   	   	   International	  consultation	  on	  incontinence	  	  ICS	  	   	   	   International	  continence	  society	  IDO	  	  	   	   	   Idiopathic	  Detrusor	  Overactivity	  IOAB	   	   	   Idiopathic	  OAB	  	  KHQ	  	   	   	   King’s	  health	  questionnaire	  	  LUTD	  	   	   Lower	  urinary	  tract	  dysfunction	  LUTS	  	   	   Lower	  urinary	  tract	  dysfunction	  MAPK	  	  	   	   mitogen-­‐activated	  protein	  kinase	  	  MCC	   	   	   	  maximum	  cystometric	  capacity,	  	  MSU	  	  	   	   	  midstream	  specimen	  of	  urine	  	  MUI	  	  	   	   	   Mixed	  urinary	  incontinence,	  	  NDO	  	  	  	   	   	  Neurogenic	  DO	  ng/g	  	   	   	   	  nano	  grams/gram	  NGF	   	   	   Nerve	  growth	  factor	  NGF/Cr	   	   Nerve	  growth	  factor/creatinine	  ratio	  NICE	  	  	   	   National	  Institute	  for	  health	  and	  care	  excellence	  	  NOAB	  	   	   Neurogenic	  Overactive	  Bladder	  NPV	  	  	  	   	   negative	  predictive	  values	  	  NT-­‐3	  	  	   	   Neurotrophin-­‐3	  	  NT-­‐4	  	  	  	   	   Neurotrophin-­‐4	  	  OAB	   	   	   Overactive	  bladder	  OAB-­‐Q	   	   overactive	  bladder	  questionnaire	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OD	  	   	   	   Optical	  Density	  	  	  pAb	   	   	   Anti-­‐NGF	  polyclonal	  antibody	  PGE2	  	  	   	   Prostaglandin	  E2	  PKC	  	   	   	   protein	  kinase	  C	  	  POPQ	  	  	   	   pelvic	  organ	  prolapse	  quantification	  PPBC	  	  	   	   Patient	  perception	  of	  bladder	  condition	  	  	  PPIUS	  	   	   Patients’	  Perception	  of	  Intensity	  of	  Urgency	  Scale	  	  	  PPV	  	   	   	   positive	  predictive	  value	  	  PRO	   	   	   	  patient	  reported	  outcomes	  PROM	  	  	   	   patient	  reported	  outcome	  measures	  	  rhNGF	  	   	   Recombinant	  human	  nerve	  growth	  factor	  	  ROC	  	   	   	   receiver-­‐operator	  characteristics	  	  SCI	  	  	   	   	   Spinal	  cord	  injury	  	  SUI	  	  	   	   	   Stress	  Urinary	  Incontinence	  TMB	  	   	   	   tetramethylbenzidine	  	  Trk-­‐A	  	  	   	   tropomyosine	  related	  kinase	  A	  receptor	  	  TRPV1	  	  	   	   transient	  receptor	  potential	  ion	  channel	  	  U	  	  	   	   	   Urgency	  	  UDS	   	   	   urodynamics	  UrNGF	  	   	   Urinary	  NGF	  	  US	  	   	   	   urge	  sensation	  USI	   	   	   Urodynamic	  stress	  urinary	  incontinence	  UTI	  	   	   	   urinary	  tract	  infection	  UUI	  	   	   	   Urgency	  urinary	  incontinence	  VALUE	  	   	   Value	  of	  Urodynamic	  Evaluation	  VAS	  	  	   	   	   Visual	  analog	  scale	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Publications:	  The	  following	  publication	  has	  resulted	  from	  this	  thesis:	  
	  
Vijaya	  G,	  Cartwright	  R,	  Derpapas	  A,	  Gallo	  P,	  Fernando	  R,	  Khullar	  V	  	  
Changes	   in	   nerve	   growth	   factor	   level	   and	   symptom	   severity	  
following	  antibiotic	  treatment	  for	  refractory	  overactive	  bladder.	  Int	  Urogynecol	  J.	  2013	  24(9):	  1523-­‐1528.	  	  	  [Reliability	  and	  validity	  of	  urinary	  nerve	  growth	  factor	  measurement	  in	  women	  with	  lower	  urinary	  tract	  symptoms	  Authors:	   Vijaya	   G,	   Cartwright	   R,	   Bhide	   A,	   Derpapas	   A,	   Fernando	   R,	  Khullar	   V.	   Manuscript	   submitted	   to	   European	   journal	   of	   obstetrics	  and	  gynaecology	  and	  reproductive	  biology]	  
	  
Abstract	  Presentations	  at	  National	  and	  International	  meetings:	  	  The	  following	  abstract	  presentations	  has	  resulted	  from	  this	  thesis:	  
• Can	   Urinary	   Nerve	   growth	   factor	   replace	   urodynamics	   to	  diagnose	   LUTS?	   -­‐	   Podium	   presentation	   at	   International	  urogynaecology	  association	  [IUGA]	  meeting,	  2011	  
• Increased	   nerve	   growth	   factor	   in	   overactive	   bladder	   :Is	   it	  caused	  by	  infection?	  Oral	  poster	  Presentation	  at	  IUGA	  meeting,	  2011.	  	  
• A	   simplified	   method	   of	   Biomarker	   normalisation	   for	   urinary	  concentration-­‐Podium	  presentation	  at	  IUGA,	  2011	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• Can	   Urinary	   Nerve	   growth	   factor	   replace	   urodynamics	   to	  diagnose	   LUTS?	   -­‐	   Oral	   presentation,	   RCOG	   Annual	   scientific	  meeting,	  Athens.	  2011.	  
• Urinary	   nerve	   growth	   factor	   levels	   are	   not	   associated	   to	  bladder	   inflammation-­‐Oral	   presentation-­‐British	   society	   of	  urogynaecology	  [BSUG]	  ARM	  2012	   	  	  
• What	   is	   the	   test-­‐retest	   reliability	   of	   urinary	   neurotrophic	  factors	   measured	   in	   women	   with	   lower	   urinary	   tract	  symptoms	  (LUTS)	  BSUG	  ARM	  2012	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INDEX	  OF	  FIGURES	  	  Figure	   2.1:	   NGF	   dimer	   (extracted	   from	   PDB	   1SG1):	   each	   subunit	   is	  made	  up	  of	  two	  pairs	  of	  non-­‐parallel	  polypeptide	  chains	  	  Figure	   2.2:	   Mechanisms	   involved	   in	   NGF	   associated	   bladder	  overactivity	  	  Figure	  4.1:	  Centrifuge	  	  Figure	  4.2:Elisa	  Analysis	  	  	  Figure	  4.	  3:	  ELISA	  plate	  with	  NGF	  standard	  in	  the	  last	  two	  columns	  	  Figure	  4.4:	  Plate	  shaker	  with	  ELISA	  plates	  	  Figure	   4.5:	   Addition	   of	   TMB	   changes	   the	   sample	   to	   blue	   colour	   in	  proportion	  to	  amount	  of	  bound	  NGF	  	  Figure	   4.	   6:	   Addition	   of	   hydrochloric	   acid	   stops	   the	   colour	   reaction	  and	  changes	  the	  blue	  to	  yellow	  colour.	  	  Figure	  4.7:	  Spectrophotometer,	  which	  measures	  the	  optical	  density	  of	  the	  samples	  	  Figure	  4.8:NGF	  standard	  curve	  Figure	  4.9:	  Bland	  Altman	  plot	  with	  95%limits	  of	  agreement.	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  Figure	   5.1:Median	   NGF	   levels	   in	   controls	   [2.05	   ng	   NGF/g	   Cr]	   and	  patients	  with	  LUTS	  [13.33	  ng	  NGF/g	  Cr]	  	  Figure	   5.2:Median	   NGF	   levels	   in	   Non	   OAB	   [5.78	   ng	   NGF/g	   Cr]	   and	  subjects	  with	  OAB	  [14.21	  ng	  NGF/g	  Cr]	  	  Figure	   5.3:Median	   NGF	   levels	   in	   Non	   SUI	   [10.60	   ng	   NGF/g	   Cr]	   and	  subjects	  with	  SUI	  [13.97	  ng	  NGF/g	  Cr]	  	  Figure	  5.4:	  Median	  NGF	  values	  in	  the	  different	  urodynamic	  groups	  	  Figure	  5.5:	  Area	  under	  the	  ROC	  curve	  for	  measurement	  of	  NGF	  levels	  in	  OAB	  patients	  	  	  Figure	  6.1:Normal	  appearance	  of	  bladder	  mucosa	  Figures	  6.2	  &	  6.3:	  severe	  erythema	  	  Figure	  6.4:	  Mild	  trabeculation	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  6.	  5:Moderate	  trabeculation	   	   	   	   	  	  Figure	  6.6:	  Scatter	  plot	  showing	  ng	  NGF/	  g	  Cr	  values	  in	  OAB	  and	  non-­‐OAB	  groups.	  Median	  ng	  NGF/	  g	  Cr	  values	  [	  25th	  –	  75	  th	  interquartile	  ranges]	   OAB	   group	   –	   10.58[2.87-­‐20.48];	   Non-­‐OAB	   group-­‐	   2.05[0.1-­‐11.88]	  Figure	   8.1:Median	   NGF/Cr	   levels	   before	   and	   after	   antibiotic	  treatment	  
	  	  	  	  
16	  
INDEX	  OF	  TABLES	  
	  Table	  2.1:NGF	  Studies	  in	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  tissue	  	  Table	  2.2:	  Summary	  of	  urinary	  NGF	  studies	  [Liu	  and	  Kuo	  group]	  	  Table	   2.3:	   Summary	   of	   urinary	   NGF	   studies	   [Liu	   and	   Kuo	   group]	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  Table	  2.4:	  Summary	  of	  NGF	  studies	  in	  LUTD	  [other	  researchers]	  	  Table	  4.1:	  Median	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  and	  results	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  Values	   are	   expressed	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   and	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   SE	  and	  95%CI	   for	   measurement	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   urinary	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  different	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  groups	  	  Table	  5.6:	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  Table	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   Comparison	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  groups	  	  Table	   5.9:	   The	   areas	   under	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   ROC	   curve,	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   95%CI	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   urinary	   NGF/Cr	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  Table:	   6.2	   Baseline	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   and	   clinical	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   of	  patients.	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  as:	  mean	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#	  Values	  are	  expressed	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  median	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  Table	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  Table	   6.4:	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  their	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  mean	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  Values	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  median	  (25th-­‐75th	  interquartile	  ranges)	  	  Table	  7.3:	  Median	  NGF/Cr	  levels	  before	  and	  after	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  repair	  	  	  Table	  7.4.	  OAB	  symptoms	  at	  baseline	  and	  at	  follow	  up	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  surgery	  *Values	  are	  expressed	  as:	  mean	  (standard	  deviation)	  
#	  Values	  are	  expressed	  as	  median	  (25th-­‐75th	  interquartile	  ranges)	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   7.5:	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  *Values	  are	  expressed	  as:	  mean	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  Values	  are	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  as	  median	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Overall	  null	  hypothesis	  
	  
Measurement	  of	  urinary	  nerve	  growth	  factor	  is	  of	  no	  
value	  in	  the	  assessment	  of	  women	  with	  lower	  urinary	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Chapter	  1:	  Setting	  	  	  The	   research	   for	   this	   thesis	   was	   carried	   out	   in	   the	   department	   of	  urogynaecology,	  St.	  Mary’s	  hospital,	  Imperial	  college	  healthcare	  NHS	  trust	   from	   September	   2010	   to	   April	   2012.The	   lab	   work	   for	   NGF	  ELISA	   analysis	   was	   carried	   out	   at	   Institute	   of	   reproductive	   and	  developmental	   biology,	   Hammersmith	   campus	   of	   Imperial	   college	  healthcare	  NHS	  trust.	  	  The	   department	   of	   urogynaecology	   is	   led	   by	   Mr	   V.	   Khullar	   and	  consisted	  of	   two	  subspecialist	  consultants,	  subspecialty	   trainee,	   two	  research	   fellows,	   Clinical	   nurse	   specialist	   and	   nurse	   practitioner	   at	  the	   time	  of	   research.	  The	  unit	   is	  a	   tertiary	  referral	   centre	  and	  often	  referrals	   are	   accepted	   from	  all	   over	  UK.	   Each	   year	  more	   than	  5000	  urogynaecology	   patients	   are	   seen	   and	   about	   1000	   urodynamic	  investigations	   are	   performed.	   The	   unit	   offers	   a	   wide	   range	   of	  diagnostic	   techniques	   including	   video	   cystourethrography,	   saline	  cystometry,	   three-­‐dimensional	   ultrasonography,	   urethral	   pressure	  profilometry	   and	   ambulatory	   urodynamics.	   There	   are	   eight	  urodynamic	   clinics	   run	   every	   week	   by	   either	   nurse	   specialists	   or	  doctors.	  Weekly	  pelvic	  floor	  clinic	  is	  run	  where	  endoanal	  ultrasound	  and	   anal	   manometry	   is	   offered	   routinely	   to	   women	   who	   had	  sustained	  obstetric	  anal	  sphincter	  injuries.	  	  	  Clinical	   assessment	   of	   patients	   includes	   urine	   analysis,	   POP-­‐Q	  examination	  and	  use	  of	  Patient	  reported	  outcome	  measures	  such	  as	  frequency	   volume	   chart,	   King’s	   health	   questionnaire,	   prolapse	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Quality	   of	   life	   questionnaire	   and	   patient	   perception	   of	   bladder	  condition.	  	  The	  department	  offers	  treatment	  for	  routine	  and	  complex	  conditions	  of	   urinary	   incontinence,	   vaginal	   prolapse,	   recurrent	   urinary	   tract	  infections,	  bladder	  pain	  and	  pelvic	  floor	  injury	  after	  childbirth.	  The	  unit	  works	   in	   close	   liaison	  with	  urologists,	   colorectal	   surgeons,	  elderly	   care	   physicians,	   microbiologists,	   pain	   team	   consultants,	  neurologist,	   physiotherapist	   and	   continence	   nurses.	   Weekly	  multidisciplinary	   meetings	   are	   conducted	   where	   management	   of	  complex	   cases	  are	  discussed.	  Monthly	   research	  meetings	  are	   run	   to	  discuss	  ongoing	  research	  projects	  and	  research	  ideas.	  	  The	   unit	   is	   actively	   involved	   in	   various	   research	   projects	   and	   is	  usually	   multidisciplinary	   involving	   other	   disciplines	   such	   as	  microbiology,	   histopathology,	   radiology,	   neurology	   and	  physiotherapy.	   Projects	   are	   focused	   on	   various	   aspects	   including	  basic	  science,	   infection	  and	  overactive	  bladder,	  biomarkers,	   imaging	  and	   other	   investigative	   methods.	   There	   is	   active	   participation	   in	  multicenter	  international	  research	  projects	  that	  includes	  surgical	  and	  drug	  trials.	  This	  attracts	  honorary	  research	  fellows	  from	  other	  parts	  of	   UK	   and	   Europe	   with	   an	   interest	   to	   get	   involved	   in	   ongoing	  research.	  In	  addition	  there	  are	  BSc	  students	  attached	  to	  the	  unit	  on	  a	  regular	  basis.	  The	   interest	   and	   commitment	   in	   research	   is	   reflected	  by	   the	   high	   volume	   of	   publications	   in	   peer	   reviewed	   journals	   and	  presentations	  at	  national	  and	  international	  meetings.	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CHAPTER	  2:	  NERVE	  GROWTH	  FACTOR	  
	  
Introduction	  	  Nerve	  growth	  factor	  (NGF)	   is	  a	  neurotrophic	   factor	  essential	   for	  the	  growth,	   differentiation	   and	  maintenance	   of	   developing	   sensory	   and	  sympathetic	   nervous	   system.	   Since	   its	   detection	   there	   has	   been	  overwhelming	   and	   emerging	   discoveries	   supporting	   its	   diverse	  action	   in	   human	   body	   such	   as	   nociceptive	   and	   tissue	   reparative	  effects.	   There	   is	   a	   growing	   interest	   in	   developing	   neurotrophic	  factors	   as	   a	   biomarker	   in	   the	   diagnosis	   of	   lower	   urinary	   tract	  dysfunction	   (LUTD)	   since	   evidence	   from	   experimental	   and	   human	  studies	   have	   found	   an	   association	   between	   increased	   levels	   of	  bladder	   and	   urine	   NGF	   and	   various	   bladder	   dysfunctions.	   NGF	   is	  postulated	   to	   play	   a	   role	   in	   neuroplasticity	   by	   mediating	  inflammation,	   as	   well	   as	   morphological	   and	   functional	   changes,	   in	  sensory	   and	   sympathetic	   neurons	   innervating	   the	   urinary	   bladder	  leading	   to	   bladder	   dysfunction.	   (Schnegelsberg	   et	   al.	   2010,	   Steers	  2002)	  	  
	  
2.1	  Structure	  and	  biological	  properties	  of	  NGF:	  	  Nerve	  growth	  factor	  [NGF]	  is	  a	  polypeptide	  discovered	  during	  1950’s	  (Levi-­‐Montalcini	   and	   Angeletti	   1968)	   by	   an	   Italian	   developmental	  biologist,	   Rita	   Levi-­‐Montalcini	   who	   won	   the	   Nobel	   Prize	   for	   it’s	  discovery	   in	   1986.	   This	   protein	   was	   termed	   Nerve	   growth	   factor	  (NGF)	  due	  to	   its	  effect	  on	  the	  growth	  of	  the	  developing	  sensory	  and	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sympathetic	  neurons(Levi-­‐Montalcini	  1964).NGF	  belongs	  to	  a	  family	  of	  neurotrophins	  and	  other	  members	  of	  this	  group	  are	  brain	  derived	  neurotrophic	  factor(BDNF),	  neurotrophins	  NT	  3	  and	  NT4/5	  .	  	  The	   26-­‐kDa	   β	   subunit	   of	   the	   130–140	   kDa	   7S	   NGF	   complex	   is	  responsible	   for	   the	   biological	   activity(Fahnestock	   et	   al.	   1991).The	  single	   gene	   encoding	  βNGF	   in	   humans	   is	   located	   on	   chromosome	  1	  (Francke	   et	   al.	   1983)	   .It	   encodes	   a	   precursor	   protein	   known	   as	  prepro-­‐NGF,	   which	   is	   sequentially	   cleaved	   into	   pro-­‐NGF	   and	   then	  active	   βNGF(Chao	   2003).	   Each	   βNGF	   subunit	   is	   made	   up	   of	   two	  identical	   pairs	   of	   antiparallel	   strands	   of	   118	   amino	   acids	   held	  together	   by	   monovalent	   bands	   (Figure2.1)(McDonald	   et	   al.	  1991).Cystine	  knots	  help	   in	  providing	   rigidity	   to	   the	   strands	   at	   one	  end	  of	  the	  protomer	  (McDonald	  and	  Chao)	  The	   action	   of	   NGF	   is	   mediated	   by	   two	   receptors	   tropomyosine	  related	  kinase	  A	  receptor	  (Trk-­‐A)	  (Patapoutian	  and	  Reichardt	  2001)	  and	   the	  p	  neurotrophin	   receptor	   (p75NTR)	   (Chao	  1994),	  which	  are	  tissue	   specific.	   Trk-­‐A	   binds	   specifically	   to	   NGF	   and	   depends	   upon	  intrinsic	   tyrosine	   kinase	   activity	   for	   its	   action(Patapoutian	   and	  Reichardt	   2001).	   After	   being	   secreted	   by	   the	   target	   organ,	   NGF	   is	  absorbed	  by	  sympathetic	  and	  small	  sensory	  fibers	  via	  a	  high	  affinity	  Trk-­‐A	  receptor	  and	  retrogradely	  transported	  to	  the	  cell	  body	  where	  it	  exerts	  its	  action(Hendry	  et	  al.	  1974,	  Thoenen	  et	  al.	  1988).	  Activation	  of	   tyrosine	   kinase	   A	   induces	   a	   cell-­‐signalling	   cascade	   involving	  mitogen-­‐activated	   protein	   kinase	   (MAPK)	   pathways(Freund-­‐Michel	  and	  Frossard	  2008,	  Steers	  and	  Tuttle	  2006).	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  Figure	  2.1:	  NGF	  dimer	   (extracted	   from	  PDB	  1SG1):	   each	   subunit	   is	  made	  up	  of	  two	  pairs	  of	  non-­‐parallel	  polypeptide	  chains	  
	  
2.2	  Sources	  of	  NGF:	  	  NGF	   is	   synthesized	   by	   neuronal	   and	   non-­‐neuronal	   cells	   (Aloe	   et	   al.	  1997).NGF	   is	   produced	   by	   neuronal	   cells	   physiologically(Aloe	   et	   al.	  2002).	   In	   the	   central	   nervous	   system	   (CNS)	   the	   highest	   amount	   of	  NGF	  is	  produced	  in	  the	  cerebral	  cortex	  and	  hippocampus	  (Aloe	  et	  al.	  1997)	   and	   there	   seems	   to	   be	   a	   reciprocal	   interaction	   between	  cholinergic	  afferents	  and	  NGF	  producing	  neurons.	  The	  acetylcholine	  increases	   the	   production	   of	   NGF,	   which	   in	   turn	   has	   an	   effect	   on	  acetylcholine	   receptors	   and	   increase	   the	   release	   of	  acetylcholine(Knipper	  et	  al.	  1994).	  	  NGF	   is	   produced	   by	   variety	   of	   other	   cells	   outside	   nervous	   system	  such	  as	  epithelial	  cells(Alleva	  and	  Santucci	  2001)	  eosinophils	  (Aloe	  et	  al.	   1997)	   lymphocytes(Aloe	   et	   al.	   1997,	   Santambrogio	   et	   al.	   1994)	  macrophages	   (Alleva	   and	   Santucci	   2001),	   mast	   cells(Leon	   et	   al.	  1994),Schwann	  cells	  and	  fibroblasts(McMahon	  1996)	  to	  name	  a	  few.	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It	  has	  been	  found	  in	  various	  immune	  organs	  including	  spleen,	  lymph	  node	   and	   thymus(Aloe	   et	   al.	   1997).The	   salivary	   gland(Nam	   et	   al.	  2007),vascular	   smooth	  muscle(Schaper	   et	   al.	   2009),cardiomyocytes	  (Kaye	   et	   al.	   2000)are	   only	   few	   among	   the	   other	   sources	   of	   NGF	  production.	  
	  
2.2.1	  Source	  of	  NGF	  in	  bladder:	  In	   bladder	   NGF	   is	   produced	   by	   smooth	   muscle(Lamb	   et	   al.	   2004,	  Steers	  et	  al.	  1991)	  and	  bladder	  epithelium(Lowe	  et	  al.	  1997,	  Oddiah	  et	  al.	  1998,	  Schnegelsberg	  et	  al.	  2010)	  TrkA	  receptors,	  which	  bind	  to	  NGF,	   are	   expressed	   in	   bladder	   urothelial	   cells	   and	   primary	  afferents(Allen	   and	   Dawbarn	   2006,	   Birder	   et	   al.	   2007,	   Steers	   and	  Tuttle	  2006).	  	  
2.3	  Functional	  properties	  of	  NGF	  and	   its	  diverse	   role	   in	  
systemic	  disorders:	  NGF	   promotes	   growth,	   differentiation	   and	   survival	   of	   central	   and	  peripheral	  nervous	  system	  neurons	  during	   fetal	   life(Levi-­‐Montalcini	  1987).	   In	  adult	   life	  NGF	  appears	   to	  play	  a	   role	   in	  neuroplasticity	  by	  stimulating	   the	   regeneration	   and	   repair	   of	   damaged	   nerve	   cells	   in	  both	   central	   and	   peripheral	   nervous	   system	   in	   response	   to	   trauma	  and	  other	  insults	  such	  as	  ischemia	  and	  degeneration	  (Sofroniew	  et	  al.	  2001)	   .	   Neural	   plasticity	   is	   the	   ability	   of	   neural	   circuits	   to	   undergo	  changes	   in	   function	   or	   organization	   to	   compensate	   for	   new	   activity	  such	   as	   injury,	   disease,	   change	   in	   the	   environment	   etc.	   NGF	   has	   a	  diverse	  role,	  which	  includes	  its	  trophic	  effects	  on	  neurons	  as	  well	  as	  non-­‐neuronal	  cells(Chaldakov	  2011,	  Sofroniew	  et	  al.	  2001).	  
	  	  	  	  
28	  
NGF	   plays	   a	   vital	   role	   in	   mediating	   pain	   in	   inflammatory	  conditions(Anand	   1995,	   Chuang	   et	   al.	   2001,	   McMahon	   1996,	   Pezet	  and	  McMahon	  2006).	   It	   serves	   as	   a	   link	   between	   inflammation	   and	  hyperalgesia.	   Increased	   NGF	   levels	   in	   experimental	   inflammatory	  conditions	   are	   found	   to	   be	   associated	   with	   hyperalgesia,	   which	   is	  blocked	   by	   anti-­‐NGF	   antibodies(Woolf	   et	   al.	   1994).	   Increased	   NGF	  levels	   in	   response	   to	   noxious	   stimuli	   leads	   to	   both	   peripheral	  sensitization	  of	  nociceptors	   and	   central	   sensitization	  of	  dorsal	  horn	  neurons(Dray	   1995,	   McMahon	   1996,	   Woolf	   1996)	   NGF-­‐mediated	  modification	   of	   gene	   expression	   in	   the	   dorsal	   root	   ganglion	   during	  inflammation	  contributes	  to	  persistent	  pain(Woolf	  1996).	  	  	  NGF	  may	  produce	   hyperalgesia	   by	   acting	   directly	   on	   sensory	   nerve	  endings	   or	   by	   promoting	   the	   synthesis	   and	   release	   of	   sensory	  neuropeptides,	   substance	   p	   and	   calcitonin	   gene	   related	   peptide	  (CGRP),	  which	  facilitates	  some	  of	  the	  peripheral	  and	  central	  effects	  of	  inflammation(Anand	   1995,	   Donnerer	   et	   al.	   1992,	   Lindsay	   and	  Harmar	   1989,	   McMahon	   1996,	   Schnegelsberg	   et	   al.	   2010).The	  phenotype	   changes	   produced	   by	   NGF	   during	   inflammation	   include	  the	   upregulation	   of	   growth	   related	  molecules,	  which	  may	   lead	   to	   a	  hyper	   innervation	   of	   injured	   tissue	   by	   promoting	   terminal	  sprouting(Woolf	   1996).	   NGF	   might	   also	   regulate	   nociceptive	  signalling	   by	   altering	   the	   expression	   of	   brain	   derived	   neurotrophic	  factor	   (BDNF)(Allen	   and	   Dawbarn	   2006),[QiaoLY	   2013]	   voltage-­‐gated	   sodium	   channels	   as	   well	   as	   membrane	   ion	   channels	   such	   as	  transient	  receptor	  potential	  ion	  channel	  [TRPV1]	  that	  are	  thought	  to	  play	  a	  central	  role	  in	  inflammation	  or	  tissue	  injury	  induced	  pain	  and	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hypersensitivity(Amaya	  et	  al.	  2004,	  Pezet	  and	  McMahon	  2006,	  Woolf	  1996).	  The	   role	   of	   NGF	   in	   allergic	   inflammation	   is	   explained	   by	   two	  hypotheses.	  NGF	  might	  have	  a	  modulatory	  role	  or	  may	  represent	  the	  product	  of	  inflammatory	  cells	  (Bonini	  et	  al.	  1999).NGF	  is	  found	  to	  be	  a	   stimulus	   for	   mast	   cell	   production(Levi-­‐Montalcini	   et	   al.	   1996,	  Marshall	   et	   al.	   1990,	   Matsuda	   et	   al.	   1991)	   as	   well	   as	   an	   important	  mediator	   of	   mast	   cell	   function	   in	   normal	   and	   pathological	   states	  (Horigome	   et	   al.	   1993)	   .Further	   supporting	   the	   role	   of	   NGF	   in	  inflammation,	   NGF	   has	   been	   shown	   to	   cause	   release	   of	   histamine	  from	  mast	   cells	   (Horigome	   et	   al.	   1994)and	   basophils	   (Bischoff	   and	  Dahinden	  1992).	  	  Increased	   NGF	   expression	   has	   been	   found	   in	   animal	   models	   of	  pancreatitis(Toma	   et	   al.	   2000)gastric	   ulcers(Bielefeldt	   et	   al.	   2003),	  bowel	   obstruction(Williams	   et	   al.	   1993)	   as	  well	   as	   in	   patients	  with	  inflammatory	   bowel	   disease(di	   Mola	   et	   al.	   2000)	   	   and	   pancreatitis	  (Friess	  et	  al.	  1999).	  Increased	  serum	  NGF	  levels	  have	  been	  found	  in	  a	  multitude	   of	   other	   disorders	   such	   as	   systemic	   lupus	   erythematosus	  (Bracci-­‐Laudiero	   et	   al.	   1993),	   arthritis	   (Falcini	   et	   al.	   1996)	   ,anxiety	  	  disorders	   (Aloe	   et	   al.	   1997),	   asthma(Bonini	   et	   al.	   1999),	   allergic	  disorders	   (Bonini	   et	   al.	   1999),	   keratoconjunctivitis	   (Lambiase	   et	   al.	  1995),	   stroke(Stanzani	   et	   al.	   2001)	   ,cardiac	   failure(Singh	   et	   al.	  2013),renal	  disorders	   (Bonofiglio	  et	  al.),emotional	   stress(Laurent	  et	  al.	  2013)	  and	  physical	  stress(Alleva	  and	  Santucci	  2001).	  	  In	  the	  reproductive	  system,	  NGF	  and	  other	  neurotrophic	  factors	  was	  found	   to	   play	   a	   role	   in	   oocyte	   maturation(Linher-­‐Melville	   and	   Li	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2013).	  Increased	  NGF	  levels	  in	  the	  peritoneal	  fluid	  has	  been	  found	  in	  patients	   with	   endometriosis	   postulating	   NGF	   to	   be	   involved	   in	   the	  endometriosis	  associated	  pain(Kajitani	  et	  al.	  2013)	  .	  	  NGF	  demonstrates	  angiogenic	  properties	  (Blais	  et	  al.)	  and	  is	  found	  to	  promote	   tumour	  progression	   in	  human	  cholangiocarcinoma	   (Yue	  et	  al.	   2013)	   and	   stimulate	   cellular	   proliferation	   in	   epithelial	   ovarian	  cancer(Urzua	  et	  al.	  2012)	   .NGF	  receptor	  expression	  has	  been	   linked	  with	  specific	  subtypes	  of	  	  breast	  cancer	  (Tsang	  et	  al.	  2013).	  	  Decreased	  levels	  of	  NGF	  have	  been	  found	  in	  experimentally	   induced	  diabetic	   states(Dey	   et	   al.	   2013,	   Tong	   and	   Cheng	   2005),	   depressed	  patients(Diniz	  et	  al.	  2013)as	  well	  as	  in	  atherosclerotic	  coronary	  walls	  in	   clinical	   studies(Chaldakov	   2011).NGF	   signalling	   seems	   to	   be	  altered	  in	  Alzheimer’s	  disease(Salehi	  et	  al.	  2004).	  	  Thus	   NGF	   seems	   to	   play	   an	   important	   role	   in	   the	   pathogenesis	   of	  plethora	   of	   neurological,	   inflammatory,	   allergic,	   autoimmune,	  infective	   and	   degenerative	   disorders.	   NGF	   is	   described	   to	   have	  neurotrophic,	   immunotrophic,	   nociceptive,	   epitheliotrophic	   and	  metabotrophic	  functions(Chaldakov	  2011).	  	  
2.4	  Clinical	  applications	  of	  NGF	  	  Potential	   therapeutic	   properties	   of	   NGF	   in	   both	   central	   and	  peripheral	   nervous	   system	  disorders,	   cardio	  metabolic	   disorders	   as	  well	  as	  diseases	  of	  eye	  and	  skin	  ulcers	  have	  been	  explored	  recently	  in	  both	   experimental	   and	   clinical	   studies(Aloe	   2011).	   There	   is	   also	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interest	   in	   developing	   	   Recombinant	   human	   nerve	   growth	   factor	  (rhNGF)	  and	  recombinant	  human	  mAb	  against	  NGF.	  Anti	   NGF	   therapy	   in	   mouse	  models	   has	   shown	   reduction	   in	   tumor	  induced	   nerve	   sprouting	   and	   cancer	   pain(Jimenez-­‐Andrade	   et	   al.	  2011)	   .It	   has	   been	   shown	   in	   experimental	   and	   clinical	   studies	   that	  NGF	   may	   have	   profound	   effects	   on	   reparative	   process	   and	   tissue	  regeneration	   (Bernabei	   et	   al.	   1999,	   Kolostova	   et	   al.	   2011).	  Therapeutic	   potential	   of	   NGF	   in	   ocular	   diseases	   such	   as	   glaucoma,	  corneal	   ulcers	   and	   retinitis	   pigmentosa	   has	   been	   experimented	   in	  animal	  studies.	  Topical	  treatment	  with	  NGF	  eye	  drops	  has	  shown	  to	  be	   effective	   in	   the	   treatment	   of	   patients	   with	   neurotrophic	   and	  herpetic	  keratitis,	  and	  glaucoma(Lambiase	  et	  al.	  2011)	  .	  	  NGF	  therapy	  in	  both	  experimental	  and	  clinical	  studies	  for	  Alzheimer’s	  disease	   has	   shown	   encouraging	   results	   (Covaceuszach	   et	   al.	   2009,	  Tuszynski	  et	  al.	  2005)	  The	  use	  of	  rhNGF	  in	  symptomatic	  diabetic	  polyneuropathy	  was	  found	  to	  be	  effective	   in	  phase	   II	   trial,	  however	   the	  development	  of	  painful	  side	  effects	  was	  a	  major	  drawback(Apfel	  2002).	  AntiNGF	  monoclonal	  antibodies	   has	   been	   used	   in	   clinical	   trials	   as	   analgesics	   for	   varied	  conditions	   such	   as	   osteo	   arthritis,	   lower	   back	   pain	   and	   interstitial	  cystitis	   with	   favourable	   and	   nonfavourable	   results(Bannwarth	   and	  Kostine	   2014,	   Lewin	   et	   al.	   2014).In	   a	   randomised	   double	   blinded	  placebo	  controlled	  phase	  2	  study	  tanezumab	  ,a	  humanised	  monclonal	  antibody	   was	   used	   to	   treat	   patients	   with	   interstitial	   cystitis.There	  was	  a	   significant	   reduction	   in	  pain	  and	  urgency	  episodes	   compared	  to	   placebo	   group	  with	   commonest	   adverse	   effects	   of	   headache	   and	  paraesthesia(Evans	  et	  al.	  2011).	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  Although	   some	   of	   the	   preliminary	   studies	   have	   shown	   promising	  results	   the	   safety,	  mode	   of	   administration,	   dosage	   etc.	   of	   both	  NGF	  and	  anti	  NGF	  therapy	  is	  yet	  to	  be	  established.	  	  
	  
2.5	  Evidence	  from	  animal	  studies	  supporting	  the	  role	  of	  
NGF	  in	  LUTD:	  The	  role	  of	  NGF	  in	  the	  pathophysiology	  of	  LUTD	  has	  been	  explored	  in	  animal	   experiments,	   which	   demonstrates	   a	   strong	   link	   between	  increased	  NGF	  levels	  and	  bladder	  dysfunction.	  NGF	  seems	  to	  regulate	  neuroplasticity	  in	  micturition	  pathways.	  The	  key	  results	  from	  various	  studies	  are	  summarized	  below.	  
	  
2.5.1	  Effects	  of	  endogenous	  and	  exogenous	  NGF:	  	  Generation	   of	   mouse	   models	   that	   overexpress	   NGF	   were	   found	   to	  have	  marked	  sensory	  and	  sympathetic	  nerve	  fibre	  hyperplasia	  in	  the	  submucosa	   and	   detrusor	   smooth	   muscle	   and	   elevated	   numbers	   of	  tissue	  mast	   cells.	   These	  mice	   had	   reduced	   urinary	   bladder	   capacity	  and	  an	  increase	  in	  the	  number	  and	  amplitude	  of	  nonvoiding	  bladder	  contractions	   Interestingly	   there	   was	   also	   increased	   referred	  [secondary]	  somatic	  hypersensitivity	  in	  the	  pelvic	  area	  and	  hind	  paw,	  which	   supports	   the	   role	   of	   NGF	   in	   somatosensory	  nociception(Schnegelsberg	  et	  al.	  2010).	  	  	  Intravesical	   administration	   of	  NGF	   has	   been	   shown	   to	   sensitize	   the	  bladder	   afferent	   fibres	   (A	   delta	   and	   C	   fibres)(Dmitrieva	   and	  McMahon	  1996).It	  also	  produced	  bladder	  hyperreflexia(Dmitrieva	  et	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al.	   1997)	   and	   reduced	   volume	   threshold	   for	   micturition	   in	  experimental	  rodents	  compared	  to	  controls	  (Chuang	  et	  al.	  2001).	  	  In	   another	   animal	   experiment	   viral	   vectors	   encoding	   for	  NGF	  were	  injected	  into	  bladder	  wall	  of	  rats	  .NGF	  protein	  levels	  in	  the	  bladder	  of	  these	   animals	   increased	   significantly	   compared	   to	   that	   of	   controls.	  Bladder	   overactivity	   was	   also	   demonstrated	   in	   these	   animals	   on	  cystometrogram(Lamb	  et	  al.	  2004).	  	  Similarly	  infusion	  of	  NGF	  into	  the	  bladder	  wall	  of	  rats	  was	  also	  found	  to	   reduce	   bladder	   capacity,	   reduce	   the	   intercontraction	   interval	   of	  bladder	   and	   increase	   the	   amplitude	   of	   non-­‐voiding	   contractions.	  There	  was	   also	   increased	   expression	   of	   Fos	   protein	   in	   L6-­‐S1	   spinal	  cord,	   which	   is	   an	   indicator	   for	   neuroplasticity	   and,	   CGRP	  immunoreactivity	   in	   the	   lumbosacral	   cord	   in	   response	   to	   this	  experiment	  (Zvara	  and	  Vizzard	  2007).	  	  Furthermore	   intrathecal	   administration	   of	   NGF	   in	   animal	  experiments	   at	   L6-­‐S1	   level	   was	   found	   to	   result	   in	   bladder	  overactivity.	   There	   was	   also	   evidence	   of	   increased	   tetradoxin	  resistant	  Na+	  currents	  and	  reduction	  in	  K	  +	  current	  in	  C	  fibre	  bladder	  afferent	   neurons	  which	   could	   contribute	   to	   the	   hyperexcitability	   of	  bladder	  afferent	  neurons	  and	  bladder	  overactivity	   (Yoshimura	  et	  al.	  2006).Intraperitoneal	  injections	  of	  NGF	  in	  TRP1	  knockout	  mice	  were	  found	   to	   be	   associated	   with	   significant	   reduction	   in	   bladder	  overactivity	  compared	  to	  controls,	  postulating	  TRP1	  to	  play	  a	  major	  role	  in	  the	  NGF	  driven	  bladder	  overactivity(Frias	  et	  al.).	  
2.5.2	  Bladder	  outlet	  obstruction	  and	  NGF:	  Steer	  et	  al	  demonstrated	  (Steers	  et	  al.	  1991)	  about	  two	  decades	  ago	  that	  bladder	  outlet	  obstruction	  (BOO)	  in	  rodents	  was	  associated	  with	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bladder	   hypertrophy	   and	   increased	   urinary	   frequency.	   There	   was	  also	   evidence	   of	   hypertrophy	   of	   dorsal	   root	   ganglia	   (DRG)	   that	  provide	  sensory	  afferent	  fibres	  to	  the	  bladder	  and	  increased	  growth	  of	   afferent	   and	  efferent	  neurons.	  Hypertrophied	  bladders	   contained	  significantly	  more	  NGF	  levels	  than	  normal	  bladders.	   	  The	  rise	   in	  the	  NGF	  levels	  occurred	  before	  the	  neuronal	  hypertrophy	  and	  increased	  urinary	   frequency.	   Autoimmunity	   to	   NGF	   was	   found	   to	   reduce	   the	  neuronal	   hypertrophy.	   Further	   supporting	   these	   findings	   NGF	  immune	  rats	  did	  not	  show	  increased	  expression	  of	  GAP	  43,	  which	  is	  a	  marker	   for	   axonal	   sprouting,	   following	   urethral	   obstruction.	   These	  findings	  support	  the	  link	  between	  NGF	  and	  neuronal	  hypertrophy	  as	  found	  in	  other	  systems(Steers	  and	  Tuttle	  2006).	  	  Evidence	   that	   increase	   in	  bladder	  NGF	   levels	  are	  specific	   to	  bladder	  pathology	   also	   comes	   from	   the	   same	   study	  where	  NGF	   levels	  were	  measured	   in	  bladder	   tissue,	  abdominal	  aorta	  and	   lung	  specimens	  of	  both	   normal	   and	   obstructed	   animals.	   There	   was	   a	   significant	  difference	   in	  NGF	   levels	   between	   the	   control	   and	   obstructed	   group	  only	   in	   the	   bladder	   specimen.	   The	   numbers	   in	   subgroups	   are	   very	  small,	  therefore	  larger	  studies	  are	  needed	  to	  provide	  more	  evidence	  for	  the	  specificity	  of	  measuring	  bladder	  NGF	  levels.	  Chronic	   BOO	   results	   in	   stretching	   of	   the	   urothelium	   and	   smooth	  muscle,	  which	   can	   stimulate	  NGF	   production.	   In	   vitro	   experimental	  models	   have	   demonstrated	   that	   repetitive	   stretch	   stimulation	   of	  bladder	   smooth	   muscle	   cells,	   which	   mimics	   the	   effects	   of	   outlet	  obstruction,	   resulted	   in	   increased	  expression	  of	   a	   variety	  of	   growth	  factors	  like	  NGF(Persson	  et	  al.	  1995,	  Yamaguchi	  2004).	  	  Relief	   of	   obstruction	   only	   caused	   a	   partial	   reversal	   of	   neuronal	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hypertrophy	  as	  well	  as	  increased	  NGF	  level.	  This	  incomplete	  reversal	  of	   neuronal	   plasticity	   could	   be	   the	   etiology	   for	   the	   incomplete	  eradication	  of	  symptoms	  after	  relief	  of	  obstruction(Steers	  and	  Tuttle	  2006).	   Corroborating	   these	   findings,	   transient	   receptor	   potential	  vanilloid	   receptor	   TRPV1	   which	   is	   a	   regulator	   of	   bladder	   reflex	  activity	  and	  bladder	  NGF	  levels	  were	  found	  to	  be	  elevated	  in	  animal	  models	  with	  persistent	  detrusor	  overactivity	  (DO)	  after	  relief	  of	  BOO	  compared	  with	  controls(Kim	  et	  al.	  2004,	  Zvara	  et	  al.	  2002)	  	  
	  
2.5.3	  Inflammation	  and	  NGF:	  Experiments	  done	  in	  rodents	  have	  shown	  that	  chemical	  inflammation	  of	   the	   bladder	   is	   associated	   with	   increased	   NGF	   levels	   postulating	  NGF	   to	   be	   the	   mediator	   of	   sensory	   disorders	   associated	   with	  inflammation(Oddiah	  et	  al.	  1998,	  Vizzard	  2000).	  Beta	  NGF	  expression	  in	  the	  bladder	  was	  found	  to	  be	  increased	  also	  in	  response	  to	  animal	  models	  of	  cystitis	  induced	  by	  bacterial	  endotoxin	  lipopolysaccharide	  and	  substance	  P(Saban	  et	  al.	  2002).	  	  In	  another	  animal	  experiment	  varying	  models	  of	   inflammation	  were	  induced	   in	   animal	   bladders	   using	   formalin	   to	   reproduce	   chemical	  cystitis,	   lipopolysaccharide	   to	   reproduce	   bacterial	   cystitis	   and	  chromic	  catgut	  to	  reproduce	  a	  foreign	  body	  irritant.	  	  This	  resulted	  in	  increased	  NGF	  levels	  as	  well	  as	  morphological	  changes	  in	  the	  sensory	  and	   motor	   neurons	   innervating	   the	   bladder(Dupont	   et	   al.	  2001).Cystitis	   and	   NGF	   overexpression	   in	   the	   bladder	   triggered	  bladder	   hyperactivity(Bielefeldt	   et	   al.	   2006)as	   well	   as	   mechanical	  and	  thermal	  hypersensitivity	  in	  cutaneous	  referral	  sites(Guerios	  et	  al.	  2006).	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Cats	  diagnosed	  with	  feline	  interstitial	  cystitis	  (IC)	  were	  found	  to	  have	  increased	  levels	  of	  NGF	  and	  substance	  P	  in	  the	  urothelium	  compared	  to	   control	   animals.	   The	   DRG	   neurons	   in	   these	   cats	   were	   also	  hypertrophied(Birder	  et	  al.	  2010).	  
	  
2.5.4	  Spinal	  cord	  injury	  and	  NGF	  Spinal	   cord	   injury	   (SCI)	   in	   animal	   experiments	  was	   associated	  with	  increase	   in	   bladder	   NGF	  mRNA	   levels	   compared	   to	   controls.	   There	  was	  also	   increase	   in	  other	  neurotrophic	   factors	  such	  as	  BDNF,	  glial-­‐derived	   neurotrophic	   factor	   (GDNF),	   neurotrophin-­‐3	   and	  neurotrophin-­‐4	   (Vizzard	   2000).	   Increased	   levels	   of	   NGF	   in	   the	  bladder,	   spinal	   cord	   and	   dorsal	   root	   ganglia	   were	   associated	   with	  bladder	   hyperreflexia	   after	   SCI.	   Intrathecal	   administration	   of	   NGF	  antibody	  in	  spinal	  cord	  injured	  rats	  suppressed	  NGF	  levels	  in	  the	  L6	  to	   S1	   dorsal	   root	   ganglia,	   which	   contain	   bladder	   afferent	   neurons,	  and	  also	  suppressed	  bladder	  hyperreflexia(Seki	  et	  al.	  2002).	  	  
	  
2.5.5	  Effect	  of	  antibodies	  to	  counteract	  the	  action	  of	  NGF	  	  Antibodies	  to	  NGF	  (Hu	  et	  al.	  2005,	  Steers	  et	  al.	  1991)	  or	   to	   the	  NGF	  Trk-­‐A	   receptor	   (Dmitrieva	   and	  McMahon	   1996)	   seemed	   to	   prevent	  the	  morphological	  and	  functional	  changes	  of	  the	  nervous	  system	  and	  urinary	  frequency	  associated	  with	  obstruction	  or	  inflammation.	  NGF	  neutralizing	  antibody	  attenuated	  the	  bladder	  hypertrophy	  associated	  with	   cyclophosphamide	   induced	   cystitis	   (Chung	   et	   al.	   2010)	   Down	  regulation	   of	   NGF	   expression	   using	   antisense	   oligonucleotides	   was	  found	   to	   suppress	   bladder	   overactivity	   in	   an	   experimental	   study	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which	   provides	   scope	   for	   antiNGF	   treatment	   in	   OAB(Kashyap	   et	  al.2013).These	  data	  consolidate	  the	  evidence	   linking	  NGF	  and	   lower	  urinary	  tract	  dysfunction.	  
	  
2.5.6	  Effects	  of	  treatment	  for	  LUTD	  and	  NGF	  	  Studies	  have	  also	  explored	  the	  effect	  of	   treatment	   for	  LUTD	  on	  NGF	  levels.	   Hyaluronic	   acid	   that	   is	   used	   for	   the	   treatment	   of	   IC	  significantly	   reduced	   the	   production	   of	   urinary	   NGF	   in	   response	   to	  chemically	   induced	   cystitis	   in	   rodents(Ho	   et	   al.	   2011).	   Botulinum	  toxin	  reduced	  the	  expression	  of	  NGF	  in	  the	  urothelium	  and	  detrusor	  muscle	  of	  experimentally	  induced	  BOO	  in	  rodents	  and	  also	  recovery	  of	  overactive	  bladder	  (Ha	  et	  al.	  2011).	  
	  
2.5.7	  Other	  interesting	  studies:	  Other	   animal	   experiments	   have	   studied	   the	   relationship	   between	  NGF	   and	   pelvic	   ischemia,	   nerve	   injury	   and	   diabetic	   state.	  Experimentally	  induced	  pelvic	  ischemia	  in	  rabbit	  models	  resulted	  in	  overactive	   bladder	   and	   was	   also	   associated	   with	   increased	  expression	  of	  NGF	  in	  bladder	  tissue(Azadzoi	  et	  al.	  2011).	  	  Pudendal	   nerve	   injury	   resulted	   in	   increased	   bladder	   NGF	   levels,	  overactive	   bladder	   and	   stress	   urinary	   incontinence	   (SUI)(Furuta	   et	  al.	   2008).	   	   It	   is	   postulated	   that	   pudendal	   nerve	   injury	   induces	  irritation	  of	  afferent	  pudendal	  nerves	  and	   increase	   levels	  of	  bladder	  NGF.	   This	   in	   turn	   sensitizes	   bladder	   afferent	   pathways	   and	   induces	  bladder	   overactivity.	   A	   recent	   study	   in	   rodents	   has	   provided	  intriguing	  evidence	  linking	  increased	  NGF	  levels	  and	  SUI.SUI	  induced	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by	   urethrolysis	   in	   rodents	   was	   found	   to	   be	   associated	   with	   a	  significant	   increase	   in	  urethral	  NGF	   levels	   compared	   to	   controls(Ko	  et	  al.	  2011).	  In	   diabetic	   rats	   NGF	   levels	   were	   found	   to	   increase	   rapidly	   at	   one	  week	  after	  induction	  of	  diabetic	  state	  but	  then	  declined	  over	  the	  next	  few	  weeks(Steinbacher	  and	  Nadelhaft	  1998).NGF	  levels	  were	   low	  in	  bladder	  tissue	  of	  diabetic	  rats	  compared	  to	  controls,	  which	  returned	  to	  normal	  after	  treatment	  for	  diabetes(Tong	  and	  Cheng	  2005).	  Goins	  et	  al	  has	  demonstrated	  the	  effectiveness	  of	  NGF	  gene	  transfer	  to	  the	  bladder	   and	   bladder	   afferent	   pathways	   in	   an	   animal	   study	   and	   has	  postulated	   that	   this	   technique	   might	   be	   useful	   in	   treating	   diabetic	  cystopathy	   in	   which	   decreased	   NGF	   transport	   may	   be	   a	   causative	  factor(Goins	  et	  al.	  2001).	  Sohrabji	  F	  et	   al	  hypothesized	   that	  oestrogen	  may	   regulate	  neuronal	  sensitivity	  of	  neurotrophins	  such	  as	  NGF	  since	  oestrogen	  was	  found	  to	  upregulate	  NGF	  receptor	  mRNA	  in	  sensory	  neurons(Sohrabji	  et	  al.	  1994).	   However	   this	   interesting	   finding	   has	   not	   been	   investigated	  widely	   to	   study	   the	   relationship	   between	   oestrogen	   and	   NGF	   in	  LUTD.	  	  
2.6	  Evidence	  from	  human	  studies	  supporting	  the	  role	  of	  
NGF	  in	  LUTD	  	  The	   established	   link	   between	   altered	   NGF	   levels	   and	   LUTD	   in	  experimental	   studies	   has	   been	   investigated	   in	   clinical	   studies	   over	  the	  past	  few	  years.	  NGF	  levels	  have	  been	  measured	  in	  bladder	  tissue,	  urine,	  serum	  and	  prostatic	  fluid.	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2.6.1	  Studies	  done	  on	  bladder	  tissue	  Increased	  bladder	  tissue	  NGF	  levels	  have	  been	  found	  in	  patients	  with	  idiopathic	   sensory	   urgency,	   chronic	   cystitis,	   IC(Lowe	   et	   al.	   1997)	  	  idiopathic	  DO	   (Tanner	  et	   al.	   2000)	  and	  Neurogenic	  DO(Giannantoni	  et	  al.	  2006).	  However	  NGF	  levels	  were	  not	  increased	  in	  patients	  with	  urodynamic	  stress	  incontinence	  (USI)(Lowe	  et	  al.	  1997).	  	  Treatment	  with	  Botox	   in	  patients	  was	   found	  to	  decrease	  NGF	   levels	  in	   patients	   with	   neurogenic	   DO.	   It	   is	   postulated	   that	   Botox	   by	  reducing	   the	   release	   of	   acetylcholine	   and	   neurotransmitters	   might	  reduce	   the	  NGF	   production(Giannantoni	   et	   al.	   2006).	   In	   contrast	   to	  the	   above	   studies	   Birder	   et	   al	   did	   not	   find	   an	   association	   between	  increased	   NGF	   levels	   and	   DO(Birder	   et	   al.	   2007).	   The	   results	   are	  summarised	  on	  table	  2.1.	  
	  
2.6.2	  Studies	  done	  in	  urine,	  serum	  and	  prostatic	  fluid:	  
	  
2.6.2.1	  Studies	  done	  in	  LUTD	  by	  Liu	  and	  Kuo	  group:	  	  Liu	  and	  Kuo	  et	  al	  have	  conducted	  the	  majority	  of	  studies	  in	  patients	  with	  LUTD	  and	  they	  have	  proposed	  NGF	  could	  be	  used	  as	  a	  diagnostic	  biomarker	  as	  well	  as	  to	  assess	  treatment	  response.	  The	  studies	  done	  by	   Liu	   and	   Kuo	   et	   al	   are	   summarized	   on	   table	   2.2	   and	   2.3	   and	  elaborated	  below.	  Urinary	  NGF	  [UrNGF]	  levels	  were	  found	  to	  be	  raised	  in	  patients	  with	  overactive	   bladder	   (OAB),	   DO,	   mixed	   urinary	   incontinence	   and	  denovo	   DO	   after	   continence	   surgery.	   UrNGF	   levels	   were	   higher	   in	  patients	   with	   OAB	   wet	   when	   compared	   to	   that	   of	   OAB	   dry.	   The	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UrNGF	   levels	   were	   low	   in	   USI	   and	   persistent	   USI	   after	   continence	  surgery(Liu,	   Chen,	   et	   al.	   2010,	   Liu	   and	  Kuo	  2008).	  NGF	   levels	  were	  also	  increased	  in	  patients	  with	  IC	  but	  not	   in	  patients	  with	  increased	  bladder	  sensation	  (IBS)(Liu,	  Tyagi,	  et	  al.	  2010)	   (Liu	  and	  Kuo	  2012).	  UrNGF	  levels	  were	  significantly	  higher	  in	  patients	  with	  BOO	  and	  OAB.	  The	  levels	  were	  low	  in	  patients	  with	  controls,	  BOO/non	  OAB	  and	  well	  treated	   BOO.	   However	   it	   is	   difficult	   to	   draw	   conclusions	   from	   this	  study	  since	  no	  pre-­‐treatment	  levels	  were	  done	  (Liu	  and	  Kuo	  2008).	  Patients	  with	  urethral,	  renal	  stone	  and	  urothelial	  cancer	  were	  among	  other	  patient	  groups	  who	  were	  found	  to	  have	  elevated	  UrNGF	  levels.	  Benign	   tumours	  and	  muscle	   invasive	   transitional	  cell	  carcinoma	  did	  not	  have	  high	  UrNGF	  levels.	  Patients	  with	  bacterial	  cystitis	  had	  raised	  UrNGF	   levels,	  which	   reduced	   significantly	   after	   antibiotic	   treatment	  (Kuo	  et	  al.	  2010)	  UrNGF	   levels	  were	   raised	   in	  patients	  with	   cerebrovascular	   accident	  and	  also	  correlated	  with	  the	  severity	  of	  the	  neurological	  impairment.	  However	   in	   this	   study	   the	   NGF	   levels	   did	   not	   correlate	   with	   the	  urinary	   symptoms	   or	   urodynamic	   findings	   .It	   was	   thought	   that	   the	  elevated	   NGF	   was	   due	   to	   neurological	   impairment	   rather	   that	  LUTD(Liu,	  Liu,	  et	  al.	  2009).	  
	  
2.6.2.2	  Studies	  done	  in	  LUTD	  by	  other	  researchers:	  Other	   researchers	   have	   also	   explored	   the	   role	   of	   NGF	   in	   LUTD	   and	  the	   key	   studies	   are	   summarised	   on	   table	   2.4.	   Increased	   level	   of	  urinary	  NGF	  has	  been	  demonstrated	  in	  patients	  with	  IC	  (Jacobs	  et	  al.	  2010,	   Okragly	   et	   al.	   1999),	   sensory	   urgency(Yokoyama	   et	   al.	  2008),OAB(Antunes-­‐Lopes	   et	   al.	   2011),	   Neurogenic	   Overactive	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Bladder	   [NOAB](Jacobs	   et	   al.	   2010),	   neurogenic	   DO	   due	   to	  SCI(Yokoyama	   et	   al.	   2008),BOO(Yokoyama	   et	   al.	   2008)and	   bladder	  cancer(Okragly	   et	   al.	   1999).	   Contrary	   to	  other	   studies	  UrNGF	   levels	  were	  not	   increased	   in	  patients	  with	   idiopathic	  DO	  without	  BOO	  and	  neurogenic	   DO	   due	   to	   cerebrovascular	   disease(Yokoyama	   et	   al.	  2008).	  A	  study	  done	  by	  Kim	  et	  al	  found	  an	  increased	  level	  of	  urinary	  NGF	   in	   patients	   with	   OAB	   but	   these	   levels	   did	   not	   correlate	   with	  urodynamics	  parameters(Kim	  et	  al.	  2006).	  In	   contrast	   to	   the	   evidence	   from	   animal	   studies	   where	   bacterial	  cystitis	  produced	  increased	  NGF	  levels,	  there	  was	  no	  difference	  in	  the	  UrNGF	  levels	  between	  UTI	  patients	  and	  controls(Okragly	  et	  al.	  1999).	  	  Increased	  NGF	   levels	   have	   been	   found	   in	   prostatic	   fluid	   of	   patients	  with	   chronic	   prostatitis	   /chronic	   pelvic	   pain	   syndrome	   (CP/CPPS).	  There	  was	  also	  a	   correlation	  between	   the	   increased	  NGF	   levels	   and	  symptom	   severity(Miller	   et	   al.	   2002).	   The	   NGF	   levels	   decreased	  significantly	   in	   patients	   who	   responded	   to	   treatment	   of	   chronic	  prostatitis.	  Therefore	   the	  authors	  proposed	   that	  UrNGF	   levels	  could	  be	  used	  as	  a	  biomarker	   for	   the	  diagnosis	  of	  CP/CPPS,	  as	  well	  as	   for	  the	   assessment	   of	   successful	   treatment	   outcome	   of	  CP/CPPS(Watanabe	  et	  al.	  2011).	  	  
2.6.2.3	  Studies	  related	  to	  urine	  sample	  collection:	  	  	  Few	  studies	  have	  explored	  the	  relationship	  between	  the	  UrNGF	  levels	  and	   sample	   collection.	   Liu	   et	   al	   studied	   the	   association	   between	  UrNGF	   levels	  and	  sensations	  during	   filling.	  Urinary	  NGF	   levels	  were	  very	   low	   at	   first	   sensation	   of	   filling	   (FSF)	   and	   were	   significantly	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higher	   at	   urge	   sensation	   in	  normal	   controls.	   Patients	  with	  OAB	  had	  significantly	   higher	   urinary	   NGF/Cr	   levels	   both	   at	   FSF	   and	   urge	  sensation	   when	   compared	   to	   controls.	   The	   difference	   in	   urinary	  NGF/Cr	   levels	   between	   FSF	   and	   urge	   sensation	   in	   OAB	   patients,	  however,	   was	   not	   significant.	   The	   NGF	   levels	   were	   thought	   to	  increase	  at	  urge	  to	  void	  physiologically	  in	  asymptomatic	  controls	  but	  in	  OAB	  patients	  were	  said	  to	  increase	  pathologically	  at	  small	  bladder	  volume(Liu	   and	   Kuo	   2009)	   .	   Interestingly	   in	   another	   study	   urinary	  NGF/Cr	   levels	   were	   very	   low	  when	   the	   bladder	  was	   not	   distended	  and	  significantly	  elevated	  with	  a	  full	  bladder	  in	  patients	  with	  IC/BPS	  (Interstitial	  cystitis/bladder	  pain	  syndrome)(Liu,	  Tyagi,	  et	  al.	  2009)	  .	  UrNGF	   levels	  were	   also	   found	   to	   significantly	   increase	   after	  natural	  filling	   but	   not	   after	   artificial	   filling	   with	   normal	   saline	   in	   OAB	  patients(Kuo	   et	   al.	   2010).	   Antunes-­‐Lopes	   and	   his	   co	   workers	   have	  shown	   that	   Ur	   NGF	   levels	   are	   stable	   regardless	   of	   the	   time	   of	  collection	  during	  the	  day	  in	  healthy	  volunteers	  (Antunes-­‐Lopes	  et	  al.	  2013)	  .	  	  
2.6.2.4	  Studies	  related	  to	  NGF	  levels	  and	  patient	  characteristics:	  	  Liu	  et	  al	  did	  not	   find	  any	  significant	  correlation	  between	  NGF	   levels	  and	   body	   mass	   index.	   However	   there	   was	   a	   significant	   correlation	  between	   NGF	   levels	   and	   age.	   There	   was	   no	   significant	   difference	  between	   the	  menopausal	   state	   and	  NGF	   levels	   in	   OAB	  wet	   patients	  but	  in	  OAB	  dry	  patients	  the	  NGF	  levels	  were	  higher	  in	  premenopausal	  age	  group(Liu,	  Chen,	  et	  al.	  2011)	  .	  Study	  done	  by	  Antunes–Lopes	  at	  al	  in	   healthy	   volunteers	   showed	   that	   there	   were	   no	   significant	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difference	   in	   the	   NGF	   levels	   between	   men	   and	   women	   (Antunes-­‐Lopes	  et	  al.	  2013).	  	  
	  
2.6.2.5	  Studies	  done	  to	  assess	  treatment	  response:	  	  NGF	  levels	  were	  found	  to	  decrease	  after	  antimuscarinic	  treatment	  in	  patients	   who	   responded	   to	   treatment	   (Antunes-­‐Lopes	   et	   al.	   2013)	  but	   not	   in	   non-­‐responders.	   Persistent	   high	   urinary	   NGF/Creatinine	  level	   [NGF/Cr]	   was	   thought	   to	   be	   due	   to	   either	   very	   high	   NGF	  production	   or	   persistent	   inflammation	   in	   the	   urothelium	   and	  suburothelium.	   Changes	   in	   the	   urinary	   NGF	   levels	   were	   associated	  with	  the	  changes	  in	  the	  urgency	  severity	  scale.(Liu,	  Chancellor,	  et	  al.	  2009)Patients	  who	   responded	   to	   treatment	   for	   IC	   and	  who	   had	   an	  improvement	   in	   visual	   analogue	   scale	   (VAS)	   for	   pain	   of	   ≥2	   had	  significantly	  lower	  NGF/Cr	  levels	  than	  nonresponders	  who	  had	  a	  VAS	  improvement	  of	  <2	  (Liu,	  Tyagi,	  et	  al.	  2009).	  Patients	  who	  responded	  to	   Botox	   treatment	   had	   reduced	   NGF	   levels	   compared	   to	   baseline	  levels.	  Patients	  who	  did	  not	  respond	  to	  Botox	  had	  significantly	  high	  NGF	   levels.	   The	   NGF/CR	   levels	   also	   correlated	   with	   the	   urgency	  severity	   scale	   (Liu,	   Chancellor,	   et	   al.	   2009).	   NGF	   levels	   seem	   to	  correlate	  with	  symptom	  severity	  and	   treatment	   response.	  However,	  since	   these	   studies	   were	   not	   placebo	   controlled,	   results	   should	   be	  interpreted	  with	  caution.	  	  Serum	  and	  urinary	  NGF	  levels	  were	  found	  to	  be	  high	  in	  patients	  who	  were	  refractory	   to	  antimuscarinics	  and	   there	  was	  also	  a	  correlation	  between	  serum	  and	  urinary	  NGF	  levels.	  The	  authors	  postulated	  that	  systemic	  inflammation	  might	  exist	  in	  some	  of	  the	  OAB	  patients	  which	  contributed	  to	  raised	  serum	  NGF	   levels(Liu,	  Lin,	  et	  al.	  2011).	  Serum	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NGF	   levels	   have	   been	   shown	   to	   decrease	   after	   Botox	   treatment	   in	  patients	   with	   idiopathic	   OAB(Knippschild	   et	   al.	   2012).	   However	  serum	  NGF	  levels	  can	  be	  affected	  by	  systemic	  conditions	  since	  serum	  NGF	   levels	   is	   increased	   in	   a	   variety	   of	   conditions	   including	   asthma,	  allergic	   conditions,	   keratoconjunctivitis,	   stress	   etc.	   It	   can	   also	   be	  raised	  in	  asymptomatic	  healthy	  individuals(Lang	  et	  al.	  2003).	  In	  studies	  done	  by	  Liu	  et	  al	  urinary	  NGF	  levels	  were	  low	  (0.05	  or	  less)	  in	   up	   to	   30%	   of	   patients	   with	   OAB	   dry,	   BOO	   or	   OAB	   wet.	   It	   was	  postulated	  by	  the	  authors	  that	  that	  the	  cause	  of	  OAB	  in	  these	  patients	  might	   have	   originated	   from	   pathways	   other	   than	   NGF(Liu,	  Chancellor,	  et	  al.	  2009).	  	  To	   summarise	   there	   is	   some	  evidence	   in	  human	   studies	   supporting	  the	   link	   between	   NGF	   and	   bladder	   dysfunction,	   however	   there	   are	  certain	   conflicting	   data.	   Liu	   et	   al	   (Liu,	   Chancellor,	   et	   al.	   2009)have	  found	  an	  association	  between	  increased	  NGF	  levels	  and	  DO,	  however	  other	   studies	   show	   conflicting	   data(Birder	   et	   al.	   2007,	   Kim	   et	   al.	  2006,	  Yokoyama	  et	  al.	  2008).	  Liu	  et	  al	  (Liu,	  Tyagi,	  et	  al.	  2010)did	  not	  find	  an	  association	  between	  increased	  NGF	  levels	  and	  IBS	  but	  studies	  done	  by	  others	  did	  find	  an	  association	  between	  raised	  NGF	  levels	  and	  sensory	   urgency(Lowe	   et	   al.	   1997,	   Yokoyama	   et	   al.	   2008).	   Urinary	  NGF	   levels	   have	   not	   been	   observed	   to	   be	   elevated	   in	   women	   with	  urodynamic	  stress	  urinary	  incontinence	  (Liu	  et	  al.	  2008),	  however	  a	  recent	  study	  in	  a	  rat	  model	  has	  provided	  interesting	  evidence	  linking	  increased	  NGF	  levels	  and	  rat	  model	  of	  SUI	  (Ko	  et	  al.	  2011)Care	  should	  be	   taken	   to	   interpret	   the	   findings	   since	   the	   studies	   are	   designed	  differently	  with	   heterogonous	   study	   groups	   and	   are	   not	   adequately	  powered.	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Abbreviations	  used	  in	  tables:	  	  OAB-­‐Overactive	  bladder,	  SUI:	  Stress	  Urinary	  Incontinence,	  MUI:	  Mixed	  urinary	  incontinence,	  	  USI:	  urodynamic	  stress	  urinary	  incontinence,	  BDNF:	  Brain	  derived	  neurotrophic	  factor	  C:	  Control,	  CP/CPPS:	  Chronic	  prostatitis/Chronic	  pelvic	  pain	  syndrome	  IDO:	  Idiopathic	  Detrusor	  Overactivity,	  NDO:	  Neurogenic	  DO,	  DO:	  Detrusor	  overactivity,	  	  BOO:	  Bladder	  outlet	  obstruction,	  IOAB:	  Idiopathic	  OAB,	  NOAB:	  Neurogenic	  Overactive	  Bladder	  	  IC:	  Interstitial	  cystitis,	  IC/PBS:	  Interstitial	  cystitis/Painful	  bladder	  syndrome	  	  IBS:Increased	  bladder	  sensation,	  UUI:	  Urgency	  urinary	  incontinence	  	  SCI:	  Spinal	  cord	  injury,	  CVD:	  Cerebrovascular	  disease,	  CVA:	  Cerebrovascular	  accident	  	  FSF:	  First	  sensation	  of	  filling,	  US:	  urge	  sensation,	  FDV:	  First	  desire	  to	  void	  	  MCC:	  maximum	  cystometric	  capacity,	  VAS:	  Visual	  analog	  scale	  	  PGE2:	  Prostoglandin	  E2,	  UTI:	  urinary	  tract	  infection	  	  






Finding	   Drawbacks	  
E.M	  Lowe	  
1997	  
IC,	  Sensory	  urgency,	  Chronic	  cystitis	  [4	  each]	  SUI-­‐controls	   Increased	  NGF	  levels	  in	  all	  3	  groups	  including	  sensory	  urgency	  but	  no	  significant	  difference	  among	  groups	  
Small	  numbers	  and	  	  SUI-­‐controls	  
R.Tanner	  
2000	  




NDO:	  23	  	  [13	  male	  and	  10	  female]	  	  baseline,	  1	  
and	  3	  months	  post	  
Botox	  injection	  
Post	  Botox:	  significant	  decrease	  in	  NGF	  bladder	  tissue	  content	  	   	  
Birder	  2007	   	  DO:	  12	  Controls:	  15	   NGF	  was	  not	  significantly	  associated	  with	  DO	   NGF	  levels	  	  decreased	  with	  storage.	  	  7	  patients	  had	  supra	  pontine	  lesions	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Table	  2.2:	  Summary	  of	  urinary	  NGF	  studies	  [Liu	  and	  Kuo	  group]	  	  	  




Author/Year	  	   Patient	  Groups	  And	  Sample	  
Size	   Results	   Drawbacks/Interesting	  Points	  
Liu	  2008	   C=40;	  IBS=23;	  OAB	  dry	  =54;	  OAB	  wet	  =80	  (UDS	  in	  52	  and	  DO	  =40)	  
OAB	  wet:	  1uui/day	  
NGF	  levels	  increased	  in	  OAB	  wet	  more	  than	  dry	  and	  low	  in	  controls	  and	  IBS	   NGF	  levels	  were	  low	  in	  a	  certain	  percentage	  of	  patients	  with	  OAB	  	  IBS	  –	  no	  urgency,	  but	  frequency	  	  Centrifuged	  within	  1	  hour	  	  	  
Liu	  2009	   35	  controls,	  39	  OAB	  	  	  
Urine	  samples	  were	  collected	  
at	  the	  first	  sensation	  of	  bladder	  
filling	  (FSF)	  and	  at	  urge	  
sensation	  (US)	  
NGF	  levels	  in	  normal	  controls	  were	  very	  low	  at	  FSF	  and	  were	  significantly	  higher	  at	  US.	  Patients	  with	  OAB	  had	  significantly	  higher	  urinary	  NGF	  levels	  at	  FSF	  compared	  to	  controls.	  	  The	  difference	  in	  urinary	  NGF	  levels	  between	  FSF	  and	  US	  in	  OAB	  patients,	  however,	  was	  not	  significant	  
Some	  patients	  with	  OAB	  did	  not	  have	  a	  high	  urinary	  NGF	  level	  
Liu	  2008	   DO=26;	  USI=17;	  MUI=21;	  USI	  after	  continence	  surgery=6;	  	  De	  novo	  DO	  =15;	  controls=31	  	  
NGF	  levels	  were	  low	  in	  the	  controls,	  pure	  USI	  and	  persistent	  USI	  after	  anti-­‐incontinence	  surgery.	  	  The	  urinary	  NGF	  levels	  were	  significantly	  higher	  in	  women	  with	  USI	  and	  DO,	  pure	  DO	  and	  de	  novo	  DO	  	  
Only	  17	  had	  USI	  
Liu	  2009	  
[Pre	  and	  post	  
Botox]	  
38	  controls.143	  (IDO:	  40	  failed	  treatment;	  66	  untreated,	  37	  well	  treated);	  100	  –NDO	  (16	  well	  treated;	  59	  untreated;	  25	  failed	  treatment)	  	  
Increased	  in	  IDO	  and	  NDO	  and	  who	  have	  not	  responded	  to	  treatment	  and	  un	  treated	  but	  decreases	  after	  Botox	  treatment.	  	  	  NGF	  levels	  were	  significantly	  higher	  in	  patients	  who	  had	  a	  higher	  urgency	  severity	  score	  	  
Lack	  of	  controls	  
Liu	  2008	   38	  controls;	  BOO=153(21=no	  OAB;	  25=OAB;	  47=DO;	  OAB	  treated=60)	   NGF	  levels	  are	  low	  in	  controls	  and	  BOO	  with	  non-­‐OAB	  and	  treated	  [medical	  trt]	  OAB.	  	  High	  in	  BOO	  and	  OAB	  and	  DO	  	   Wide	  standard	  deviation	  	  No	  pre-­‐treatment	  levels	  but	  conclusion	  that	  treatment	  decreases	  NGF	  levels	  were	  made	  
	  Liu	  2009	   40=IC;	  54=OAB;	  [23	  –DO;	  31	  IBS]	  27=controls	   NGF	  levels	  higher	  in	  patients	  with	  DO	  and	  IC	  but	  not	  in	  IBS	  and	  controls.	  	  PGE2:	  no	  significant	  difference	  in	  subgroups.no	  correlation	  between	  PGE2	  and	  NGF	  in	  any	  of	  the	  subgroups.	  	  Based	  on	  a	  urinary	  NGF/Cr	  threshold	  of	  0.015,the	  sensitivity	  and	  specificity	  of	  diagnosing	  IC/BPS	  was	  75%	  and	  65.5%,	  respectively	  	  
	  
	  Liu	  2009	   28	  controls;	  122	  patients	  IC	   NGF	  levels	  high	  in	  patients	  with	  IC	  and	  decreased	  in	  patients	  who	  responded	  to	  treatment	  associated	  with	  improvement	  in	  VAS.	  	  




28	  controls;	  30	  patients	  IC	   Urinary	  and	  serum	  NGF	  levels	  high	  in	  patients	  with	  IC,	  but	  no	  correlation	  between	  urinary	  and	  serum	  NGF	  levels	   No	  correlation	  between	  serum	  NGF	  levels	  and	  clinical	  features	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Table	  2.3:	  Summary	  of	  urinary	  NGF	  studies	  [Liu	  and	  Kuo	  group]	  continued	  
	  
*Serum	  and	  urinary	  NGF	  levels	  measure	  	  	  
Author/Year	  	   Patient	  Groups	  
And	  Sample	  
Size	   Diagnostic	  criteria	   Results	   Drawbacks/Interesting	  Points	  
	  Liu	  2009	   C=40	  CVA=	  93	   	   NGF	  levels	  correlated	  well	  with	  the	  severity	  of	  neurological	  impairment,	  NGF	  levels	  were	  not	  correlated	  with	  age,	  location	  of	  CVA,	  multiplicity	  of	  CVA,	  duration	  of	  CVA,	  urodynamic	  findings	  or	  the	  presence	  of	  UUI.	  
T	  	  	  	  	  no	  significant	  difference	  in	  NGF	  levels	  among	  the	  symptomatic	  or	  urodynamic	  subgroups.	  
Liu	  2009	  	  
	  
38-­‐C,	  	  70	  –OAB	  
[Baseline,	  1,	  2	  
and	  3	  months	  
after	  
antimuscarinics	  




Urgency	  or	  urgency	  incontinence	  at	  least	  1	  per	  day	  were	  diagnosed	  to	  have	  OAB.	  
OAB	  -­‐significantly	  higher	  baseline	  urinary	  NGF	  levels	  than	  the	  controls.	  NGF	  levels	  were	  significantly	  reduced	  at	  3	  months	  in	  responders	  but	  not	  in	  the	  non-­‐responders.	  However,	  after	  discontinuing	  antimuscarinic	  treatment	  for	  1	  month,	  the	  NGF	  level	  was	  elevated	  in	  23	  responders	  and	  in	  five	  non-­‐responders	  	  
No	  significant	  difference	  in	  NGF	  levels	  between	  the	  age	  groups	  30%	  had	  zero	  NGF	  levels	  	  Limitation:	  lack	  of	  a	  control	  arm	  
Liu	  2011	   113-­‐OAB	  dry;	  106-­‐OAB	  wet;	  84	  controls	   OAB-­‐dry	  (i.e.	  urgency	  at	  least	  once	  per	  day	  without	  urgency	  incontinence)	  or	  OAB-­‐wet	  (i.e.	  at	  least	  one	  episode	  of	  UUI	  per	  3days	  
Mean	  age	  of	  the	  controls	  was	  significantly	  less	  than	  OAB	  women.	  No	  significant	  correlation	  between	  	  	  NGF	  and	  age	  or	  BMI	  in	  women	  with	  OAB.	  However	  in	  the	  overall	  subjects	  NGF	  levels	  significantly	  correlated	  with	  age	  but	  not	  with	  BMI	  .no	  significant	  difference	  in	  NGF	  levels	  was	  found	  between	  pre-­‐menopausal	  and	  post-­‐menopausal	  women	  with	  OAB-­‐wet	  	  NGF	  levels	  high	  in	  OAB	  wet	  and	  OAB	  dry	  compared	  to	  that	  of	  controls.	  Threshold	  value	  of	  urinary	  NGF/Cr	  level	  of	  0.085	  provided	  a	  sensitivity	  of	  84.9%	  and	  specificity	  of	  84.5%	  for	  differentiation	  of	  OAB-­‐wet	  and	  controls	  .The	  area	  below	  the	  curve	  was	  0.766	  for	  urinary	  NGF/Cr,	  for	  differentiation	  of	  overall	  OAB	  patients	  and	  controls	  	  





34	  [17	  OAB	  dry;	  17	  OAB	  wet];	  31	  –c	  
Baseline	  and	  3	  
months	  after	  
antimuscarinics	  	  
Failed	  antimuscarinic	  therapy	  3	  episodes	  of	  urgency/urgency	  incontinence	  within	  3	  days	  in	  patients	  diagnosed	  as	  OAB.	  
Serum	  and	  urinary	  NGF	  levels	  were	  significantly	  elevated	  in	  OAB	  compared	  to	  the	  controls.	  Serum	  NGF	  levels	  significantly	  correlated	  with	  urinary	  NGF	  in	  OAB	  patients.	  The	  serum	  and	  urinary	  NGF	  levels	  remained	  unchanged	  in	  OAB	  patients	  after	  failed	  solifenacin	  therapy.	  	  
There	  was	  no	  significant	  difference	  of	  serum	  NGF	  levels	  between	  OAB-­‐dry	  and	  OAB-­‐wet.	  	  Patients	  were	  on	  tolterodine	  when	  baseline	  levels	  were	  taken	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Table	  2.4:	  Summary	  of	  NGF	  studies	  in	  LUTD	  [other	  researchers]	  
Author/Year	  	   Patient	  Groups	  And	  
Sample	  Size	  
Results	   Drawbacks/Interesting	  Points	  
Okragly1999	  
UrNGF	  
4	  IC	  	  6	  past	  h/o	  bladder	  cancer	  7	  UTI	  7	  C	  	  
Increase	  in	  Trytpase	  and	  increase	  in	  3	  neurotrophic	  factors	  [neurotrophin-­‐3,	  nerve	  growth	  factor,	  glial	  cell	  line-­‐derived	  neurotrophic	  factor]	  in	  IC	  and	  cancer	  	  No	  sig.	  difference	  in	  chemokine	  levels	  
No	  difference	  between	  C	  &	  UTI	  	  Acid	  treatment	  of	  urine	  prior	  to	  analysis	  	  
Kim	  2006	  
UrNGF	  
65	  OAB	  20	  C	   	  NGF,	  PGE2,	  PGF2	  increased	  in	  OAB	  compared	  to	  controls	  	  Only	  PGE	  2	  but	  not	  NGF	  correlated	  positively	  with	  FDV	  and	  MCC	  




13	  IDO	  without	  BOO	  	  6	  IOAB	  without	  DO	  (sensory	  urgency)	  	  16	  BOO,	  	  16	  NDO	  	  32	  C	  	  
NGF	  levels	  in	  patients	  with	  NDO	  due	  to	  SCI,	  BOO	  and	  sensory	  urgency	  were	  significantly	  higher	  compared	  with	  those	  of	  controls.	  	  	  However,	  the	  levels	  of	  urinary	  NGF	  were	  not	  statistically	  significant	  between	  patients	  with	  IDO	  without	  BOO,	  NDO	  due	  to	  CVD	  and	  patients	  with	  normal	  cystometric	  findings	  
	  Controls-­‐	  urodynamics	  prior	  to	  prolapse	  The	  levels	  of	  urinary	  NGF	  in	  patients	  with	  sensory	  urgency	  were	  significantly	  higher	  than	  those	  of	  controls.	  	  In	  contrast,	  the	  levels	  of	  urinary	  NGF	  of	  patients	  with	  idiopathic	  DO	  and	  neurogenic	  DO	  due	  to	  CVD	  were	  not	  significantly	  elevated.	  	  	  Urine	  centrifuged	  within	  3	  hours	  at	  5000rpm	  Acid	  treatment	  prior	  to	  analysis	  Analysis:	  average	  of	  duplicate	  	  
Jacobs	  2010	  
UrNGF	  
	  NOAB	  =	  13,	  IOAB=	  17,	  IC/PBS	  =	  8,	  Prostate	  cancer	  =	  7,	  Active	  bladder	  cancer	  =	  4	  H/o	  prostate	  cancer	  status	  post	  robot-­‐assisted	  laparoscopic	  prostatectomy	  =	  6;	  nephrolithiasis	  =	  4	  C	  =	  13	  	  
Urinary	  NGF	  levels	  were	  significantly	  elevated	  in	  patients	  with	  NOAB	  and	  IC/PBS	  and	  approached	  significance	  in	  patients	  with	  nephrolithiasis	  compared	  to	  controls	  





20	  CP/CPPS	  4	  C	  	  
	  [Levels	  measured	  at	  baseline	  
and	  8	  week	  after	  trt]	  	  







C=40	  OAB=37	  	  
[Post	  antimuscarinic	  trt].	  	  
NGF	  and	  BDNF	  decreased	  after	  antimuscarinic	  treatment	  	  There	  was	  no	  circadian	  variation	  to	  urinary	  NGF/Cr	  levels	  





[Before	  and	  after	  Botox	  
treatment]	  
	  NGF	  level	  decreased	  after	  Botox	  in	  IOAB	  patients	  	   	  
	  	  	  	  
49	  
	  
2.7	   Mechanisms	   underlying	   the	   role	   of	   NGF	   in	   the	  
pathophysiology	  of	  LUTD	  	  Evidence	   from	   experimental	   and	   human	   studies	   links	   raised	   NGF	  levels	   and	   bladder	   dysfunction	   such	   as	   BOO,	   IC/BPS,	   OAB,	   SUI,	  bladder	   inflammation,	   SCI,	   nerve	   denervation,	   UTI,	   urinary	   tract	  stone,	   urothelial	   tumour	   and	   prostatitis.	   Antibodies	   to	   NGF	   or	   the	  receptor	  prevents	  the	  neural	  plasticity	  associated	  with	  NGF	  action.	  	  NGF	   has	   been	   implicated	   as	   a	   chemical	   mediator	   in	   bladder	  dysfunction	   such	   as	   BOO	   and	   inflammation	   resulting	   in	   bladder	  overactivity	   (Steers	  2002,	  Steers	  and	  Tuttle	  2006,	  Vizzard	  2000).	   In	  response	   to	  BOO,	   inflammation	   and	  SCI	   the	  bladder	   smooth	  muscle	  and	  urothelium	  produce	  increased	  levels	  of	  NGF(Dupont	  et	  al.	  2001,	  Oddiah	  et	  al.	  1998,	  Steers	  et	  al.	  1991,	  Vizzard	  2000).	  	  	  After	   being	   secreted	   by	   target	   organ	   [smooth	   muscle	   cells	   or	  urothelium],	   NGF	   is	   absorbed	   by	   sympathetic	   and	   small	   sensory	  fibers	  via	  a	  high	  affinity	  Trk-­‐A	  receptor	  and	  retrogradely	  transported	  to	   the	   cell	   body	   where	   it	   exerts	   its	   action(Hendry	   et	   al.	   1974,	  Thoenen	  et	  al.	  1988).	  Activation	  of	   tyrosine	  kinase	  A	   induces	  a	  cell-­‐signalling	   cascade	   involving	   MAPK	   pathways(Freund-­‐Michel	   and	  Frossard	  2008,	  Steers	  and	  Tuttle	  2006).	  Increased	  NGF	  levels	  results	  in	   reduced	   threshold	   or	   increased	   excitability	   of	   bladder	   afferent	  fibres(Dmitrieva	  and	  McMahon	  1996,	  Yoshimura	  and	  de	  Groat	  1999)	  and	   enhanced	   spinal	   reflex(Steers	   and	   Tuttle	   2006).	   Change	   in	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Figure	   2.2:	   Possible	   mechanisms	   involved	   in	   NGF	   associated	   bladder	  
overactivity	  
	  
2.8	   Other	   serum	   and	   urinary	   biomarkers	   studied	   in	  
patients	  with	  LUTD	  	  A	   biomarker	   is	   defined	   as	   “a	   characteristic	   that	   is	   objectively	  measured	  and	  evaluated	  as	  an	  indicator	  of	  normal	  biologic	  processes,	  pathogenic	   processes,	   or	   pharmacologic	   responses	   to	   a	   therapeutic	  intervention	   ”	   by	   the	   Biomarkers	   and	   surrogate	   endpoint	  Working	  
NGF	  binds	  to	  Trk-­‐A	  receptor	  
*release	  of	  neuro	  transmitters	  &	  inflammatory	  
mediators	  such	  as	  substance	  P,CGRP,mast	  cells	  etc.	  
*alter	  the	  expression	  of	  BDNF	  
*modulate	  voltage	  gated	  ion	  channels[Na]	  
*increase	  TRPV	  1	  activity	  
*activate	  MAPK	  pathway	  	  
sensitises	  bladder	  afferent	  pathway	  	  increased	  urinary	  frequency	  and	  bladder	  contractions	  
Mechanisms	  of	  action	  	  
Release	  of	  NGF	  in	  response	  of	  
injury,	  infection,	  inflammation	  
or	  obstruction	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Group	   (Naylor	   2003).	   It	   can	   be	   a	   substance	   e.g.	   protein,	   enzyme,	  hormone	  or	  gene	  that	   is	  measured	   in	  blood,	  urine	  or	  bodily	   fluid	  or	  can	  be	  an	  imaging	  biomarker.	  It	  can	  be	  used	  for	  screening,	  diagnosis,	  risk	   stratification,	   measure	   disease	   severity,	   monitor	   disease	  progression,	   predict	   treatment	   response	   and	   monitor	   response	   to	  therapy.	  	  
	  Urinary	   NGF	   is	   the	  widely	   studied	   biomarker	   both	   in	   experimental	  and	   clinical	   studies.	   Few	  other	  urinary	   and	   serum	  biomarkers	  have	  been	  studied	  in	  LUTD	  but	  the	  evidence	  available	  is	  very	  sparse.	  	  BDNF	   is	   a	   neurotrophin	   with	   functional	   properties	   similar	   to	   NGF.	  Researchers	   have	   assessed	   urinary	   levels	   of	   BDNF	   in	   OAB	   patients	  and	  found	  an	  increased	  level	  of	  BDNF	  compared	  to	  controls(Antunes-­‐Lopes	  et	  al.	  2011,	  Wang	  et	  al.	  2014).	  Urinary	  BDNF	  was	  also	  found	  to	  be	   elevated	   in	   IC/BPS	   patients	   and	   to	   significantly	   reduce	   after	  botulinum	   toxin	   administration	   to	   the	   bladder	   trigone(Pinto	   et	   al.	  2010)but	  not	  after	  treatment	  with	  hyaluronic	  acid(Jiang	  et	  al.	  2014).	  Preliminary	  studies	  although	  few	  in	  number	  are	  promising.	  But	  large	  studies	  are	  needed	  to	  evaluate	  its	  role	  further	  as	  a	  biomarker	  in	  the	  assessment	  of	  patients	  with	  LUTD.	  	  Few	   studies	   have	   been	   done	   on	   inflammatory	   markers	   such	   as	  prostaglandins,	  cytokines,	  chemokines	  and	  CRP	  to	  assess	  their	  role	  as	  biomarkers	  in	  LUTD.	  A	  study	  done	  by	  Kim	  et	  al	  in	  patients	  with	  OAB	  demonstrated	  raised	  levels	   of	   urinary	   NGF,	   prostaglandins	   PGE2	   and	   PGF2	   compared	   to	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controls(Kim	  et	  al.	  2006).	  However	  a	  study	  done	  by	  Liu	  et	  al	  did	  not	  find	  urinary	  PGE2	  to	  be	  significantly	  different	  between	  patients	  with	  OAB,	  IC	  and	  controls	  (Liu,	  Tyagi,	  et	  al.	  2010).	  Prostaglandins	  E2	  also	  did	  not	   decrease	   after	   successful	   treatment	  with	   anticholinergics	   in	  patients	   with	   OAB(Cho	   et	   al.	   2013)	   .The	   available	   evidence	   for	  utilizing	  prostaglandin,	  as	  a	  biomarker	  is	  not	  convincing.	  	  	  ATP	  and	  its	  relationship	  with	  LUTS	  has	  been	  explored	  and	  increased	  levels	   in	   the	   urine	   have	   been	   found	   in	   in	   patients	   with	   interstitial	  cystitis(Sun	  et	   al.	   2001)	   and	  patients	  with	  OAB	   in	   an	   another	   small	  case	   control	   study.(Silva-­‐Ramos	   et	   al.	   2013)	   Elevated	   levels	   of	   a	  selective	   subset	   of	   chemokines	   and	   cytokines	   have	   been	  demonstrated	   in	   the	   urine	   of	   OAB	   patients	   compared	   to	   controls.	  (Ghoniem	  et	  al.	  2011,	  Tyagi	  et	  al.	  2010)	  However	  the	  studies	  involve	  a	   very	   small	   number	   of	   patients,	   therefore	  much	   larger	   studies	   are	  needed	   to	   explore	   the	   role	   of	   measurement	   of	   urinary	   ATP	   and	  cytokines	  as	  diagnostic	  biomarkers.	  	  In	  a	  recent	  study	  pro-­‐inflammatory	  cytokines/chemokine	  (IL-­‐1β,	  IL-­‐6,	   TNF-­‐α,	   and	   IL-­‐8A),	   CRP	   and	   NGF	   were	   found	   to	   be	   significantly	  increased	   in	   the	   sera	   of	   patients	   with	   IC/BPS	   compared	   to	  controls(Jiang	   et	   al.	   2013)	   .Other	   studies	   have	   also	   demonstrated	  raised	   serum	   CRP	   levels	   in	   patients	  with	   OAB	   and	   IC	   (Chung	   et	   al.	  2011,	   Hsiao	   et	   al.	   2012).	   However	   serum	   CRP	   levels	   can	   be	  influenced	   by	   systemic	   conditions	   therefore	   the	   feasibility	   of	   using	  CRP	  and	  serum	  NGF	  as	  potential	  biomarker	  needs	  to	  be	   interpreted	  with	  caution.	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  Although	  various	  biomarkers	  such	  as	  prostaglandins,	  cytokines,	  CRP	  etc.	  have	  been	  explored	  for	  their	  role	  in	  the	  assessment	  of	  LUTD,	  the	  neurotrophins	   NGF	   and	   BDNF	   seem	   to	   have	   the	   most	   promising	  evidence.	   However	   a	   lot	   of	   work	   is	   needed	   to	   evaluate	   the	   role	   of	  urinary	  NGF	  	  	  for	  its	  appropriateness	  of	  use	  in	  clinical	  practice.	  
	  
	  
2.9	  Conclusion:	  	  	  NGF	   since	   its	   discovery	   in	   1950’s	   has	   been	   studied	   considerably	   in	  experimental	   and	   human	   studies.	   In	   lower	   urinary	   tract,	   NGF	   is	  increased	   in	  various	  conditions	  of	  bladder	  dysfunction	  and	   it	  seems	  to	   correlate	   with	   the	   severity	   of	   symptoms	   and	   also	   shown	   to	  decrease	   after	   successful	   treatment	   of	   overactive	   bladder.	   It	   is	   not	  clear	   whether	   NGF	   might	   be	   one	   of	   the	   causative	   factors	   in	   the	  pathophysiology	   of	   overactive	   bladder	   or	   whether	   it	   might	   be	   a	  consequence	   of	   overactive	   bladder.	   The	   concept	   of	   using	   NGF,	   as	   a	  biomarker	  of	  LUTD	  is	  appealing	  but	  research	  into	  converting	  urinary	  NGF	  measurement	  as	  a	  bedside	  tool	  is	  far	  from	  complete.	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CHAPTER	   3:	   ASSESSMENT	   TOOLS	   COMMONLY	   USED	   IN	  
LOWER	  URINARY	  TRACT	  DYSFUNCTION	  [LUTD]	  	  	  
3.1	  Assessment	  tools:	  Lower	  urinary	   tract	   symptoms	  comprise	  a	  wide	  range	  of	   symptoms	  and	   various	   assessment	   tools	   are	   used	   in	   clinical	   practice	   to	   define	  the	   diagnosis,	   exclude	   other	   pathologies	   and	   to	   guide	   the	   correct	  management.	   The	   most	   commonly	   used	   assessment	   tools	   are	  discussed	  here.	  
	  
3.1.1	  Patient	  reported	  outcome	  measures:	  	  Patient	   self	   completed	   questionnaires	   or	   patient	   reported	   outcome	  measures	   [PROM]	   (Comperat	   et	   al.2006)	   are	   used	   as	   an	   objective	  assessment	  of	  patient’s	  subjective	  experience	  of	  symptoms(D.Staskin	  2009)	   .	   There	   are	   several	   PROMs	   available	  which	   address	   different	  concepts	   such	   as	   Health	   related	   quality	   of	   life	   measures	   [HRQoL],	  patient	   satisfaction,	   symptom	   bother,	   impact	   of	   urgency	   and	  screening.	  At	  the	  international	  consultation	  on	  incontinence	  [ICI],	  the	  international	   continence	   society	   committee	   has	   put	   forward	  standardized	   grades	   of	   recommendations	   for	   the	   various	  questionnaires.	  Assessment	  of	  patient	  symptoms	  by	  clinicians	  tends	  to	  be	  inaccurate	  and	   irreproducible,	   hence	   it	   is	   essential	   to	   use	   PROM	   in	   the	  evaluation	   of	   patients	   with	   lower	   urinary	   tract	   symptoms	   [LUTS].	  PROMs	   are	   useful	   in	   guiding	   the	   clinician	   to	   manage	   the	   patient’s	  condition	   since	   it	   provides	   information	   about	   the	   severity	   of	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symptoms	   form	   a	   patient’s	   perspective	   and	   its	   impact	   on	   health	  related	   quality	   of	   life.	   It	   helps	   patients	   to	   contribute	   to	   their	  treatment.	   They	   are	   very	   often	   used	   in	   clinical	   trials	   to	   evaluate	  treatment	  efficacy.	  	  The	   disadvantages	   of	   some	   of	   the	   questionnaires	   are	   their	  lengthiness	  and	  difficulty	  in	  interpreting	  results	  such	  as	  King’s	  health	  questionnaire	   [KHQ](Kelleher	   et	   al	   1997)	   and	   overactive	   bladder	  questionnaire	  [OAB-­‐Q](Coyne	  et	  al	  2002).	  Questionnaires	  such	  as	  the	  urogenital	   distress	   inventory	   have	   limited	   information	   due	   to	   its	  specific	   content.	   Single	   reported	   outcome	  measures	   tend	   to	   be	   too	  focused	  and	  fail	  to	  provide	  an	  overall	  reflection	  of	  patient’s	  condition.	  PROMs	   such	   as	   visual	   analog	   scales	   are	   not	   validated,	   can	   be	   very	  subjective	  and	  lack	  specificity	  for	  patients	  with	  LUTS(Khullar	  2012)	  .	  In	   addition	   PROMs	   may	   not	   correlate	   well	   with	   other	   clinical	  outcome	   measures	   such	   as	   urodynamics(Albo	   et	   al.	   2007).	   Hence	  care	   should	   be	   taken	   in	   choosing	   a	   PROM	   for	   clinical	   evaluation,	  which	  is	  appropriate	  to	  the	  patient	  group.	  
	  
3.1.2	  Bladder	  diaries:	  	  Bladder	  diaries	  are	  used	  in	  clinical	  practice	  as	  well	  as	  in	  clinical	  trials	  as	   an	   objective	   tool	   to	   evaluate	   patient’s	   lower	   urinary	   tract	  symptoms.	   They	   range	   from	   simple	   micturition	   time	   charts,	  Frequency-­‐volume	   charts	   to	  more	   detailed	   Bladder	   diaries	   and	   the	  extent	   of	   information	   recorded	   in	   each	   format	   varies.	   The	  information	  recorded	  in	  these	  diaries	  could	  include	  time	  of	  each	  void,	  voided	   volumes,	   fluid	   intake,	   incontinence	   episodes,	   pad	   usage	   and	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degree	  of	  urgency/incontinence.	  The	  bladder	  diaries	  are	  recorded	  for	  a	  minimum	  of	  one	  day	  to	  a	  maximum	  of	  14	  days.	  	  Bladder	  diaries	  are	  prospective	  assessment	  tools	  that	  reduces	  recall	  error	  and	  has	  the	  advantage	  of	  assessing	  incontinence	  in	  the	  patient’s	  own	  environment	  and	  under	  actual	  daily	  life	  conditions(Locher	  et	  al.	  2001).	  	  	  From	   the	   data	   recorded	   the	   clinician	   can	   obtain	   information	   about	  the	   patient’s	   diurnal	   and	   nocturnal	   frequency,	   functional	   bladder	  capacity,	   severity	   of	   urgency/leakage,	   diagnose	   fluid	   restriction,	  nocturnal	   polyuria	   and	   verify	   patient’s	   symptoms.	   Bladder	   diaries	  can	  also	  be	  used	   to	  monitor	  effects	  of	   treatment	  and	  are	  commonly	  used	  in	  clinical	  trials	  to	  assess	  treatment	  efficacy.	  	  A	   recent	   review	   of	   the	   published	   literature	   on	   bladder	   diaries	  confirmed	  that	  there	  was	  limited	  evidence	  regarding	  the	  validation	  of	  dairy	   content	   and	   format	   (Bright	   et	   al.	   2011).However	   in	   a	   recent	  cross	   sectional	   prospective	   study	   the	   3	   day	   bladder	   diary	   showed	  good	   feasibility,	   reliability	   and	  moderate	   validity	   to	   be	   used	   in	   the	  assessment	  of	  LUTS	   in	  women.(Jimenez-­‐Cidre	  et	  al.	  2013).	  However	  there	  was	   low	  agreement	  between	   the	  urodynamic	  variables	  and	   in	  addition	   bladder	   diary	  was	   found	   to	   under	   diagnose	   stress	   urinary	  incontinence.	  	  Bladder	  diaries	  can	  reflect	  patient’s	  symptoms	  and	  severity	  but	  tend	  to	   have	   poor	   discriminatory	   value	   in	   differentiating	   the	   type	   of	  incontinence.	   It	   also	   has	   the	   potential	   effect	   of	   changing	   the	  monitored	   behaviour(Locher	   et	   al.	   2001)	   .One	   of	   the	   other	   main	  problems	  with	  bladder	  diaries	   is	  patient	  compliance	  (Khullar	  2012)	  especially	  with	  diaries	  of	  longer	  duration.	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3.1.3	  Urodynamic	  assessment:	  	  Conventional	   urodynamics	   is	   an	   objective	   test,	   which	   involves	  artificial	   filling	  of	  bladder	  and	  simultaneous	  recording	  of	  abdominal	  and	   intravesical	   pressure	   that	   helps	   in	   studying	   the	   detrusor	  function.	   The	   test	   commonly	   includes	   free	   flow	   study,	   dual	   channel	  filling	  cystometry	  and	  pressure	  flow	  study.	  	  Urodynamics	   is	   the	   only	   objective	   test	   that	   aims	   to	   reproduce	  patients’	  symptoms	  as	  well	  as	  determining	  the	  cause	  for	  their	  LUTS.	  It	  can	  help	  in	  predicting	  the	  outcome	  of	  planned	  treatment	  or	  surgery	  and	  also	  in	  understanding	  the	  reasons	  for	  previous	  failed	  continence	  surgery(G.Hosker	   2009)	   .The	   evaluation	   helps	   the	   clinician	   to	  counsel	   patients	   appropriately	   and	   manage	   patient’s	   expectations	  before	  any	  invasive	  treatment.	  It	  can	  also	  help	  the	  clinician	  to	  predict	  consequences	  of	  LUT	  dysfunction	  on	  the	  upper	  renal	  tract	  as	  a	  result	  of	  high	  detrusor	  pressures(G.Hosker	  2009).	  However	   urodynamics	   is	   an	   invasive	   test	   with	   a	   small	   risk	   of	  infection(Foon	  et	  al.	  2012).	  There	   is	   no	   consensus	   among	   experts	   regarding	   the	   indications	   for	  urodynamics.	   Urodynamics	   has	   not	   shown	   to	   be	   cost	   effective	   in	  patients	  with	  pure	   stress	  urinary	   incontinence	   (Weber	   and	  Walters	  2000).The	  NICE	  recommendations	  are	  to	  perform	  urodynamics	  prior	  to	   surgery	   only	   in	   patients	   with	   mixed	   urinary	   incontinence	   or	  voiding	   difficulties	   or	   anterior	   compartment	   prolapse	   or	   when	  previous	   surgery	   has	   failed(NICE	   2013).	   A	   recent	   systemic	   review	  found	   that	   valsalva	   leak	   point	   pressures	   during	   urodynamics	   may	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help	   in	   predicting	   the	   outcome	   of	   midurethral	   sling	   surgery	  (Kawasaki	  et	  al	  2012].	  However	  a	  multicentre	  trial	   [VALUE]	  did	  not	  find	  urodynamics	  prior	  to	  SUI	  surgery	  in	  patients	  with	  predominant	  SUI	   symptoms	   to	   correlate	   with	   treatment	   success.(Zimmern	   et	  al.2014	  )	  	  A	  number	  of	  studies	  have	  reported	  up	  to	  15%	  test	  retest	  variation	  as	  well	   as	   clinically	   relevant	   inter-­‐rater/observer	   variation(G.Hosker	  2009)	   so	   it	   is	   recommended	   that	   clinicians	   take	   this	   into	   account	  during	   their	   interpretation.	   	   Not	   all	   patients	   with	   OAB	   symptoms	  have	   DO	   on	   urodynamics	   and	   not	   all	   patients	   with	   DO	   have	   OAB	  symptoms(Digesu	  et	  al.	  2003,	  Hashim	  and	  Abrams	  2006).	  Moreover	  up	   to	  30	  %	  of	   asymptomatic	  patients	   can	  have	  DO	  on	  urodynamics	  (Hashim	  and	  Abrams	  2006),	  which	   raises	   concerns	   not	   only	   on	   the	  reliability	  of	  subjective	  reporting	  of	  symptoms	  but	  also	  the	  credibility	  of	  urodynamics.	  	  
	  
3.2	  The	  rationale	  for	  use	  of	  a	  urinary	  biomarker	  in	  LUTD	  Overactive	   bladder	   is	   characterized	   by	   urinary	   urgency	   with	   or	  without	  urgency	  urinary	  incontinence	  usually	  with	  urinary	  frequency	  and	  nocturia.	   (Haylen	  B.T	   et	   al	   2010).	  Urgency	   is	   the	   key	   symptom	  and	  the	  degree	  of	  urgency	  is	  measured	  subjectively	  using	  an	  urgency	  severity	   scale(Abrams	   2005,	   Nixon	   et	   al.	   2005).	   However	   patients	  might	   find	   it	   difficult	   to	   understand	   and	   differentiate	   urgency	   and	  urge	  to	  void	  as	  well	  as	  difficult	  to	  grade	  the	  urgency.	  Patient	  reported	  symptoms	   that	  are	  commonly	  used	   in	  clinical	  practice	   for	  diagnosis	  and	  to	  evaluate	  efficacy	  of	  treatment	  can	  be	  inconsistent	  and	  biased	  due	   to	   their	   subjective	   nature.	   In	   addition	   there	   is	   considerable	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overlapping	   of	   symptoms	   in	   various	   lower	   urinary	   tract	   disorders	  such	  as	  overactive	  bladder,	  IC/BPS	  and	  BOO	  which	  makes	  the	  correct	  diagnosis	  difficult.	  	  Patient	   reported	  outcome	  measures	   as	  mentioned	   above	  have	   their	  shortcomings	   in	   spite	  of	   being	  used	  widely	   as	  objective	   assessment	  tools.	  Urodynamics	   is	   considered	   to	  be	   the	  best	  available	  objective	   test	   in	  evaluating	  LUTD,	  however	  there	  are	  a	  few	  studies	  that	  raise	  concerns	  about	  its	  reliability	  and	  to	  add	  it	  is	  an	  expensive	  and	  invasive	  test.	  	  Therefore	   the	   concept	   of	   developing	   a	   urinary	   biomarker,	   which	   is	  easily	   accessible,	   affordable,	   noninvasive,	   reliable	   and	   superior	   or	  comparable	  to	  the	  current	  diagnostic	  tools	  in	  LUTD,	  is	  appealing.	  
	  
3.3	  NGF	  as	  a	  potential	  urinary	  biomarker	  NGF	  measurements	   have	   been	   done	   on	   bladder	   biopsies	   as	  well	   as	  urine	   	   	   samples	   in	  experimental	  and	  human	  studies.	   It	   is	  postulated	  that	  NGF	   in	   urothelium	   and	   detrusor	  muscle	   is	   secreted	   into	   urine.	  Urine	   collection	   is	   easily	   accessible	   compared	   to	   bladder	   biopsies.	  NGF	   measurements	   in	   urine	   are	   simple	   compared	   to	   NGF	  measurements	  in	  bladder	  biopsies,	  which	  are	  very	  complex.	  	  Urinary	   NGF	   levels	   are	   quantified	   using	   enzyme	   linked	  immunosorbent	   assay	   (ELISA),	   which	   is	   non-­‐invasive	   and	   more	  affordable	   when	   compared	   to	   UDS.	   Measurement	   of	   urinary	   NGF	  levels	  can	  be	  affected	  by	  various	  factors	  since	  there	  is	  room	  for	  error	  in	   urine	   sample	   handling,	   sample	   processing,	   centrifugation	   steps	  and	  ELISA	  analysis.	  The	   test	   retest	   variability	  of	  ELISA	  analysis	  has	  not	  been	  reported	  yet.	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The	   role	   of	   urinary	   NGF	   as	   a	   diagnostic	   biomarker	   needs	   further	  exploration	  since	   the	  reports	  regarding	  sensitivity	  and	  specificity	  of	  NGF	   assays	   seem	   to	   be	   varied.	   Using	   a	   cut	   off	   value	   of	   more	   than	  0.05pg/ml,	  the	  sensitivity	  of	  a	  urinary	  NGF/Cr	  level	   in	  the	  diagnosis	  of	   overactive	  bladder	  was	  67.9%	  and	   the	   specificity	  was	  93.8%(Liu	  and	   Kuo	   2008).	   However	   a	   study	   done	   by	   Antunes-­‐Lopes	   et	   al	  reported	   lower	   values	   of	   sensitivity	   and	   specificity	   for	  NGF/creatinine	   ratio	   [>200pg/mg]	  with	   an	   area	  under	   the	   curve	   in	  receiver-­‐operator	   characteristics	   (ROC)	   analysis	   of	   only	  0.68(Antunes-­‐Lopes	   et	   al.	   2011).	   Diagnostic	   accuracy	   of	   a	   test	   is	  usually	   assessed	   by	   comparing	   with	   a	   reference	   standard	   and	   in	  LUTD	   urodynamics	   is	   the	   best	   available	   objective	   test.	   The	   study	  done	  so	  far	  to	  compare	  NGF	  levels	  and	  various	  urodynamic	  diagnoses	  was	  of	  a	  very	  small	  sample	  size(Liu	  and	  Kuo	  2008).	  	  In	  all	   the	  studies	  done	  so	  far	  there	  are	  no	  uniform	  inclusion	  criteria	  e.g.	  two	  different	  classifications	  have	  been	  used	  to	  classify	  patients	  as	  OAB	  wet	  by	  the	  same	  group	  of	  researchers(Liu,	  Chen,	  et	  al.	  2011,	  Liu	  and	   Kuo	   2008).	   Patients	   used	   as	   controls	   can	   range	   from	  asymptomatic	  patients	  to	  patients	  with	  USI	  or	  bladder	  cancer	  (Lowe	  et	   al.	   1997),	   which	   could	   bias	   the	   results	   since	   some	   studies	   have	  shown	  an	  association	  between	  increased	  	  NGF	  levels	  and	  SUI(Furuta	  et	   al.	   2008,	   Ko	   et	   al.	   2011).	   There	   are	   also	   some	   inconsistent	   data	  regarding	  NGF	  levels	  in	  DO,	  SUI	  and	  IBS	  in	  the	  available	  evidence	  as	  stated	  earlier	  in	  chapter	  2	  	  In	   vitro	   experimental	   models	   have	   demonstrated	   that	   repetitive	  stretch	   stimulation	   of	   bladder	   smooth	   muscle	   cells	   which	   mimic	  
	  	  	  	  
63	  
bladder	  outlet	  obstruction	  result	   in	   increased	  NGF	  levels(Persson	  et	  al.	   1995).	   Bladder	   outlet	   obstruction	   in	   men	   is	   associated	   with	  increased	  NGF	  levels(Liu	  and	  Kuo	  2008).	  	  Bladder	  outlet	  obstruction	  is	  uncommon	  in	  women	  however	  anterior	  wall	   prolapse	   /cystocele	   is	   common	   and	   the	   relationship	   between	  anterior	  vaginal	  wall	  prolapse	  and	  NGF	  levels	  have	  not	  been	  studied	  so	  far.	   It	   is	  possible	  that	  anterior	  vaginal	  wall	  stretching	  in	  prolapse	  results	   in	   raised	  NGF	   levels	  and	  hence	  results	   in	  overactive	  bladder	  symptoms.	   If	   this	   is	   true	   then	   this	   has	   an	   implication	   of	  measuring	  UrNGF	  levels	  in	  women	  with	  anterior	  vaginal	  wall	  prolapse.	  	  The	  available	  evidence	  regarding	  the	  role	  of	  Ur	  NGF,	  as	  a	  biomarker	  in	  LUTD	  is	  inconsistent	  and	  sparse,	  therefore	  based	  on	  the	  available	  and	   the	   absence	   of	   evidence	   the	   following	   hypotheses	   were	  formulated	  on	  which	  the	  research	  studies	  were	  based	  on.	  
	  
Hypothesis	  1:	  	  NGF	   in	   urine	   sample	   is	   quantified	   using	   Enzyme	   linked	  immunosorbent	  assay	  [ELISA]	  .The	  test-­‐retest	  reliability	  of	  currently	  used	   urinary	   NGF	   ELISA	   assays	   has	   not	   yet	   been	   reported	   yet.	  Therefore	  the	  hypothesis	  for	  the	  first	  study	  was	  as	  follows:	  
	  
Enzyme	  linked	  immunosorbent	  assay	  is	  not	  a	  reliable	  technique	  to	  
measure	  NGF	  levels	  in	  urine	  
	  
Hypothesis	  2:	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  The	  validity	  of	  urinary	  NGF	  as	  a	  diagnostic	  biomarker	  in	  women	  with	  LUTD	  is	  still	  unclear	  due	  to	  conflicting	  reports	   in	  the	   literature.	  The	  following	   hypothesis	   was	  made	   for	   the	   second	   project	   and	   urinary	  NGF	   levels	   were	   compared	   with	   various	   LUTD	   and	   urodynamic	  diagnoses	  to	  evaluate	  the	  validity	  of	  urinary	  NGF	  measurement:	  
	  
Urinary	  NGF	   level	  measurement	   is	  not	  a	  valid	   test	   in	  assessment	  
of	  women	  with	  LUTD	  with	  poor	  sensitivity,	  specificity,	  positive	  and	  
negative	   predictive	   values	   and	   has	   no	   discriminatory	   ability	   to	  
differentiate	  the	  different	  symptomatic	  and	  urodynamic	  groups	  
	  
Hypothesis	  3:	  	  Nerve	  growth	  factor	  (NGF)	  is	  one	  of	  the	  neurotrophic	  factors,	  which	  is	   considered	   as	   a	   key	   regulator	   of	   neurogenic	   inflammation	   in	  several	  tissues	  including	  the	  bladder.	  Increased	  urinary	  NGF	  levels	  in	  OAB	  might	  be	  associated	  with	  severity	  of	  bladder	   inflammation	  and	  may	   be	   used	   as	   a	   non-­‐invasive	   biomarker	   to	   predict	   the	  inflammatory	   status	   of	   bladder	   if	   it	   correlates	  with	   cystoscopy	   and	  histology	   findings.	   This	   speculation	   led	   to	   the	   hypothesis	   for	   third	  study:	  
	  
Urinary	   NGF	   levels	   are	   not	   associated	   with	   cystoscopic	   and	  
histology	  findings	  of	  inflammation	  in	  women	  with	  refractory	  OAB	  
and	   cannot	   be	   used	   as	   a	   non-­‐invasive	   biomarker	   to	   predict	   the	  
inflammatory	  status	  of	  bladder.	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Hypothesis	  4:	  	  Women	   with	   anterior	   vaginal	   wall	   prolapse	   frequently	   suffer	   with	  overactive	   bladder	   symptoms.	   Overactive	   bladder	   symptoms	   have	  been	   shown	   to	   improve	   significantly	   after	   anterior	   colporrhaphy.	   If	  increased	   NGF	   levels	   are	   contributing	   to	   the	   overactive	   bladder	  symptoms	   then	  NGF	   levels	   should	   decrease	   after	   anterior	   repair	   in	  women	  who	   have	   had	   an	   improvement	   in	   their	   overactive	   bladder	  symptoms.	   On	   this	   postulation	   the	   hypothesis	   was	   made	   for	   the	  fourth	  study	  as	  follows:	  
	  
NGF	  levels	  do	  not	  change	  in	  women	  who	  have	  had	  improvement	  in	  
their	  overactive	  bladder	  symptoms	  after	  anterior	  colporrhaphy.	  
	  
Hypothesis	  5:	  NGF	  has	  been	  suggested	  as	  a	  biomarker	  to	  assess	  treatment	  response	  for	   overactive	   bladder	   and	   few	   studies	   have	   demonstrated	   to	   this	  effect.	   There	   is	   emerging	   evidence	   linking	   infection	   to	   overactive	  bladder	   and	   use	   of	   antibiotics	   to	   treat	   symptoms	   of	   refractory	  overactive	   bladder.	   The	   role	   of	   urinary	   NGF	   to	   assess	   response	   to	  antibiotic	   therapy	   in	   patients	   with	   refractory	   OAB	  was	   explored	   in	  the	  final	  study	  and	  the	  hypothesis	  was	  as	  follows:	  
	  
Urinary	   NGF	   level	  measurement	   does	   not	   change	   in	   response	   to	  
antibiotic	  therapy	  for	  refractory	  OAB	  and	  cannot	  be	  used	  to	  assess	  
treatment	  response.	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CHAPTER	  4:	  NGF	  ASSAY	  AND	  RELIABILITY	  OF	  NGF	  ASSAY	  	  Investigational	   studies	   performed	   so	   far	   to	   quantify	   NGF	   in	   urine	  samples	   have	   used	   sandwich	   ELISA	   kits.	   	   The	   measurement	   of	  urinary	  NGF	  concentration	  in	  this	  project	  was	  performed	  by	  Enzyme	  linked	   immunosorbent	   assay	   [ELISA]	   using	   the	   NGF	   Emax®	  ImmunoAssay	   System	   (Promega,	  Madison,	  WI,	   USA).	   	   This	   immune	  assay	  system	  is	  designed	   for	  sensitive	  and	  specific	  detection	  of	  NGF	  in	   tissue	   culture	   supernatants	   or	   tissue	   extracts	   in	   an	   antibody	  sandwich	  format.	  The	  steps	  involved	  in	  the	  NGF	  assay	  including	  the	  sample	  collection,	  storage	  and	  the	  ELISA	  technique	  are	  detailed	  in	  this	  chapter	  with	  an	  assessment	  of	  the	  reliability	  and	  discussion	  of	  this	  technique.	  
	  
4.1	  Technique	  for	  analysis	  of	  NGF	  levels	  in	  urine	  
	  
4.1.1	  Sample	  collection	  and	  handling:	  	  There	   have	   been	   few	   studies	   pertaining	   to	   the	   collection	   of	   urine	  samples	   and	  NGF	   levels.	   Urinary	  NGF	   levels	  were	   found	   to	   be	   very	  low	  at	  first	  sensation	  of	  filling	  (FSF)	  and	  were	  significantly	  higher	  at	  the	  sensation	  of	  urge	  in	  normal	  controls	  in	  a	  study	  conducted	  by	  Liu	  and	   co	  workers.	   Patients	  with	  OAB	  had	   significantly	   higher	   urinary	  NGF/Cr	   levels	   both	   at	   FSF	   and	   urge	   sensation	   when	   compared	   to	  controls.	   The	   difference	   in	   urinary	   NGF/Cr	   levels	   between	   FSF	   and	  urge	   sensation	   in	   OAB	   patients,	   however,	   was	   not	   significant.	   The	  NGF	  levels	  were	  thought	  to	  increase	  at	  urge	  to	  void	  physiologically	  in	  asymptomatic	   controls	   but	   in	   OAB	   patients	   were	   said	   to	   increase	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pathologically	   at	   small	   bladder	   volume(Liu	   and	   Kuo	   2009)	   .	  Interestingly	   in	  another	   study	  urinary	  NGF/Cr	   levels	  were	  very	   low	  when	  the	  bladder	  was	  not	  distended	  and	  significantly	  elevated	  with	  a	  full	  bladder	  in	  patients	  with	  IC/BPS	  (Interstitial	  cystitis/bladder	  pain	  syndrome)(Liu	  et	  al.	  2009)	  .	  But	  in	  most	  of	  the	  studies	  urine	  samples	  have	   been	   collected	   from	   participants	   when	   they	   reported	   a	  comfortably	  full	  bladder(Antunes-­‐Lopes	  et	  al.	  2013,	  Liu	  et	  al.	  2010).	  NGF	   levels	   were	   also	   found	   to	   significantly	   increase	   after	   natural	  filling	   but	   not	   after	   artificial	   filling	   with	   normal	   saline	   in	   OAB	  patients(Kuo	   et	   al.	   2010).	   Study	   done	   by	   Antunes–Lopes	   et	   al	   in	  healthy	  volunteers	  showed	  there	  was	  no	  significant	  difference	  in	  the	  NGF	  levels	  irrespective	  of	  time	  of	  the	  day	  of	  urine	  sampling(Antunes-­‐Lopes	  et	  al.	  2013).	  	  Therefore	  in	  this	  project	  urine	  was	  collected	  from	  participants	  prior	  to	   urodynamics	   or	   cystoscopy	   or	   during	   their	   clinic	   appointment	  when	   they	   had	   a	   comfortably	   full	   bladder.	   Participants	   were	  requested	   to	  provide	  a	  midstream	  sample	  of	  urine.	  A	  urine	  dipstick	  analysis	  was	   done	   to	   rule	   out	   urine	   infection	  prior	   to	   further	   urine	  sample	  handling.	  All	  participants	  were	  given	  an	  information	  sheet	  about	  the	  study	  and	  a	   written	   consent	   was	   obtained.	   Women	   were	   recruited	   following	  ethical	  approval	  (REC	  reference	  number:11/LO/1029)	  into	  this	  study	  from	  October	  2011	  to	  March	  2012.	  
	  
4.1.2	  Centrifugation:	  	  Collected	   urine	   samples	   [about	   1.5-­‐2	   ml]	   were	   immediately	  refrigerated	  or	  placed	  in	  ice	  and	  centrifuged	  at	  3000rpm	  at	  4	  0	  C	  for	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10	  minutes	  within	   20	  minutes	   of	   collection	   [Figure	   4.1].	   Urine	  was	  centrifuged	   immediately	   since	   the	   room	   temperature	   and	   exposure	  to	   air	   can	   induce	   chemical	   reactions	   in	   the	   urine	   and	   protein	   can	  become	  unstable	  at	  room	  temperature.	  	  
	  
	  
Figure	  4.1:	  Centrifuge	  
	  
	  
4.1.3	  Storage:	  	  The	  centrifuged	  supernatant	  urine	  was	  pipetted	  and	  stored	  at	  -­‐80°0C	  in	  ependorfs	  until	  further	  processing.	  
4.1.4	  Analysis:	  	  In	  this	  study	  the	  NGF	  assays	  was	  performed	  in	  batches	  between	  3-­‐4	  months	  after	  collection	  of	  the	  urine	  samples.	  Protein	  degradation	  has	  been	  said	  to	  take	  place	  with	  prolonged	  storage.	  A	  small	  study	  done	  by	  Birder	  et	   al	   showed	   that	  NGF	  concentration	   in	  bladder	   tissue	  had	  a	  trend	  to	  decrease	  after	  prolonged	  storage(Birder	  et	  al.	  2007)	  .Assays	  were	  repeated	  at	  storage	  intervals	  of	  13,22	  and	  58	  days.	  The	  storage	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time	  was	  speculated	  to	  have	  influenced	  the	  variability	  of	  NGF	  results	  however	   it	   didn't	   seem	   to	   affect	   the	   conclusions	   drawn	   from	   the	  study.	  	  The	   urine	   samples	   were	   allowed	   to	   defrost	   naturally	   and	   then	  urinary	  NGF	  levels	  were	  measured	  by	  enzyme	  linked	  immunosorbent	  assay	   (ELISA)	  using	   the	  NGF	  Emax	   Immunoassay	  System	  (Promega,	  Madison,	  WI,	  USA).	  A	  standardized	  protocol	  was	  followed	  as	  advised	  by	   the	   manufacturers	   on	   the	   technical	   bulletin	   of	   NGF	   Emax	  Immunoassay	   System,	   Promega.	   The	   system	   uses	   an	   antibody	  sandwich	   format	   for	   detection	   of	   free	   NGF	   in	   the	   range	   of	   3.9-­‐250pg/ml.	   The	   manufactures	   quote	   less	   than	   3%	   cross	   reactivity	  with	   other	   structurally	   related	   growth	   factors	  Human	  Recombinant	  Brain	   Derived	   Neurotrophic	   Factor,	   Neurotrophin-­‐3	   (rhNT-­‐3)	   and	  Neurotrophin-­‐4	  (rhNT-­‐4).	  	  	  
The	  ELISA	  analysis	  [Figure	  4.2]	  is	  detailed	  in	  the	  following	  steps:	  
	  
4.1.4.1	  Step	  1:	  10μl	   Anti-­‐NGF	   polyclonal	   antibody	   (pAb)	   was	   mixed	   with	   10ml	  carbonate	   coating	   buffer	   (pH	   9.7).	   This	   anti-­‐	   NGF	   pAb	   was	   coated	  onto	  a	  96	  well	  micro	  titre	  plate	  [100μl/well]	  and	  incubated	  overnight	  at	  4	   0	  C.	  This	  will	   prevent	  other	  proteins	   in	   the	   sample	   adsorbed	   to	  the	   ELISA	   plate	   surface.	   Each	   ELISA	   plate	   has	   eight	   rows	   and	   12	  columns	  [Figure	  3]	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Figure	  4.2:Elisa	  Analysis	  	  
	  
4.1.4.2	  Step	  2:	  	  a]	   Block	   &	   Sample	   Buffer	   was	   prepared	   to	   the	   correct	   dilution	   by	  mixing	  with	  deionized	  water.	  The	  plate	  was	  washed	  and	  then	  200μl	  was	   added	   to	   each	   well	   and	   incubated	   for	   1	   hour	   at	   room	  temperature.	  This	  was	  done	  to	  block	  non-­‐specific	  binding.	  b]	   The	   plates	   were	   washed	   once	   and	   100	   μl	   urine	   samples	   were	  added	  to	  the	  wells,	  except	  for	  the	  last	  two	  columns	  [Figure	  4.3]	  .The	  soluble	  NGF	  in	  urine	  sample	  is	  immobilized	  on	  the	  solid	  surface	  of	  the	  wells	  with	  the	  anti-­‐	  NGF	  pAb.	  	  	  The	  NGF	  Standard	  was	  diluted	  with	  the	  NGF	  Block	  &	  Sample	  Buffer	  to	   produce	   the	   recommended	   dilution.	   Last	   two	   columns	   are	  designated	   to	   prepare	   the	   standard	   curve	   and	   provide	   a	   reference	  
Step	  4:	  	  Addition	  of	  Anti-­‐Rat	  IgG,	  HRP	  conjugate	  
Step	  5:	  Addition	  of	  TMB	  substrate	  
Step	  3:	  Addition	  of	  anti-­‐NGF	  monoclonal	  antibody	  
Step	  2:Addition	  of	  urine	  sample	  
Step	  1:	  	  Addition	  of	  pAb	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standard.200μl	  of	  diluted	  NGF	  standard	  was	  added	  to	  row	  A,	  columns	  11	  and	  12	  of	  a	  96-­‐well	  plate	  and	  six	  1:2	  serial	  dilutions	  [100	  μl	  each	  well]	   were	   performed	   .In	   the	   last	   row	   NGF	   standard	   is	   not	   added.	  This	  will	  produce	  a	   final	  concentration	  ranging	   from	  0-­‐250pg/ml	  of	  NGF	   in	   the	   last	   two	   columns,	  which	  will	   act	   as	   reference	   standard.	  
	  	  	  
Figure	  4.	  3:	  ELISA	  plate	  with	  NGF	  standard	  in	  the	  last	  two	  columns	  The	   plates	   were	   incubated	   with	   shaking	   for	   6	   hours	   at	   room	  temperature	  and	  then	  washed	  5	  times.	  [Figure4.	  4]	  	  
	  
Figure	  4.4:	  Plate	  shaker	  with	  ELISA	  plates	  
Last	  two	  columns	  are	  designated	  to	  prepare	  the	  NGF	  standard	  curve	  	  
Urine	  samples	  are	  added	  to	  the	  wells	  except	  the	  last	  two	  columns	  of	  the	  ELISA	  plate	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4.1.4.3	  Step	  3:	  	  Anti-­‐	  NGF	  monoclonal	  antibody	  was	  mixed	  with	  NGF	  Block	  &	  Sample	  Buffer	   to	   produce	   the	   recommended	   dilution	   and	   100μl/well	   was	  added	   which	   binds	   to	   the	   captured	   NGF,	   and	   incubated	   overnight	  again	  at	  4°C.	  	  
	  
4.1.4.4	  Step	  4:	  	  The	   following	   day	   the	   plates	   were	   washed	   5	   times.	   Anti-­‐Rat	   IgG,	  horseradish	  peroxidase	   [HRP]	  conjugate	  was	  mixed	  with	  NGF	  Block	  &	   Sample	   Buffer	   to	   produce	   the	   recommended	   dilution	   and	   100μl	  was	   added	   to	   each	  well	   to	   detect	   the	   amount	   of	   specifically	   bound	  monoclonal	  antibody.	  The	   plates	   were	   incubated	   with	   shaking	   for	   2.5	   hours	   at	   room	  temperature;	   and	   then	   washed	   5	   times	   to	   remove	   the	   unbound	  conjugate.	  	  
	  
4.1.4.5	  Step	  5:	  	  And	  the	  final	  step	  is	  addition	  of	  100μ	  of	  [tetramethylbenzidine]	  TMB	  at	   room	  temperature	   to	  each	  well.	  TMB	   is	  a	  chromogenic	  substrate,	  which	  changes	  the	  colour	  of	  the	  solution	  to	  blue	  in	  proportion	  to	  the	  amount	  of	  bound	  beta	  NGF	   in	   the	   sample	   [Figure	  4.	  5]	   .The	  plate	   is	  incubated	  with	  shaking	  for	  10	  minutes	  and	  the	  colour	  reaction	  is	  stopped	  with	  100μl/well	  1N	  hydrochloric	  acid	  and	   this	   changes	   the	  blue	  to	  yellow	  colour	  [Figure	  4.6].	  




Figure	   4.5:	   Addition	   of	   TMB	   changes	   the	   sample	   to	   blue	   colour	   in	  
proportion	  to	  amount	  of	  bound	  NGF	  
	  
Figure	   4.	   6:	   Addition	   of	   hydrochloric	   acid	   stops	   the	   colour	   reaction	   and	  
changes	  the	  blue	  to	  yellow	  colour	  
	  
4.1.5	  Quantification	  of	  NGF:	  Intensity	   of	   colour	   absorbance	   was	   measured	   at	   450nm	   using	   a	  spectrophotometer,	  OptiMax	  micro	  plate	  reader	  (Molecular	  Devices,	  Sunnyvale,	   CA,	   USA)	   within	   30	   minutes	   of	   stopping	   the	   colour	  reaction	   [Figure	   4.7].	   The	   spectrophotometer	   is	   employed	   to	  measure	   the	   amount	   of	   light	   the	   sample	   absorbs	   at	   a	   particular	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wavelength,	   which	   is	   proportional	   to	   the	   concentration	   of	   the	  substance.	  
	  
Figure	  4.7:	  Spectrophotometer,	  which	  measures	   the	  optical	  density	  of	   the	  
samples	  A	  linear	  NGF	  standard	  curve	  [figure	  4.8]	  was	  created	  from	  the	  known	  concentrations	  of	   the	  NGF	  solutions	  produced	  by	  serial	  dilution	  and	  their	  corresponding	  optical	  density.	  	  
	  
Figure	  4.8:NGF	  standard	  curve	  
The	   standard	   curve	   demonstrates	   a	   direct	   relationship	   between	   Optical	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from	   the	  NGF	   standard	   curve.	   This	  was	   done	   by	   using	   curve	   fitting	  analysis.	   In	   SPSS,	   curve	   fitting	   analysis	  was	   used	   to	   check	   different	  regressions	   of	   the	   average	   optical	   density	   of	   the	   last	   two	   columns	  against	   the	   different	   known	   NGF	   standard	   concentrations.	   Cubic	  model	  provided	  the	  best	  fit	  (r2=1)	  and	  using	  cubic	  equation	  the	  NGF	  concentration	  in	  the	  urine	  samples	  was	  calculated	  using	  their	  optical	  densities.	  Values	  below	  zero	  were	  transformed	  to	  0.1	  For	  each	  urine	  sample	  assays	  were	  done	  in	  triplicates	  and	  an	  average	  was	  taken	  as	  done	  by	  other	  researchers(Kuo	  et	  al.	  2010).	  	  
4.2	  Creatinine	  correction:	  	  	  An	  aliquot	  of	  whole	  urine	  was	  also	  used	  to	  measure	  urine	  creatinine.	  Urine	  creatinine	  was	  quantified	  in	  the	  lab	  by	  modified	  Jaffe	  method,	  which	   is	   a	   colorimetric	   method	   used	   for	   measurement	   of	   urine	  creatinine.	  The	   total	  urinary	  NGF	   levels	  were	   further	  normalized	   to	  the	  concentration	  of	  urinary	  creatinine	  (NGF/Cr)	  to	  take	  into	  account	  the	  variation	  in	  urine	  osmolality.	  Urinary	  creatinine	  is	  usually	  used	  to	  correct	   for	   variations	   in	   concentration	   for	   proteomic	   studies	   e.g.	  protein	   creatinine	   ratio	   for	   diagnosis	   of	   preeclampsia(Tyagi	   et	   al.	  2010).	  	  
	  
4.3	  Units	  of	  measurement:	  	  	  NGF/Cr	   concentrations	   were	   multiplied	   by	   factor	   of	   109	   and	   the	  values	  were	  expressed	   in	  ng/g	  units.	   In	   the	   studies	   reported	  by	  Liu	  and	  co	  workers	  NGF/Cr	  concentration	  is	  expressed	  in	  pg/ml.	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4.4	   General	   considerations	   regarding	   storage	   and	  
analysis:	  	  	  A	   standardised	   protocol	   was	   followed	   as	   suggested	   by	   the	  manufacturers.	   The	   materials	   used	   for	   NGF	   quantification	   such	   as	  ELISA	   plates,	   plate	   shaker,	   plate	   reader	   etc.	   were	   as	   per	  recommendations.	  	  Improper	   storage	   of	   reagents	   can	  make	   the	   solutions	   unstable.	   The	  reagents	   in	   the	   assay	   were	   stored	   at	   -­‐20	   0	   C	   until	   analysis.	   Once	  thawed	  the	  reagents	  were	  stored	  at	  40	  C	  and	  were	  used	  within	  three	  months.	  The	  diluted	  reagents	  were	  used	  only	  on	  the	  day	  of	  dilution.	  The	   reagents	  were	   kept	   on	   ice	  while	   carrying	   out	   the	   experiments.	  The	   urine	   sample	   was	   defrosted	   thoroughly	   in	   natural	   conditions	  before	  use.	  Care	   was	   taken	   while	   transferring	   the	   samples,	   antibodies	   and	  reagents	  to	  the	  wells	  in	  the	  ELISA	  plate	  with	  a	  pipette	  since	  pipettes	  can	   scratch	   the	   surface	   of	   the	   wells	   and	   dislodge	   the	   coated	  antibodies.	  Extreme	  care	  was	  taken	  to	  accurately	  dilute	  the	  reagents	  and	  maintain	  pH	  of	  coating	  buffer	  as	  per	  manufacturers	  instructions	  as	  well	  as	  while	  adding	  the	  reagents	  and	  samples	  to	  the	  ELISA	  plate	  by	   using	   calibrated	   pipettes.	   The	   pipette	   tips	   were	   changed	   after	  using	  each	  reagent.	  	  An	  automatic	  plate	  washer	  was	  used	  to	  wash	  the	  plates	  as	  necessary.	  The	   plates	   were	   sealed	   with	   plate	   sealer	   to	   avoid	   exposure	   to	   air	  during	   incubation	   and	   washing.	   A	   timer	   was	   used	   to	   maintain	   the	  specific	   time	   advised	   by	   technical	   bulletin	   for	   incubation,	   washing	  plates,	  shaking	  plates	  and	  for	  colour	  development.	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4.5	  Cost	  issues:	  	  The	  cost	  for	  one	  ELISA	  plate	  is	  £105and	  26	  samples	  can	  be	  analysed	  in	  one	  plate.	   In	  addition	   to	   the	  cost	  of	   the	  ELISA	  kit,	   the	  cost	  of	   the	  consumables	  and	  lab	  facilities	  has	  to	  be	  into	  account.	  
	  
4.6	  Pitfalls	  in	  NGF	  ELISA	  analysis:	  	  Enzyme	   linked	   immunosorbent	   assay	   [ELISA]	   is	   a	   laborious	   -­‐3	   day	  process	  and	  needs	  to	  be	  done	  in	  batches	  with	  no	  rapid	  turn	  over.	  The	  procedure	   needs	   technical	   expertise.	   Urine	   creatinine	   need	   to	   be	  measured	  to	  correct	  for	  urine	  concentration.	  	  There	  is	  room	  for	  error	  in	  ELISA	  analysis	  at	  every	  single	  step	  such	  as	  urine	   sample	   handling,	   sample	   processing,	   centrifugation	   steps	   and	  ELISA	  analysis,	  hence	  manufacturer’s	  instructions	  needs	  to	  be	  strictly	  adhered	   to.	   Obtaining	   a	   perfect	   linear	   NGF	   standard	   curve	   is	  important	   since	   this	  will	   invariably	   affect	   the	   quantification	   of	  NGF	  level	  in	  the	  urine	  samples.	  
 
4.7	  TEST	  RETEST	  RELIABILITY	  	  	  
4.7.1	  Introduction:	  The	   test-­‐retest	   reliability	   of	   currently	   available	   urinary	   NGF	   assays	  by	   ELISA	   has	   not	   yet	   been	   reported	   in	   human	   studies.	   Reliability	  studies	   are	   important	   because	   they	   provide	   information	   about	   the	  amount	   of	   error	   in-­‐built	   in	   any	  measurement,	  which	   influences	   the	  validity	   of	   the	   measurements(Kottner	   et	   al.	   2011).	   Assessment	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outcomes	   cannot	   be	   meaningfully	   reproduced	   or	   interpreted	   if	   the	  tests	  are	  unreliable.	  An	  ideal	  test	  has	  to	  be	  reproducible	  over	  time	  as	  well	  have	  satisfactory	  inter	  and	  intraobserver	  reliability.	  The	   aim	   of	   this	   study	  was	   to	   assess	   the	   intraobserver	   reliability	   of	  urinary	   nerve	   growth	   factor	   (NGF)	  measurement	   by	   enzyme-­‐linked	  immunosorbent	  assay	  (ELISA)	  analysis.	  	  
4.7.2	  Method:	  The	  urine	   samples	   of	   13	   symptomatic	   patients	  who	   reported	   lower	  urinary	   tract	   symptoms	   were	   chosen	   randomly.	   NGF	   assays	   were	  performed	   by	   ELISA	   using	   the	   NGF	   Emax®	   ImmunoAssay	   System	  (Promega,	  Madison,	  WI,	  USA)	  and	  the	  NGF	  assays	  were	  repeated	  four	  weeks	   later.	   The	   assays	   were	   performed	   using	   the	   manufacturer’s	  technical	  bulletin	  as	  described	  previously	  in	  this	  chapter.	  	  The	  same	  two	  researchers	  conducted	  the	  test	  and	  the	  retest	  analysis.	  The	   researchers	   were	   blinded	   to	   patient’s	   symptoms.	   The	   two	  researchers	  performing	   the	  NGF	  assays	  obtained	   training	  by	   expert	  lab	  technicians	  and	  research	  associates	  regarding	  every	  step	  involved	  in	   the	   NGF	   assays.	   The	   data	  were	   not	   normally	   distributed	   using	   a	  one-­‐sample	   Kolmogorov-­‐Smirnov	   test	   with	   a	   p	   value	   of	  0.997;therefore	  non-­‐parametric	  tests	  were	  used.	  	  Median	   values	   of	   the	   two	   measurements	   were	   compared	   using	  Wilcoxon	  signed	  Rank	   test.	   Spearman	  correlation	  was	   run	   to	  assess	  the	  correlation	  between	  the	  two	  measurements.	  	  Test	   retest	   analysis	   of	   NGF	   measurements	   was	   conducted	   using	  Intraclass	   Correlation	   Coefficient	   [ICC]	   to	   assess	   the	   consistency	   of	  measurements	  on	   repeating	   it	   on	   two	  occasions	   .The	  Bland–Altman	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plot	   (difference	   vs.	   mean	   plot)	   was	   used	   to	   show	   the	   degree	   of	  agreement	   between	   the	   measurements.	   In	   this	   plot	   the	   differences	  between	   the	   two	  measurements	   are	  plotted	  against	   the	  averages	  of	  the	   two	   measurements.	   Horizontal	   lines	   are	   drawn	   at	   the	   mean	  difference	   and	   at	   the	   limits	   of	   agreement,	  which	   are	   defined	   as	   the	  mean	   difference	   ±1.96	   times	   the	   standard	   deviation	   of	   the	  differences.	   This	   range	   of	   values	   defines	   the	   95	   %	   limits	   of	  agreement,	   which	   indicates	   an	   interval	   within	   which	   95	   %	   of	  differences	  between	  measurements	  by	  the	  two	  methods	  are	  expected	  to	   lie(Bland	   and	   Altman	   1999,	   Bland	   and	   Altman	   1986).	   	   Analyses	  were	  carried	  out	  using	  SPSS	  version	  20,	  Chicago,	  IL,	  USA.	  	  
	  
4.7.3	  Results:	  There	  was	  no	  significant	  difference	  between	  the	  median	  values	  of	  the	  two	   measurements;	   p	   =0.116[Wilcoxon	   signed	   Rank	   test]	   .The	  median	  values	  and	  the	  interquartile	  ranges	  are	  summarised	  on	  table	  4.1.	  	  	  
Table	  4.1:	  Median	  values	  and	  results	  of	  	  
Values	  are	  expressed	  in	  pg/ml	  and	  standard	  deviation	  is	  shown	  in	  brackets	  	  	  
	  
	  	   Median	  value	  1	  [Interquartile	  range]	  	  
Median	  value	  2	  [Interquartile	  range]	   Z	  value	   P	  NGF	  pg/ml	   10.66[4.32-­‐22.37]	   6.96[2.86-­‐18.64]	   -­‐1.572	   0.116	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There	   was	   a	   strong	   positive	   correlation	   between	   the	   two	  measurements	   rho=0.879;	   p<0.001(Spearman	   correlation	   test).	   On	  test	  retest	  reliability	  analysis	  of	  13	  samples	  there	  was	  almost	  perfect	  reliability	   with	   an	   Intraclass	   correlation	   coefficient	   of	   0.889;	   95%	  C.I=0.676-­‐0.965;p<0.001.	  On	  Bland	  Altman	  plot,	   all	   the	   values	  were	  within	  limits	  of	  agreement,	  see	  figure	  4.9.	  	  	  
	  
	  
Figure	  4.9:	  Bland	  Altman	  plot	  with	  95%limits	  of	  agreement.	  
	  Mean	  NGF	  difference=2.5016[±5.668]	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4.7.4	  Discussion:	  	  This	  study	  is	  the	  first	  to	  report	  test	  retest	   intra	  –observer	  reliability	  of	  urinary	  NGF	  assays,	  which	  offers	  evidence	  that	  it	  is	  a	  reliable	  test	  with	   an	   ICC	   of	   0.889.	   Test-­‐retest	   assessments	   were	   done	   within	   a	  short	  time	  interval	  of	  four	  weeks	  and	  these	  measurements	  represent	  the	   reproducibility	   only	   within	   this	   particular	   time	   interval.	  Measurements	   can	   be	   affected	   by	   prolonged	   intervals	   due	   to	  uncontrolled	   variables	   such	   as	   degeneration	   of	   protein.	   Further	  studies	  with	  large	  numbers	  need	  to	  be	  done	  at	  various	  time	  intervals	  to	   account	   for	   variations	   in	   the	   assays.	   In	   this	   study	   only	   intra	  observer	  reliability	  has	  been	  assessed	  and	  it	  is	  important	  to	  also	  test	  for	  interobserver	  reliability	  in	  future	  studies.	  
  








CHAPTER	  5	  	  
	  
	  
VALIDITY	  OF	  URINARY	  NGF	  MEASUREMENT	  IN	  
WOMEN	  WITH	  LOWER	  URINARY	  TRACT	  
SYMPTOMS	  	  	  	  	  
Hypothesis:	  Urinary	  NGF	  level	  measurement	  is	  not	  a	  valid	  test	  in	  
assessment	  of	  women	  with	  LUTD	  with	  poor	  sensitivity,	  specificity,	  
positive	  and	  negative	  predictive	  values	  and	  has	  no	  discriminatory	  
ability	  to	  differentiate	  the	  different	  symptomatic	  and	  urodynamic	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CHAPTER	  5:	  VALIDITY	  OF	  URINARY	  NGF	  MEASUREMENT	  
IN	  WOMEN	  WITH	  LOWER	  URINARY	  TRACT	  SYMPTOMS	  
	  
5.1	  Introduction:	  	  Over	  recent	  years	  there	  has	  been	  a	  growing	  interest	  in	  developing	  a	  biomarker,	  which	  could	  be	  an	  objective	  measure	  of	  patient	  reported	  symptoms	  in	  diagnosing	  and	  assessing	  treatment	  outcome	  for	  lower	  urinary	  tract	  symptoms	  [LUTS].	  Current	  diagnostic	  strategies	  employ	  various	  tools	  including	  self-­‐completed	  symptom	  scales,	  quality	  of	  life	  questionnaires	   (D.Staskin	   2009,	   Khullar	   2012,	   Shy	   and	   Fletcher	  2013),	  bladder	  diaries	  (Al	  Afraa	  et	  al.	  2012),	  pelvic	   floor	  ultrasound	  (Derpapas	  et	  al.	  2011),	  and	  urodynamics	  (Massey	  and	  Abrams	  1985).	  Although	   there	   is	   good	   evidence	   of	   validity	   for	   patient	   reported	  measures	  (D.Staskin	  2009)	  there	  remains	  concern	  that	  patients	  may	  not	   themselves	   easily	   distinguish	   between	   symptoms	   (Digesu	   et	   al.	  2008),	  and	  that	  such	  scales	  may	  not	  provide	  adequate	  discrimination	  between	   pathophysiological	   complexes	  with	   overlapping	   symptoms	  such	  as	  overactive	  bladder	  (OAB),	  bladder	  pain	  syndrome	  (BPS)	  and	  dysfunctional	  voiding.	  Urodynamics	   is	   commonly	  used	   for	   objective	  diagnosis,	   but	   despite	  decades	   of	   development,	   there	   remain	   concerns	   about	   both	   the	  reliability	   of	   urodynamic	   diagnoses	   (Renganathan	   et	   al.	   2009)	   and	  the	   frequent	  mismatch	   between	   symptoms	   and	   cystometry	   (Digesu	  et	   al.	   2003,	   Hashim	   and	   Abrams	   2006).	   Urodynamics	   is	   also	   an	  expensive	  and	  moderately	  invasive	  test;	  therefore	  it	  is	  reasonable	  to	  develop	  an	  affordable,	  and	  non-­‐invasive	  diagnostic	  tool,	  which	  can	  be	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used	   in	   the	  diagnostic	  work	  up	  of	  patients	  with	   lower	  urinary	   tract	  dysfunction	   [LUTD].	   A	   urinary	   biomarker	   that	   effectively	  discriminated	  between	  different	  types	  of	  bladder	  dysfunction	  would	  be	  valuable	  in	  directing	  management.	  	  Measurement	  of	  urinary	  NGF	  concentrations	  has	  potential	  both	  as	  a	  diagnostic	   biomarker	   for	   LUTD,	   as	   well	   as	   for	   the	   assessment	   of	  therapeutic	  outcome	  in	  patients	  with	  OAB	  (Liu	  et	  al.	  2008,	  Liu,	  Chen,	  et	   al.	   2010).	   However,	   available	   studies	   report	   conflicting	   data	  regarding	  an	  association	  between	  LUTS	  and	  urinary	  NGF,	  and	  there	  is	  limited	  evidence	  for	  the	  validity,	  reliability	  and	  feasibility	  of	  urinary	  NGF	   assays	   in	   this	   population.	   Although	   increased	   urinary	   NGF	  concentrations	   have	   been	   reported	   in	   women	   with	   detrusor	  overactivity	   [DO]	   other	   researchers	   have	   not	   found	   the	   same	  association(Birder	  et	  al.	  2007,	  Kim	  et	  al.	  2006,	  Yokoyama	  et	  al.	  2008).	  Conflicting	   reports	   have	   found	   either	   no	   association	   between	   NGF	  concentrations	   and	   increased	   bladder	   sensation	   (Liu,	   Tyagi,	   et	   al.	  2010),	  or	  highly	  elevated	  NGF	  in	  women	  with	  sensory	  urgency(Lowe	  et	  al.	  1997,	  Yokoyama	  et	  al.	  2008).	  Urinary	  NGF	  levels	  have	  not	  been	  observed	   to	   be	   elevated	   in	  women	  with	   urodynamic	   stress	   urinary	  incontinence	  (Liu	  et	  al.	  2008),	  however	  a	  recent	  study	  in	  a	  rat	  model	  has	   provided	   interesting	   evidence	   linking	   increased	  NGF	   levels	   and	  rat	  model	   of	   SUI	   (Ko	   et	   al.	   2011).	   The	   validity	   of	   urinary	  NGF	   as	   a	  diagnostic	  biomarker	  in	  women	  with	  LUTD	  is	  still	  unclear.	  	  	  	  The	   aim	   of	   this	   study	   was	   to	   compare	   urinary	   NGF	   concentration	  with	  different	  LUTD	  and	  urodynamic	  diagnoses	   and	   to	   evaluate	   the	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validity	   of	   urinary	   NGF	   measurement	   in	   patients	   with	   LUTD	   and	  healthy	  volunteers.	  Although	  urodynamics	  has	   its	  shortcomings	   it	   is	  the	  best	  objective	  test	  available	  for	  evaluating	  LUTD,	  therefore	  it	  was	  used	  as	  a	  reference	  standard	  to	  compare	  the	  validity	  of	  urinary	  NGF	  measurements.	  	  
5.2	  Materials	  and	  methods:	  	  	  Women	   were	   recruited	   from	   a	   tertiary	   urogynaecology	   referral	  centre	   following	   ethical	   approval	   (REC	   reference	   number:	  11/LO/1029)	   into	   this	   case	   control	   study	   from	   October	   2011	   to	  March	  2012.	  	  	  
	  
5.2.1	  Inclusion	  and	  exclusion	  criteria:	  Women	   above	   the	   age	   of	   18	  who	  were	   undergoing	   urodynamics	   to	  investigate	   their	   LUTS	   were	   included	   in	   the	   study.	   Women	   were	  excluded	   if	   they	   had	   a	   history	   of	   neurological	   dysfunction,	   bladder	  cancer,	  bladder	  or	  renal	  calculi,	  previous	  continence	  surgery,	  current	  use	  of	  antimuscarinics	  at	  the	  time	  of	  recruitment,	  presence	  of	  voiding	  dysfunction,	   vaginal	   prolapse	   [≥	   Stage	   II	   on	   POPQ]	   or	   UTI.	  Asymptomatic	   volunteers	   and	   patients	   from	   general	   gynaecology	  clinics	  who	  did	  not	  have	  any	  LUTS	  on	  their	  KHQ	  served	  as	  controls.	  
5.2.2	  Assessment:	  All	   eligible	   symptomatic	   women	   completed	   a	   three-­‐day	   frequency-­‐volume	   chart,	   a	   King’s	   Health	   Questionnaire	   (KHQ)(Kelleher	   et	   al.	  1997),	  and	  underwent	  urodynamics	  in	  accordance	  to	  ICS	  guidelines.	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5.2.3	  Urodynamic	  assessment:	  	  	  Dual	   channel	   cystometry	   was	   performed	   with	   each	   woman	   supine	  and	  the	  bladder	  filled	  through	  a	  10Ffilling	  catheter;	  a	  fluid-­‐filled	  4.5F	  catheter	   was	   used	   to	   measure	   the	   intravesical	   and	   abdominal	  pressures.	   The	   bladder	   was	   filled	   with	   room-­‐temperature	   saline	   at	  100	   mL/min.	   The	   filling	   catheter	   was	   removed	   when	   the	   patient	  developed	  a	   strong	  desire	   to	  void	  or	  500	  mL	  had	  been	   infused	   into	  the	  bladder.	  Provocative	  manoeuvres	  were	  used	  with	  each	  woman	  in	  a	   standing	   position.	  Women	  were	   asked	   to	   cough	   1,	   3,	   and	   5	   times	  with	  maximal	  effort	  and	  then	  listen	  to	  running	  water	  and	  wash	  their	  hands	   in	   cold	   water.	   Finally,	   they	   were	   seated	   for	   a	   pressure-­‐flow	  study	  that	  was	  performed	  in	  private.	  Urodynamics	  was	  carried	  out	  by	  certified	  urodynamicists.	  
5.2.4	  NGF	  assays:	  A	   midstream	   specimen	   of	   urine	   was	   collected	   from	   symptomatic	  patients	   after	   obtaining	   their	   consent,	   prior	   to	   urodynamics	   and	  immediately	   centrifuged	   at	   3000	   rpm	   at	   4	   0	   C	   for	   10	   minutes.	   An	  aliquot	  of	  whole	  urine	  was	  sent	  to	  the	  lab	  for	  measurement	  of	  urine	  creatinine.	  The	  centrifuged	  supernatant	  fluid	  was	  then	  frozen	  at	  -­‐800	  C.	   	   Once	   defrosted	   the	  measurement	   of	   urinary	   NGF	   concentration	  was	   performed	   by	   ELISA	   using	   the	   NGF	   Emax®	   ImmunoAssay	  System	   (Promega,	   Madison,	   WI,	   USA)	   as	   described	   previously	   in	  chapter	  4.	  	  The	   total	   urinary	  NGF	   concentration	  was	   further	   normalized	   to	   the	  concentration	   of	   urinary	   creatinine	   (NGF/Cr).	   Urine	   samples	   from	  asymptomatic	   volunteers	  were	   also	   processed	   to	  measure	   the	   NGF	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concentration.	  The	  NGF	  assays	  were	  done	  between	  3-­‐4	  months	  after	  collection	  of	  the	  urine	  samples.	  The	  researchers	  conducting	  the	  NGF	  assays	   were	   blinded	   to	   the	   patient	   symptoms	   and	   urodynamic	  diagnoses.	  	  
5.2.5	  Group	  stratification	  in	  symptomatic	  patients:	  	  Women	   were	   classified	   into	   symptomatic	   groups	   based	   on	   patient	  reported	  symptoms	  on	  the	  KHQ,	  bladder	  diary	  and	  confirmed	  by	  self-­‐reported	  symptoms.	  Some	  patients	  were	  assigned	  to	  more	  than	  one	  group	   due	   to	   overlapping	   of	   symptoms.	   Women	   who	   reported	  moderate	  or	  severe	  urinary	  urgency	  with	  or	  without	  urgency	  urinary	  incontinence	  were	  classified	  as	  having	  overactive	  bladder.	  They	  were	  classified	  as	  OAB	  wet	  if	  they	  reported	  at	  least	  one	  episode	  of	  urinary	  incontinence	  on	  their	  3-­‐day	  frequency	  volume	  chart.	   	  However	  both	  OAB	  dry	  and	  OAB	  wet	  were	  considered	  as	  one	  group	  for	  analysis	  due	  to	   small	   number	   of	   patients	   in	   the	   OAB	   dry	   group.	   Patients	   who	  reported	   moderate	   or	   severe	   urinary	   incontinence	   with	   physical	  activity	   e.g.	   coughing	   running	   etc.	   were	   classified	   as	   the	   SUI	   group	  Patients	   were	   classified	   as	   having	   Bladder	   pain	   syndrome	   [BPS]	   if	  they	   reported	   to	   have	   bladder	   pain	   for	   at	   least	   for	   six	   months	  duration	   and	   accompanied	   by	   either	   urinary	   urgency	   or	  frequency(van	  de	  Merwe	  et	  al.	  2008).	  
5.2.6	  Statistics:	  	  
Sample	   size	   calculation:	   To	   achieve	   an	   80%	   power	   and	   a	  significance	   of	   .05	   for	   a	   0.60	   standard	   deviations	   difference	   in	  NGF	  level	  between	  groups,	  28	  subjects	  were	  needed	  in	  each	  group	  of	  cases	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and	   controls.	   Shapiro-­‐Wilk	   test	   was	   used	   to	   test	   the	   normality	   of	  NGF/Cr	   values	   and	   the	   values	   were	   not	   normally	   distributed.	  Therefore	  non-­‐parametric	  tests	  were	  used	  for	  statistical	  analysis.	  	  Independent	  sample	  T	  test	  was	  used	  to	  compare	  the	  age	  between	  the	  asymptomatic	   group	  and	   symptomatic	   group.	   Spearman	   correlation	  test	  was	  used	  to	  assess	  the	  relationship	  between	  age,	  voided	  volume	  and	   NGF	   levels	   in	   the	   study	   population.	   Kruskal	   –Wallis	   Test	   was	  used	  to	  compare	  the	  NGF	  levels	  between	  the	  different	  ethnic	  groups	  in	  the	  symptomatic	  group.	  	  	  Urinary	  NGF	  concentrations	  were	  compared	  between	  these	  symptom	  subgroups	  as	  well	  as	  between	  the	  symptomatic	  groups	  and	  controls	  using	   Mann	   Whitney	   U	   test.	   Urinary	   NGF	   concentrations	   were	  compared	   between	   groups	   of	   women	   with	   different	   urodynamic	  diagnoses	   using	   the	   Kruskal	   Wallis	   test.	   Cumulative	   odds	   ordinal	  logistic	   regression	   was	   run	   to	   determine	   the	   association	   between	  increased	   NGF	   levels	   and	   the	   severity	   of	   symptoms	   such	   as	  frequency,	   nocturia,	   urgency,	   urgency	   urinary	   incontinence	   [UUI],	  stress	  urinary	   incontinence	  [SUI]	  and	  bladder	  pain	  [BP]	  as	  reported	  on	   KHQ.	   Odds	   ratios	   were	   also	   calculated	   after	   adjusting	   for	   age.	  Univariate	   and	   multivariate	   logistic	   regression	   was	   performed	   to	  predict	   the	   presence	   of	   urinary	   urgency;	   UUI	   and	   OAB	   using	   NGF	  level	  as	  predictor.	  A	  multivariate	  logistic	  regression	  were	  performed	  to	   ascertain	   the	   effects	   of	   urodynamic	   diagnosis	   and	   age	   on	   the	  likelihood	  of	  participants	  having	  raised	  NGF	  of	  more	  than	  13	  ng	  NGF	  /	  g	  Cr.	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The	   validity	   of	   urinary	   NGF	   concentration	   was	   further	   evaluated	  using	   the	   receiver	   operating	   characteristic	   curve	   to	   determine	   the	  diagnostic	  performance	  of	  measuring	  urinary	  NGF/Cr	  concentration	  in	   differentiating	   the	   symptomatic	   and	   urodynamic	   groups.	  Sensitivity,	   specificity,	   positive	   predictive	   value	   [PPV]	   and	   negative	  predictive	  values]	  NPV]	  of	  diagnosing	  were	  calculated	  using	  a	  cut	  off	  value	  for	  NGF	  levels.	  All	  analyses	  were	  carried	  out	  using	  SPSS	  version	  20,	  Chicago,	  IL,	  USA).	  	  	  
5.3	  Results:	  	  
5.3.1	  Demographics	  of	  the	  study	  population	  A	   total	   of	   236	   women	   were	   recruited.	   Of	   these,	   205	   women	   were	  symptomatic	   with	   LUTS	   and	   had	   undergone	   urodynamics	   and	   the	  remaining	  31	  women	  were	  asymptomatic.	  The	  demographics	  of	   the	  study	  group	  is	  summarised	  on	  table	  5.1.	  There	   was	   a	   significant	   difference	   in	   the	   mean	   age	   between	   the	  asymptomatic	   group	   and	   symptomatic	   group	   (36.5[±11.6]	   vs.	   52.8	  [±13.9]	   Independent	   sample	   T	   test;	   p	   <0.001).	   There	   was	   a	   poor	  positive	   correlation	   between	   the	   age	   and	  NGF	   concentration	   in	   the	  entire	  study	  population	  including	  asymptomatic	  subjects	  [Spearman	  correlation	   rho=	   0.259;p<0.001].	   The	   median	   parity	   of	   the	  symptomatic	  group	  was	  2	  and	  the	  mean	  BMI	  was	  25.2.	  	  There	   was	   no	   significant	   difference	   in	   the	   NGF	   levels	   between	   the	  different	   ethnic	   groups	   in	   the	   symptomatic	   group	   [Kruskal	   –Wallis	  Test;	  p	  =0.217].	  There	  were	  101	  Caucasians,	  23	  Middle	  East,	  21	  Afro	  Caribbean,	  12	  Asians,	  3	  Chinese	  and	  2	  were	  mixed	  race.	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Voided	  volume	  at	  the	  collection	  of	  urine	  sample	  was	  documented	  for	  117	  patients.	   The	  mean	   voided	   volume	  was	  314.14	  ±	  250ml.	   There	  was	   no	   correlation	   between	   NGF	   levels	   and	   the	   voided	   volume	  [Spearman	  correlation	  rho=	  0.045;p=0.629].	  	  	  
Table:	  5.1	  Baseline	  demographics	  and	  clinical	  characteristics	  	  
*Values	  are	  expressed	  as:	  mean	  (standard	  deviation)	  
# 	  Values	  are	  expressed	  as	  median	  (25th-­‐75th	  interquartile	  ranges)	  
NA:	  not	  available	  	  
	  
5.3.2	  NGF	   levels	   and	   association	  with	   patient	   reported	   urinary	  
symptoms:	  
	  
5.3.2.1	  Comparison	  between	  controls	  and	  symptomatic	  groups:	  	  The	   median	   creatinine	   corrected	   NGF	   concentration	   in	   the	  asymptomatic	   group	   of	  women	  was	   significantly	   different	   from	   the	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Controls	  [n=31]	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Symptomatic	  patients	  [n=205]	  Mean	  Age	   36.5(±11.6)*	   52.8(±13.9)*	  Median	  Parity	   NA	   2.0(0	  to	  3)#	  Mean	  BMI	   NA	   25.2	  Mean	  day	  time	  frequency	   6.01[(±1.03)*	   8.07(±3.93)*	  Median	  Nocturia	  	   0	   2.0(1.0	  to	  3.0)#	  	  Ethnic	  groups	   NA	   Documented	  in	  162	  101	   Caucasians,	   23	   Middle	  East,	   21	   Afro	   Caribbean,	   12	  Asians,	  3	  Chinese	  and	  2	  were	  mixed	  race	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median	   creatinine	   corrected	  NGF	   concentration	   in	   the	   symptomatic	  patients	  with	  LUTS	  (2.05	  vs.13.33	  ng	  NGF/	  g	  Cr	  Mann	  Whitney	  test,	  Z	  value-­‐3.899;	  p	  <0.001)	  Figure	  5.	  1.	  There	  was	  a	  similar	  finding	  in	  the	  median	   NGF/Cr	   concentrations	   between	   the	   controls	   and	   the	  different	  individual	  symptomatic	  groups	  [Table	  5.2].	  	   	  	  	  	  	  	  	  	  	  
	  
Table	   5.2:	   Comparison	   of	   NGF/Cr	   concentrations	   between	   controls	   and	  
symptomatic	  groups.	  	  	  
	  
	  
Symptom	  Groups	   n	   Median	  ng	  NGF/	  g	  Cr	  	  [Interquartile	  range]	   p	  (comparison	  with	  controls)	  Control	   31	   2.05[0.1-­‐11.88]	   	  LUTS	  	   205	   13.33[2.98-­‐43.69]	   <0.001	  OAB	  	   165	   14.21[3.50-­‐52.73]	   <0.001	  SUI	   104	   13.97[2.31-­‐53.53]	   <0.001	  BPS	   54	   11.04[3.37-­‐34.84]	   <0.002	  
Figure	   5.1:Median	   NGF	   levels	   in	   controls	   [2.05	   ng	   NGF/g	   Cr]	   and	   patients	   with	  
LUTS	  [13.33	  ng	  NGF/g	  Cr]	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Table	  5.3:	  Comparison	  of	  NGF/Cr	  concentrations	  among	  different	  symptom	  	  
groups.	  	  	  
	   Symptom	  groups	  	   n	   Median	  ng	  NGF/	  g	  Cr	  [Interquartile	  range]	   P	  value	  Group1	   Non	  OAB	   71	   5.78[0.1-­‐18.80]	   <0.001	  OAB	   165	   14.21[3.50-­‐52.73]	  Group2	   Non	  SUI	   132	   10.60[1.90-­‐28.92]	   0.152	  SUI	   104	   13.97[2.31-­‐53.53]	  Group3	   Non	  BPS	   182	   11.29[1.89-­‐35.95]	   0.876	  BPS	   54	   11.04[3.37-­‐34.84]	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Figure	  5.2:Median	  NGF	  levels	   in	  Non	  OAB	  [5.78	  ng	  NGF/g	  Cr]	  and	  subjects	  
with	  OAB	  [14.21	  ng	  NGF/g	  Cr]	  	  
	  	  
Figure	  5.3:Median	  NGF	  levels	  in	  Non	  SUI	  [10.60	  ng	  NGF/g	  Cr]	  and	  subjects	  
with	  SUI	  [13.97	  ng	  NGF/g	  Cr]	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On	   univariate	   logistic	   regression	   analysis	   NGF	   levels	   were	   not	  significant	  predictors	  of	  predicting	  the	  presence	  of	  urgency.	  	  Conversely	  when	  logistic	  regression	  was	  performed	  to	  ascertain	  the	  effects	  of	  NGF	  levels	  on	  the	  likelihood	  of	  participants	  having	  UUI,	  	  NGF	  was	  a	  good	  predictor	  of	  patients	  having	  UUI	  or	  not	  with	  an	  odds	  ratio	  [exp	  B]	  of	  1.005;CI=1.000	  to	  1.011,	  p	  =	  .038.	  This	  means	  that	  for	  every	  unit	  increase	  in	  NGF	  value	  the	  patients	  are	  1.005	  more	  likely	  to	  have	  UUI	  than	  who	  do	  not	  have	  a	  raised	  NGF	  value.	  However	   when	   multivariate	   logistic	   regression	   was	   performed	   to	  assess	   the	   effects	   of	   age	   and	  NGF	  on	  predicting	   participants	   having	  UUI,	   NGF	   was	   not	   a	   good	   predictor	   of	   patients	   having	   UUI	   or	   not	  [highlighted	  in	  red	  on	  table	  5.4].	  	  	  A	  multivariate	  logistic	  regression	  was	  also	  performed	  to	  ascertain	  the	  effects	  of	  age	  and	  NGF	  levels	  on	  the	  likelihood	  of	  participants	  having	  OAB.	   NGF	   was	   a	   good	   predictor	   of	   patients	   having	   OAB	   or	   not.	  Although	   the	   adjusted	   odds	   ratio	   was	   statistically	   significant	  [highlighted	   in	  red	  on	   table	  5.4]	   the	  value	  was	  only	  1.006.The	  Wald	  Chi	   square	   χ2	   	   	   	  values	   and	   adjusted	   odds	   ratios	   are	   summarized	   on	  table	  5.	  4].	  
Table	  5.4:	  Association	  between	  NGF	  levels	  and	  UUI	  symptom	  and	  OAB	  
group	  
	   B	   Standard	  error	  	   Wald	   Chi-­‐	  square	   df	   p	   Adjusted	  Odds	  ratio	  
[Exp	  B]	  
95%	  confidence	  intervals	  Upper	  bound	  	  	  	  	  Lower	  bound	  
UUI	   .005	   .003	   3.518	   1	   .061	   1.005	   1.000	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.010	  OAB	   .005	   .003	   3.933	   1	   .047	   1.006	   1.000	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.011	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5.3.2.3	  Diagnostic	  ability	  of	  urinary	  NGF	  levels	  to	  differentiate	  
symptomatic	  groups:	  When	   ROC	   analysis	   was	   employed	   to	   determine	   the	   diagnostic	  accuracy	   of	   measuring	   urinary	   NGF/Cr	   concentration	   in	  differentiating	   the	   symptomatic	   groups	   and	   controls	   the	  corresponding	  Areas	  Under	   the	  Curve	  were	  high,	   ranging	   from	  0.70	  to	   0.74.	   However	   this	   wasn't	   the	   same	   when	   urinary	   NGF/Cr	  concentration	   measurement	   was	   evaluated	   using	   ROC	   analysis	   to	  discriminate	  various	  symptomatic	  groups.	  The	  Areas	  under	  the	  ROC	  curve,	   SE	   and	   95%CI	   for	   measurement	   of	   urinary	   NGF	   /Cr	  concentration	   in	   the	   different	   symptomatic	   groups	   are	   summarised	  on	   table	   5.5.	   Using	   13.0	   ng/g	   as	   a	   cut	   off	   for	   urinary	   NGF/Cr	  concentration	  the	  test	  provides	  a	  sensitivity	  of	  80.7%	  and	  specificity	  of	  only	  39.4%,	  PPV	  of	  53.33%	  and	  NPV	  of	  70.42%	  in	  diagnosing	  OAB	  among	   patients	  with	   LUTS.	   In	   about	   18%of	   OAB	   group	   the	  median	  NGF	  levels	  were	  below	  2.01ng/g.	  	   	  	  	  	  	  	  	  
	  
	  
Table	  5.5:	  The	  areas	  under	  the	  ROC	  curve	  (Yamauchi	  et	  al.),	  SE	  and	  95%CI	  
for	  measurement	  of	  urinary	  NGF	  concentration	  in	  the	  different	  
symptomatic	  groups	  
Symptoms	  groups	   n	   AUC	   Standard	  error	  	   95%	  confidence	  interval	   p	  Non	  OAB	  	  	  	  	  	  	  	  	  71	  OAB	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  165	   0.66	   .04	   0.58-­‐0.	  73	   <0.001	  Non	  SUI	  	  	  	  	  	  	  	  	  	  132	  SUI	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  104	   0.55	   .04	   0.48-­‐0.	  63	   0.152	  Non	  BPS	  	  	  	  	  	  	  	  	  182	  BPS	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  54	   0.51	   .04	   0.42-­‐0.59	   0.876	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5.3.3.4	  NGF	  levels	  and	  severity	  of	  symptoms:	  	  The	   severity	   of	   symptoms	   as	   reported	   on	   KHQ	   are	   summarised	   on	  table	   5.6.	   On	   ordinal	   regression	   analysis,	   there	   was	   no	   statistical	  significant	  association	  between	  NGF	  values	  and	  the	  different	  severity	  scales	   of	   urinary	   symptoms.	   The	  Wald	   χ2	   	   	   	  values	   and	   the	   adjusted	  odds	  ratio	  for	  age	  are	  summarised	  and	  key	  results	  are	  highlighted	  in	  red	  on	  table	  5.7.	  	  
Table	  5.6:	  Severity	  of	  urinary	  symptoms	  based	  on	  KHQ	  	  	  	   Wald	  Chi-­‐	  square	   df	   p	   Adjusted	   Odds	  
ratio	  
[Exp	  B]	  
95%	  confidence	  intervals	  Upper	  bound	  	  	  	  	  Lower	  bound	  
Frequency	   .108	   1	   .743	   1.000	   .997	   1.002	  Nocturia	   .084	   1	   .771	   1.000	   .997	   1.002	  Urgency	   .009	   1	   .925	   1.000	   .998	   1.003	  UUI	   .033	   1	   .856	   1.000	   .997	   1.002	  SUI	   .580	   1	   .446	   1.001	   .998	   1.004	  BP	   .886	   1	   .346	   .999	   .996	   1.001	  
Table	  5.7:Association	  between	  NGF	  values	  and	  severity	  of	  symptoms	  	  	  
Symptom	  	   Nil	  n	   Mild	  n	   Moderate	  n	   Severe	  n	  Frequency	   11	   24	   57	   62	  Nocturia	   16	   37	   53	   48	  Urgency	   15	   32	   46	   61	  UUI	   35	   28	   43	   48	  SUI	   36	   27	   33	   58	  BP	   81	   27	   30	   16	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5.3.3	  NGF	  levels	  and	  association	  with	  urodynamic	  diagnoses:	  	  On	   comparing	   the	   median	   NGF/Cr	   concentration	   between	   the	  different	   Urodynamic	   diagnoses	   there	  was	   no	   significant	   difference	  	  (Kruskal	   Wallis	   test,	   p	   >0.05),	   as	   shown	   in	   table	   5.8	   below.	   On	  multivariate	   regression	   analysis	   of	   urodynamic	   diagnoses	   and	   age,	  UDS	  diagnosis	  of	  DO	  was	  not	  a	  good	  predictor	  of	  patients	  having	  high	  NGF	  of	  more	  than	  13	  ng	  NGF	  /	  g	  Cr.The	  logistic	  regression	  model	  was	  not	  statistically	  significant	  χ2	  (4)	  =	  7.921,	  p	  =	  .095.	  	  
	  
Table	  5.8:	  Comparison	  of	  NGF/Cr	  concentrations	  between	  different	  
urodynamic	  groups	  
	  
5.3.3.1	   Diagnostic	   ability	   of	   urinary	   NGF	   levels	   to	   differentiate	  
urodynamic	  groups:	  	  On	  applying	  ROC	  analysis	  to	  determine	  the	  diagnostic	  performance	  of	  measuring	   urinary	   NGF/Cr	   concentration	   in	   differentiating	   the	  different	   urodynamic	   groups	   the	   corresponding	   AUC’s	   were	   poor	  
Urodynamic	  Groups	   n	   Median	  	  ng	  NGF/	  g	  Cr	   IQR	   p	  Detrusor	  overactivity	  [DO]	   74	   13.84	   4.02-­‐46.26	   	  	  0.237	  Urodynamic	  stress	  urinary	  incontinence	  [USI]	   31	   20.45	   1.91-­‐82.6	  Mixed	  urinary	  incontinence	  [MUI]	   39	   21.13	   3.23-­‐82.22	  Bladder	  pain/increased	  bladder	  sensation/reduced	  bladder	  capacity	  [BP/IBS/RBC]	  
40	   8.84	   2.46-­‐24.15	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[<0.60].	   The	   areas	   under	   the	   ROC	   curve,	   SE	   and	   95%CI	   for	  measurement	   of	   urinary	   NGF/Cr	   concentration	   in	   the	   different	  Urodynamic	  groups	  are	  summarised	  on	  table	  5.9.	  Using	  13.0	  ng/g	  as	  a	  cut	  off	  for	  urinary	  NGF/Cr	  concentration	  to	  diagnose	  DO	  provided	  a	  sensitivity	  of	  65	  	  %	  and	  a	  specificity	  of	  only	  44%.	  	  	  
	  
	  	  
Table	  5.	  9:	  The	  areas	  under	  the	  ROC	  curve,	  SE	  and	  95%CI	  for	  measurement	  
of	  urinary	  NGF/Cr	  concentration	  in	  the	  different	  Urodynamic	  groups	  	  	  	  	  
5.4	  Discussion:	  	  Nerve	  growth	  factor	  is	  a	  neurotrophic	  factor	  essential	  for	  the	  growth,	  differentiation	   and	   maintenance	   of	   developing	   sensory	   and	  
Urodynamic	  Groups	   n	   AUC	   Standard	  error	   95%	  confidence	  interval	   p	  NO	  DO	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  110	  DO	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  74	   0.51	   .04	   0.43-­‐0.59	   0.83	  NO	  USI	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  153	  USI	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  31	   0.49	   .06	   0.36-­‐0.61	   0.840	  NO	  MUI	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  145	  MUI	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  39	   0.57	   .05	   0.47-­‐0.	  68	   0.161	  NO	  BP/IBS/RBC	  	  	  	  	  	  	  144	  BP/IBS/RBC	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  40	   0.59	   .05	   0.50-­‐0.	  68	   0.067	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sympathetic	  nervous	  system.	  NGF	  has	  been	  implicated	  as	  a	  chemical	  mediator	   in	   bladder	   dysfunction	   being	   released	   by	   urothelium	   and	  smooth	  muscle	  in	  bladder	  dysfunction(Jacobs	  et	  al.	  2010,	  Lowe	  et	  al.	  1997,	  Oddiah	  et	  al.	  1998,	  Okragly	  et	  al.	  1999,	  Steers	  and	  Tuttle	  2006)	  Increased	  levels	  of	  NGF	  could	  lead	  to	  reduced	  thresholds	  or	  increased	  excitability	  of	  bladder	  afferent	  fibres(Dmitrieva	  and	  McMahon	  1996,	  Yoshimura	  and	  de	  Groat	  1999)	  and	  an	  enhanced	  spinal	  reflex	  (Steers	  and	  Tuttle	  2006).	  Change	  in	  sodium	  channel	  properties	  is	  thought	  to	  be	   the	   responsible	  mechanism	   for	   the	   alteration	   in	   conductance	   of	  afferent	   nerves	   (Steers	   and	   Tuttle	   2006,	   Yoshimura	   et	   al.	   2006),	  thereby	   resulting	   in	   OAB.	   It	   has	   been	   proposed	   that	   urinary	   NGF	  could	   be	   used	   as	   a	   diagnostic	   biomarker	   in	   LUTD	   since	   there	   is	  substantial	  evidence	   linking	  NGF	  and	  LUTD	  from	  both	  experimental	  and	  human	  studies.	  Over	  the	  past	   few	  years	  the	  role	  of	  urinary	  NGF	  as	  a	  biomarker	  has	  been	  explored	  in	  various	  studies	  with	  conflicting	  data.	  The	   results	   of	   this	   study	   support	   previous	   evidence	   that	   urinary	  NGF/Cr	   concentration	   is	   increased	   in	   patients	   with	   lower	   urinary	  tract	   symptoms	   especially	   OAB	   (Liu,	   Chen,	   et	   al.	   2010)	   since	   there	  was	   a	   significant	   difference	   in	   the	   Urinary	   NGF/Cr	   concentration	  between	   controls	   and	   patients	   with	   LUTS	   [Table	   5.2]	   as	   well	   as	  patients	   with	   OAB	   and	   non	   OAB	   .However	   this	   was	   not	   the	   same	  when	   other	   symptomatic	   groups	   or	   Urodynamic	   groups	   were	  compared	   [Figure	   5.4]Applying	   ROC	   analysis	   demonstrated	   poor	  discriminant	  ability	  of	  measuring	  NGF/Cr	  concentration	   in	  different	  symptomatic	   groups	   [Table	   5.5]	   as	  well	   as	   in	   different	  Urodynamic	  groups	  [Table	  5.9]	  except	  the	  OAB	  and	  non	  OAB	  group.	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Figure	  5.4:	  Median	  NGF	  values	  in	  the	  different	  urodynamic	  groups	  
Figure	  5.5:	  Area	  under	  the	  ROC	  curve	  for	  measurement	  of	  NGF	  levels	  in	  OAB	  patients	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Contrary	   to	   previous	   evidence	   (Liu	   et	   al.	   2008)	   this	   study	   shows	  significantly	   increased	   levels	   of	   urinary	   NGF	   in	   patients	   with	   SUI	  when	   compared	   to	   controls	   [Table	   5.2]	   that	   support	   the	   evidence	  found	   in	   a	   recent	   animal	   study(Ko	   et	   al.	   2011)	   .	   Overexpression	   of	  NGF	   was	   found	   in	   the	   urethra	   and	   neuronal	   centres	   after	  transabdominal	  urethrolysis	  to	  induce	  stress	  urinary	  incontinence	  in	  rats	   (Ko	   et	   al.	   2011).	   It	   has	   been	  postulated	   that	   loss	   of	   supportive	  tissues	   or	   induction	   of	   smooth	   muscle	   atrophy	   by	   transabdominal	  urethrolysis	  might	  stimulate	  the	  neuronal	  voiding	  centers	  leading	  to	  overexpression	  of	  NGF.	  	  On	  ROC	  analysis	  of	  urinary	  NGF	  concentration,	  areas	  under	  the	  curve	  for	  differentiation	  of	  various	  symptomatic	  groups	  and	  controls	  were	  high	   ranging	   from	   0.70	   to	   0.74,	   which	   substantiates	   results	   from	  other	   research	   groups	   (Liu	   et	   al.	   2011).	   Similarly	   urinary	   NGF/Cr	  concentration	   was	   significantly	   higher	   in	   patients	   with	   OAB	  symptoms	   when	   compared	   to	   individuals	   with	   no	   OAB	   symptoms	  and	   was	   found	   to	   a	   good	   predictor	   of	   subjects	   with	   OAB	   on	  multivariate	  regression	  analysis	   [Table	  5.4].	  However	   the	  same	  was	  not	   seen	   in	   patients	   with	   SUI	   and	   patients	   with	   no	   SUI	   symptoms	  [Table	  5.3].	  	  	  When	   applying	   ROC	   analysis	   to	   assess	   the	   discriminant	   ability	   of	  measurement	  of	  urinary	  NGF/Cr	  concentration	  the	  AUC	  was	  poor	  in	  different	   symptomatic	   groups	   except	   the	   OAB	   and	   non	   OAB	   group	  where	  AUC	  value	  was	  nearly	  0.7	  [Figure	  5.5].	  These	  results	  show	  that	  although	   Urinary	   NGF/Cr	   concentration	   is	   certainly	   increased	   in	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patients	   with	   LUTS	   especially	   in	   OAB,	   it	   cannot	   be	   used	   as	   a	  discriminatory	  tool.	  	  Using	  13.0	  ng/g	  as	  a	  cut	  off	  for	  urinary	  NGF/Cr	  concentration	  the	  test	  provides	   a	   sensitivity	   of	   81%	   and	   specificity	   of	   less	   than	   40	   %	   in	  diagnosing	  OAB	  in	  patients	  with	  LUTS.	  This	  corroborates	  the	  results	  from	   the	   study	  done	  by	  Antunes-­‐Lopes	   and	   group	  who	   reports	   low	  values	  of	  sensitivity	  and	  specificity	   for	  NGF/creatinine	  ratio	  with	  an	  area	  under	  the	  curve	   in	  ROC	  analysis	  of	  only	  0.68(Antunes-­‐Lopes	  et	  al.	  2011).	  However	  Liu	  and	  co	  workers	  have	  reported	  a	  sensitivity	  of	  84.9%	   and	   specificity	   of	   84.5%	   for	   differentiation	   of	   OAB-­‐wet	   and	  controls	   using	   a	   threshold	   value	   of	   0.085	   for	   urinary	   NGF/Cr	  concentration.	   However	   patients	   in	   that	   study	   were	   requested	   to	  drink	  a	  litre	  of	  fluid	  before	  the	  test,	  which	  might	  have	  had	  an	  effect	  on	  the	  NGF	  concentration	  since	  distension	  and	  stretching	  of	  the	  bladder	  has	  shown	  to	  increase	  the	  NGF	  levels(Liu	  et	  al.	  2011)	  .	  	  There	  was	  no	  significant	  association	  between	  NGF	  levels	  and	  severity	  of	   symptoms.	  This	   is	   probably	  due	   to	   increased	   levels	   of	  NGF	   in	   all	  the	   lower	   urinary	   tract	   symptomatic	   groups	   and	   considerable	  overlapping	   of	   lower	   urinary	   tract	   symptoms	   in	   the	   various	   LUTD.	  This	  finding	  supports	  the	  lack	  of	  specificity	  and	  poor	  discriminatory	  power	  of	  NGF	  as	  a	  biomarker	  	  	  The	  diagnostic	  accuracy	  of	  urinary	  NGF	  as	  a	  biomarker	  was	   further	  explored	  by	  using	  urodynamics	  as	   the	  reference	  standard	  since	   it	   is	  the	   best	   available	   objective	   test	   to	   investigate	   patients	   with	   LUTS	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(Martin	  et	  al.	  2006).	  The	  results	  of	  this	  study	  show	  raised	  levels	  in	  	  	  USI	  and	  increased	  bladder	  sensation	  contrary	  to	  results	  found	  by	  Liu	  and	  co	  workers	  (Liu	  et	  al.	  2008,	  Liu,	  Tyagi,	  et	  al.	  2010)	  however	  the	  number	  of	   patients	   in	   their	   urodynamic	   study	   groups	  was	   small.	   In	  this	   study	   there	   was	   no	   significant	   difference	   in	   the	   NGF	  concentration	   between	   the	   different	   Urodynamic	   diagnoses	   [table5.	  8]	   and	   corresponding	   areas	   under	   the	   curve	   indicating	   poor	   test	  performance	  (AUC	  0.49-­‐0.59).	  Using	  13.0	  ng/g	  as	  a	  cut	  off	  for	  urinary	  NGF/Cr	  concentration	  to	  diagnose	  DO	  provided	  a	  poor	  specificity	  of	  only	   44%.	   This	   further	   supports	   the	   poor	   discriminant	   ability	   of	  urinary	  NGF/Cr	  concentration	  in	  patients	  with	  LUTS.	  	  	  Confounding	   factors	   such	   as	   systemic	   disorders	   and	   certain	   drugs	  that	  can	  increase	  the	  NGF	  level	  have	  not	  been	  accounted	  for,	  which	  is	  one	   of	   the	   limitations	   of	   this	   study.	   The	   control	   group	   is	   small,	  however	  on	  sample	  size	  collection	  to	  reach	  a	  statistical	  significance	  of	  .05	  only	  28	  patients	  were	  needed	  in	  each	  group	  which	  was	  achieved.	  The	  strengths	  of	  this	  study	  include	  large	  sample	  size	  especially	  of	  the	  subgroups	  with	   adequate	   power	   for	   clinically	   relevant	   associations.	  The	  results	  from	  this	  study	  have	  added	  new	  information	  with	  regards	  to	  the	  criterion	  validity	  of	  urinary	  NGF	  measurement,	  which	  helps	  in	  bridging	  the	  gaps	  in	  the	  evaluation	  of	  urinary	  NGF	  as	  a	  biomarker	  as	  well	  as	  corroborating	  and	  refuting	  some	  of	  the	  available	  evidence.	  	  	  To	   conclude	   the	   results	   of	   our	   study	   show	   that	   although	   Urinary	  NGF/Cr	   concentration	   is	   certainly	   increased	   in	   patients	   with	   LUTS	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especially	   in	   OAB,	   it	   cannot	   be	   used	   as	   a	   discriminatory	   tool.	   The	  limitations	  of	  urinary	  NGF	  assays	  seem	  to	  be	   low	  specificity,	   lack	  of	  discrimination	  power	  and	  wide	  standard	  deviations.	   It	   is	  difficult	   to	  establish	   normal	   ranges	   for	   NGF	   because	   NGF	   levels	   can	   be	  undetectable	   in	   OAB	   patients.	   Since	   urinary	   NGF	   levels	   are	  significantly	   increased	  in	  patients	  with	  OAB	  they	  may	  have	  a	  role	   in	  clinical	  trials	  as	  well	  as	  be	  used	  to	  monitor	  therapeutic	  interventions	  for	  OAB	  in	  clinical	  practice.	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  









CHAPTER	  6:	  	  	  	  	  
IS	  URINARY	  NGF	  LEVEL	  ASSOCIATED	  WITH	  
CYSTOSCOPY	  OR	  HISTOLOGY	  FINDINGS	  OF	  
BLADDER	  INFLAMMATION?	  
	  	  	  
Hypothesis	  3:	  Urinary	  NGF	  levels	  are	  not	  associated	  with	  
cystoscopic	  and	  histology	  findings	  of	  inflammation	  in	  women	  with	  
refractory	  OAB	  and	  cannot	  be	  used	  as	  a	  non-­‐invasive	  biomarker	  
to	  predict	  the	  inflammatory	  status	  of	  the	  bladder.	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CHAPTER	  6:	  IS	  URINARY	  NGF	  LEVEL	  ASSOCIATED	  WITH	  
CYSTOSCOPY	   OR	   HISTOLOGY	   FINDINGS	   OF	   BLADDER	  
INFLAMMATION?	  	  
6.1	  Introduction:	  	  Overactive	  bladder	  (OAB)	  has	  a	  multi-­‐factorial	  aetiology.	  Recently	   it	  has	  been	  suggested	  that	  urothelial	   inflammation	  plays	  an	   important	  role	  in	  the	  pathogenesis	  of	  OAB	  (Birder	  et	  al.	  2007).	  The	  urothelium	  is	  said	  to	  play	  an	  essential	  role	  in	  bladder	  function	  due	  to	  its	  sensory	  and	   signaling	   properties	   and	   ability	   to	   release	   various	   chemical	  mediators	   and	   transmitters,	   which	   can	   modulate	   the	   afferent	  nerves(Birder	   et	   al.	   2010).	   Supporting	   this	   hypothesis,	   animal	   and	  clinical	  studies	  on	  inflammatory	  biomarkers	  have	  provided	  evidence	  for	   the	  role	  of	   cytokines,	  prostaglandins	  and	  nerve	  growth	   factor	   in	  the	   development	   of	   OAB(Kim	   et	   al.	   2006,	   Steers	   and	   Tuttle	   2006,	  Tyagi	  et	  al.	  2010,	  Zvara	  and	  Vizzard	  2007).	  Chronic	  cystitis	  has	  been	  found	  in	  around	  60-­‐90%of	  patients	  on	  histopathological	  examination	  of	   bladder	   biopsies	   with	   refractory	   OAB	   (Apostolidis	   et	   al.	   2008,	  Digesu	  et	  al.	  2013),	  which	  corroborates	  these	  data	  further.	  	  A	   recent	   animal	   study	   has	   demonstrated	   that	   tolterodine	   has	   no	  effect	  on	  detrusor	  activity	  in	  rats	  with	  chemical	  cystitis	  compared	  to	  a	  sham	  group(Jin	  et	  al.	  2011).	  About	  42-­‐80%	  of	  patients	  with	  OAB	  are	  refractory	   to	   anticholinergic	   treatment(Payne	   and	   Kelleher	   2007)	   .	  Experimental	   studies	   have	   shown	   that	   anti-­‐inflammatory	   treatment	  might	  be	  beneficial	  in	  improving	  the	  overactive	  bladder(Rahnama'i	  et	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al.	   2013,	   Takagi-­‐Matsumoto	   et	   al.	   2004).	   There	   is	   also	   emerging	  evidence	   from	   animal	   and	   clinical	   studies	   that	   subclinical	   bacterial	  infection	   can	   produce	   chronic	   cystitis/OAB	   symptoms	   and	   that	  antibiotics	   might	   be	   effective	   in	   reducing	   refractory	   OAB	  symptoms(Anderson	   et	   al.	   2003,	   Khasriya	   et	   al.	   2010,	   Latthe	   et	   al.	  2008,	   Walsh	   and	   Moore	   2011).	   So	   there	   is	   a	   clear	   need	   for	   more	  research	  towards	  understanding	  the	  pathogenesis	  of	  OAB,	  which	  will	  help	  us	  to	  direct	  the	  treatment	  especially	  in	  the	  refractory	  OAB	  group	  of	  women.	  	  	  If	   urothelial	   inflammation	   is	   one	   of	   the	   causes	   for	   refractory	  overactive	   bladder	   it	   will	   be	   useful	   to	   assess	   if	   the	   urothelial	  inflammation	   resolves	   after	   novel	   treatments	   like	   antibiotics	   and	  anti-­‐inflammatory	   drugs.	   Cystoscopic	   inspection	   of	   bladder	  mucosa	  and	   histopathological	   examination	   of	   bladder	   biopsies	   has	   been	  proposed	  as	  a	  method	  of	  assessing	  urothelial	  inflammation(Digesu	  et	  al.	   2013).	   However	   this	   assessment	   is	   costly,	   invasive	   and	   has	   a	  number	   of	   risks	   associated	   with	   the	   procedure	   such	   as	   infection,	  bladder	  perforation,	  pain	  and	  haematuria.	  A	  non-­‐invasive	  biomarker	  would	   therefore	   be	   useful	   to	   provide	   diagnostic	   information	   about	  the	   inflammatory	   status	   of	   the	   bladder	   and	   it	   could	   be	   useful	   in	  assessing	  the	  therapeutic	  response.	  	  Nerve	  growth	  factor	  (NGF)	  is	  one	  of	  the	  neurotrophic	  factors,	  which	  is	   considered	   as	   a	   key	   regulator	   of	   neurogenic	   inflammation	   in	  several	   tissues(Levi-­‐Montalcini	   et	   al.	   1996)	   including	   the	  bladder(Steers	   2002).	   Increased	   NGF	   levels	   are	   found	   in	   OAB,	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detrusor	  overactivity	  (DO),	  interstitial	  cystitis	  and	  varying	  models	  of	  bladder	   inflammation	   in	   both	   animal	   and	   human	   studies	   (Liu	   et	   al.	  2010,	  Steers	  2002,	  Steers	  et	  al.	  1991).	   Increased	  urinary	  NGF	   levels	  in	   OAB	   might	   therefore	   be	   associated	   with	   severity	   of	   bladder	  inflammation	   and	   may	   be	   used	   as	   a	   non-­‐invasive	   biomarker	   to	  predict	   the	   inflammatory	   status	   of	   bladder	   if	   it	   correlates	   with	  cystoscopy	  and	  histology	  findings.	  	  Therefore	   the	   aim	   of	   this	   study	   was	   to	   evaluate	   the	   relationship	  between	   urinary	   Nerve	   Growth	   Factor	   levels	   and	   cystoscopic	   and	  histology	  findings	  of	  bladder	  inflammation	  in	  women	  with	  refractory	  OAB.	  
	  
6.2	  Methodology:	  Women	   with	   OAB	   symptoms	   who	   were	   resistant	   to	   conservative	  management	   (e.g.	   lifestyle	   modifications,	   bladder	   retraining	   and	  physiotherapy)	  and	  two	  or	  more	  anticholinergics	  were	  recruited	  into	  this	   cross	   sectional	   study.	   All	   women	   were	   studied	   with	   vaginal	  examination	   using	   a	   pelvic	   organ	   prolapse	   quantification	   system	  (POP-­‐Q)	   bladder	   diary,	   urinalysis,	   Kings	   Health	   Questionnaire,	  Patient	  perception	  of	  bladder	  condition	  [PPBC],	  Patients’	  Perception	  of	   Intensity	   of	   Urgency	   Scale	   [PPIUS]	   urodynamics	   and	   kidney–ureter–bladder	   ultrasound	   scans	   as	   per	   the	   unit	   protocol.	   Women	  were	   excluded	   if	   they	   had	   a	   neurological	   condition,	   pelvic	   organ	  prolapse,	   voiding	   dysfunction,	   urinary	   tract	   infection,	   bladder	   pain,	  bladder	  cancer	  or	  calculi.	  All	  participants	  were	  counselled,	  consented	  and	   investigated	   with	   a	   rigid	   cystoscopy,	   hydrodistension	   and	  bladder	   biopsy	   under	   general	   anaesthesia.	   Only	   those	  women	  with	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detrusor	   overactivity	   on	   urodynamics	   and	   cystoscopic	   evidence	   of	  bladder	   inflammation	   and	   histological	   confirmation	   of	   chronic	  cystitis	   were	   included	   in	   the	   study.	  Women	  were	   excluded	   if	   there	  was	  a	   cystoscopic	   appearance	  of	   interstitial	   cystitis	   as	  described	  by	  the	  European	  Society	  for	  the	  Study	  of	  interstitial	  cystitis	  (ESSIC)	  e.g.	  glomerulation	  grades	  2–3,	  and	  Hunner’s	   lesion	  (van	  de	  Merwe	  et	  al.	  2008).	  	  	  Participants	  provided	  clean	  catch	  mid-­‐stream	  urine	  samples	  prior	  to	  undergoing	   rigid	   cystoscopy.	   Urine	   samples	   from	   asymptomatic	  volunteers	  from	  general	  gynaecology	  clinics	  who	  did	  not	  complain	  of	  any	  lower	  urinary	  tract	  symptoms	  were	  also	  collected	  and	  processed	  to	  measure	  the	  NGF	  levels.	  	  Urine	  samples	  were	  immediately	  centrifuged	  at	  3000	  rpm	  at	  4	  0	  C	  for	  10	  minutes.	  An	  aliquot	  of	  whole	  urine	  was	  also	  used	  to	  measure	  urine	  creatinine.	  The	  centrifuged	  supernatant	  fluid	  was	  then	  frozen	  at	  -­‐800	  C	   until	   further	   processing.	   	   Once	   defrosted	   the	   measurement	   of	  urinary	  NGF	   concentration	  was	   performed	   by	   ELISA	   using	   the	  NGF	  Emax®	   ImmunoAssay	   System	   (Promega,	   Madison,	   WI,	   USA)	   as	  described	   on	   chapter	   4.	   The	   total	   urinary	   NGF	   levels	   were	   further	  normalized	  to	  the	  concentration	  of	  urinary	  creatinine	  (NGF/Cr	  level).	  	  	  Rigid	   cystoscopy	  with	  70-­‐degree	   cystoscope	  was	  performed	  only	   in	  symptomatic	  women	   under	   general	   anaesthesia	   after	   emptying	   the	  bladder.	   The	   bladder	   was	   distended	   with	   water	   and	   cystoscopic	  findings	  of	  presence	  or	  absence	  of	  trigonitis,	  erythema	  (vascularity),	  trabeculations,	   glomerulations,	   diverticulum,	   hunner’s	   ulcer	   and	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space	   occupying	   lesions	   were	   recorded.	   Presence	   of	   erythema	  [figures	  6.1-­‐	  6.3]	  was	   classified	  as	  mild	   if	   increased	  vascularity	  was	  present	   in	   <	   1	   quadrant,	   as	  moderate	   if	   present	   in	   >1	   quadrant	   (<	  50%	   bladder);	   and	   severe	   if	   present	   >1	   quadrant	   (>50%	   bladder).	  The	   classification	   of	   severity	   of	   vascularity	   was	   adapted	   from	   the	  Denson	   and	   colleagues	   classification	   of	   bladder	  glomerulation(Denson	   et	   al.	   2000)	   .	   The	   severity	   of	   bladder	  trabeculation	  was	  classified	  using	  the	  modified	  grading	  system	  of	  El	  Din	   et	   al,	   as	   0	   (none),	   1	   (slight),	   2	   (moderate),	   3	   (severe),	   and	   4	  (severe,	  with	  diverticula)(el	  Din	  et	  al.	  1996)[figures	  6.	  4	  &	  6.5].	  	  The	   bladder	   was	   drained,	   refilled	   and	   examined	   for	   refill	  haemorrhages.	  Finally	  deep	  bladder	  biopsy	  was	  taken	  using	  0	  degree	  cystoscope	  and	  cold	  cup	  biopsy	  forceps	  from	  the	  most	  erythematous	  area.	  The	  biopsy	  site	  was	  diathermised	  and	  the	  biopsy	  specimen	  was	  sent	  to	  the	  histopathology	  lab.	  The	  procedure	  was	  performed	  either	  by	  the	  two	  urogynaecologists	  or	  subspecialty	  trainee	  in	  the	  unit.	  	  	  Each	   biopsy	   was	   rated	   for	   cystitis	   (mild,	   moderate,	   severe)	   by	   a	  histopathologist	   blinded	   to	   clinical	   data.	   The	   bladder	   histology	  was	  classified	   according	   to	   a	   reproducible	   technique	   which	   has	   been	  previously	  described(Thilagarajah	  et	  al.	  1997).	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  Figure	  6.1:Normal	  appearance	  of	  bladder	  mucosa	  	  
	  Figures	  6.2	  &	  6.	  3:	  severe	  erythema	  	  	  	  
	  	  Figure	  6.4:	  Mild	  trabeculation	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  6.	  5:Moderate	  trabeculation	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Statistics:	   No	   sample	   size	   calculation	   could	   be	   carried	   out	   as	   this	  type	  of	  study	  has	  not	  been	  carried	  out	  previously	  and	  therefore	  this	  study	  is	  to	  be	  regarded	  as	  a	  pilot	  study.	  The	  NGF	  data	  was	  non-­‐parametric	  and	  therefore	  the	  median	  urinary	  NGF	   levels	   were	   compared	   with	   a	   control	   group	   of	   asymptomatic	  women	   using	   the	   Mann	  Whitney	   U	   test.	   Spearman	   correlation	   test	  was	  used	   to	   assess	   the	   correlation	  between	  urinary	  NGF	   levels	   and	  age.	   Cumulative	   odds	   ordinal	   logistic	   regression	   was	   run	   to	  determine	   the	   association	   between	   increased	   NGF	   levels	   and	   the	  severity	   of	   trigonitis,	   erythema	   and	   trabeculation	   on	   cystoscopy	   as	  well	  as	  grades	  of	  cystitis	  on	  histology.	  Odds	  ratio	  was	  also	  calculated	  after	   adjusting	   for	   age.	   All	   analyses	   were	   carried	   out	   using	   SPSS	  version	  20,	  Chicago,	  IL,	  USA.	  	  
6.3	  Results:	  	  In	  total	  76	  patients	  were	  recruited	  and	  9	  patients	  were	  excluded	  due	  to	   reasons	  summarised	  on	   table	  6.1.	   In	  addition	  MSU	  samples	  were	  collected	  from	  31	  asymptomatic	  women	  who	  served	  as	  controls.	  	  n	   Reason	  for	  exclusion	  4	   Not	  enough	  tissue	  for	  histology	  2	   Normal	  on	  histology	  1	   Bladder	  tumour	  2	   Signs	  of	  interstitial	  cystitis	  1-­‐presence	  of	  hunner’s	  ulcer	  1-­‐detrusor	   mastocytosis	   >	   28	   mast	  cells/mm2	  on	  histology	  
Table	  6.1:	  Reasons	  for	  exclusion	  from	  study	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  The	   demographics	   of	   the	   study	   group	   are	   summarised	   on	   the	   table	  6.2.	  There	  was	  a	  significant	  difference	   in	   the	  mean	  age	  between	  the	  asymptomatic	   group	   and	   symptomatic	   group	   (36.5[±11.6]	   vs.	   53.3	  [±14.7]	  Independent	  sample	  T	  test;	  p	  <0.001).	  However	  there	  was	  a	  very	  weak	  correlation	  between	  the	  age	  and	  NGF	  concentration	  in	  the	  symptomatic	  group	  [Spearman	  correlation	  rho=	  0.350].	  The	  median	  creatinine	  corrected	  NGF	  concentration	  in	  the	  asymptomatic	  group	  of	  women	   was	   significantly	   different	   from	   the	   median	   creatinine	  corrected	   NGF	   concentration	   in	   the	   symptomatic	   groups	   (2.05	  vs.10.58	  ng	  NGF/	  g	  Cr	  Mann	  Whitney	   test,	  Z	  value-­‐3.267;	  p	  <0.001)	  [figure	  6.6].	  	  	  
Table:	  6.2	  Baseline	  demographics	  and	  clinical	  characteristics	  of	  patients.	  	  
*Values	  are	  expressed	  as:	  mean	  (standard	  deviation)	  
# 	  Values	  are	  expressed	  as	  median	  (25th-­‐75th	  interquartile	  ranges)	  
Mean	  Age	   53.3(±14.7)*	  Mean	  duration	  of	  symptoms	  	  (months)	   26	  (±7.3)*	  Median	  Parity	   2.0(0	  to	  3)#	  Median	   Number	   of	   antimuscarinics	  tried	   3.0(2.0	  to	  4.0)#	  Mean	  day	  time	  frequency	   9.10(±2.88)*	  Median	  Nocturia	  	   2.0(1.0	  to	  3.0)#	  	  PPBC	  scores	   5.0	  (4.0	  to	  6.0)#	  PPIUS	  scores	   4.0(2.0	  to	  5.0)#	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Figure	  6.6:	  Scatter	  plot	  showing	  ng	  NGF/	  g	  Cr	  values	   in	  OAB	  and	  non-­‐OAB	  
groups.	  
Median	  ng	  NGF/	  g	  Cr	  values	  [	  25th	  –	  75	  th	  interquartile	  ranges]	  
OAB	  group	  –	  10.58[2.87-­‐20.48];	  Non-­‐OAB	  group-­‐	  2.05[0.1-­‐11.88]	  	  All	   the	   symptomatic	   patients	   had	   detrusor	   overactivity	   on	  urodynamics	  and	  of	  these	  seven	  patients	  had	  both	  urodynamic	  stress	  urinary	   incontinence	   and	   detrusor	   overactivity.	   The	   cystoscopy	  findings	   are	   summarised	   on	   table	   6.3.	   On	   histopathological	  examination	  there	  was	  mild	  chronic	  cystitis	   in	  54[80.6%],	  moderate	  chronic	  cystitis	  in	  11[16.4%]	  and	  severe	  chronic	  cystitis	  in	  two	  [3%]	  patients.	  	  	   Nil	  	  n	  [%]	   Mild:	  	  n	  [%]	   Moderate	  	  n	  [%]	   Severe	  n[%]	  Trigonitis	   8[11.9%]	   10[14.9%]	   21[31.3%]	   28[41.8%]	  Erythema	   3[4.5]	   19[28.4%]	   31[46.3%]	   14[20.9%]	  Trabeculation	   -­‐	   28[41.8%]	   31[46.3%]	   8[11.9%]	  
Table	  6.	  3:Cystoscopy	  findings	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On	   ordinal	   regression	   analysis	   there	   was	   no	   statistical	   significant	  association	  between	  NGF	  values	   and	   the	  different	   severity	   scales	  of	  trigonitis,	   trabeculation,	   erythema	  and	   cystitis.	  On	  adjusting	   for	   age	  the	  odds	  ratio	  did	  not	  change	  significantly.	  The	  Wald	  χ2	  	  	  	  values	  and	  the	   odds	   ratio	   are	   summarised	   on	   table	   6.4	   with	   key	   values	  highlighted	  in	  red.	  	  	  	  	   Wald	  Chi-­‐square	   df	   p	   Odds	  ratio	  
[Exp	  B]	  
Adjusted	  Odds	  ratio*	  [Exp	  B]	  
P*	  
Trigonitis	   2.443	   1	   .118	   .982	   .991	   .427	  Erythema	   .463	   1	   .144	   .979	   .977	   .471	  Trabeculation	   .872	   1	   .350	   .989	   .992	   .546	  Cystitis	   on	  histology	   .554	   1	   .457	   .983	   .986	   .408	  
Table	   6.4:	   Association	   between	   NGF	   values	   and	   cystoscopy	   and	   histology	  
findings	  based	  on	  their	  severity	  scale	  
*Odds	  ratio	  adjusted	  for	  age	  and	  p	  value	  	  
6.4	  Discussion:	  	   	  	  NGF	  is	  produced	  and	  utilized	  by	  neuronal	  and	  several	  non-­‐neuronal	  cell	  types	  including	  immune	  cells,	  inflammatory	  cells,	  epithelial	  cells,	  and	   smooth	   muscle	   cell(Aloe	   et	   al.	   1997,	   Birder	   et	   al.	   2010).	  	  Numerous	   inflammatory	   cytokines,	   including	   interleukin	   (IL)-­‐1,	  tumour	  necrosis	  factor	  (TNF)-­‐α	  and	  IL-­‐6,	  can	  induce	  NGF	  production	  in	  non-­‐neuronal	   cell	   types,	   such	  as	   fibroblasts,	   endothelial	   cells	  and	  glial	   cells(Birder	  et	  al.	  2010).	   	   Interestingly	  NGF	  has	  been	  shown	   to	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increase	  the	  expression	  of	  sensory	  neuropeptides	  such	  as	  substance	  P,	  CGRP	  and	  other	  neuropeptides	  (Schnegelsberg	  et	  al.	  2010)	  which	  are	   released	   peripherally	   and	   centrally	   and	   can	   initiate	   local	  neuroinflammatory	   responses	   as	   well	   as	   enhance	   sensory	   neuron	  excitability	  (Zvara	  and	  Vizzard	  2007).	  	  	  Experiments	  done	  in	  rodents	  have	  shown	  that	  chemical	  inflammation	  induced	   using	   formalin,	   cyclophosphamide	   or	   foreign	   body	   irritant	  such	   as	   chromic	   catgut	   and	   bacterial	   cystitis	   induced	   using	  lipopolysaccharide	   is	   associated	   with	   increased	   NGF	   levels	   and	  morphological	   changes	   in	   the	   sensory	   and	   motor	   neurons	  innervating	  the	  bladder	  as	  well	  as	  bladder	  overactivity(Dupont	  et	  al.	  2001,	  Hu	  et	  al.	  2005).	  	  The	  use	  of	  NGF	  sequestering	  protein	  REN	  1820	  in	   rodents	   with	   chemical	   induced	   cystitis	   reduced	   the	   bladder	  overactivity(Hu	  et	   al.	   2005).Human	   studies	  have	  demonstrated	   that	  serum	  NGF,	  urinary	  NGF	   levels	  as	  well	   as	   serum	  C-­‐reactive	  protein,	  which	   are	   inflammatory	   markers,	   are	   significantly	   elevated	   in	  patients	  with	  OAB	  compared	  with	  controls(Chung	  et	  al.	  2011,	  Liu	  et	  al.	  2011).	  Serum	  NGF	  levels	  also	  highly	  correlated	  with	  urinary	  NGF	  levels.	  These	  data	  from	  human	  studies	  seem	  to	  support	  the	  evidence	  in	   experimental	   studies	   linking	   NGF,	   inflammation	   and	   overactive	  bladder.	  	  	  In	  order	  to	  explore	  this	  link	  further	  this	  current	  study	  was	  conducted	  to	  assess	  if	  there	  is	  an	  association	  between	  NGF	  levels	  and	  cystoscopy	  or	   histology	   findings	   in	   women	   with	   OAB	   and	   DO.	   There	   was	   a	  statistical	   significant	   difference	   in	   the	   NGF	   levels	   between	   OAB	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patients	  and	  non-­‐OAB	  patients.	  	  All	  patients	  were	  found	  to	  have	  some	  degree	   of	   trabeculation	   and	   at	   least	   90%	   of	   patients	   had	   erythema	  and	  trigonitis.	  All	  patients	  with	  OAB	  had	  evidence	  of	  chronic	  cystitis	  with	   the	   majority	   (81%)showing	   mild	   chronic	   cystitis,	   which	   is	  similar	  to	  previous	  studies	  of	  patients	  with	  refractory	  OAB.	  However	  there	  was	   no	   statistical	   significant	   association	   between	  NGF	   values	  and	  the	  different	  severity	  scales	  of	  trigonitis,	  trabeculation,	  erythema	  and	   cystitis	   which	   questions	   whether	   the	   visual	   appearance	   of	   the	  bladder	   is	   a	   valid	  method	  of	   assessing	  bladder	   inflammation	  or	   the	  severity	  of	  the	  cases	  was	  similar	  such	  that	  the	  tools	  could	  not	  be	  used	  to	  discriminate	  between	  the	  different	  patients.	  	  	  Only	  patients	  with	  a	  diagnosis	  of	  detrusor	  overactivity	  and	  refractory	  OAB	  symptoms	  were	   included	   in	   this	   study	   in	  order	   to	   reduce	  bias.	  Patients	   with	   refractory	   OAB	   and	   DO	   were	   studied	   since	   it	   was	  suspected	   that	   these	   patients	   might	   have	   a	   higher	   degree	   of	  inflammation.	   Unfortunately	   without	   a	   group	   of	   OAB	   patients	   who	  responded	   to	   conventional	   treatment	   to	   compare	   we	   do	   not	   have	  data	  to	  support	  this	  hypothesis,	  which	  is	  one	  of	  the	  drawbacks	  of	  this	  study.	  	  	  This	   study	  exploring	   the	  role	  of	  NGF	  as	  an	   inflammatory	  biomarker	  did	  not	  find	  an	  association	  between	  the	  increased	  NGF	  levels	  and	  the	  severity	   of	   cystoscopy	   findings.	   This	   could	   be	   because	   urinary	  NGF	  may	   be	   a	   poor	   biomarker	   of	   bladder	   inflammation	   or	   cystoscopy	  findings	   itself	   may	   be	   poor	   indicators	   of	   bladder	   inflammation.	   In	  addition	  the	  rating	  of	  cystoscopy	  findings	  could	  be	  subjective	  which	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could	  have	  influenced	  the	  results.	  The	  role	  of	  cystoscopy	  and	  biopsy	  is	  of	  doubtful	   significance	   in	   female	  urinary	   incontinence	  and	   is	  not	  routinely	  recommended	  (Tubaro	  2009).	  However	  a	  recent	  study	  has	  shown	  that	  bladder	  trabeculations	  were	  significantly	  associated	  with	  DO	   and	   UUI	   when	   compared	   to	   patients	   with	   no	   trabeculations	  (Liang	   et	   al.	   2013).	   In	   another	   study	   the	  presence	  of	   trabeculations	  and	   increased	   vascularity	   was	   present	   in	   around	   70%	   of	   patients	  with	  chronic	  cystitis	  and	  refractory	  OAB	  and	  was	  also	  found	  to	  have	  a	  positive	  predictive	  value	  of	  over	  80%	  for	  chronic	  cystitis	   (Digesu	  et	  al.	  2013).	  	  	  There	  was	  evidence	  of	  chronic	  cystitis	   in	  all	  patients	  of	   this	  present	  study	   with	   refractory	   OAB	   symptoms	   which	   supports	   the	   findings	  found	   in	   experimental	   studies.	   Chronic	   cystitis	   induced	   in	   rodents	  resulted	  in	  increased	  NGF	  levels	  and	  bladder	  overactivity	  (Dmitrieva	  et	  al.	  1997)	  as	  well	  as	  varying	  degrees	  of	  oedema,	  vasodilatation	  and	  inflammatory	   cell	   infiltrates	  on	  histological	   analysis	   of	   bladder	  wall	  (Dupont	   et	   al.	   2001,	   Hu	   et	   al.	   2003).	   Similar	   to	   the	   findings	   in	   the	  animal	   models	   histological	   evidence	   of	   bladder	   inflammation	   has	  been	  found	  in	  patients	  with	  neurogenic	  DO	  as	  well	  as	  idiopathic	  OAB	  on	  histology(Comperat	  et	  al.	  2006,	  Loran	  et	  al.	  2007).	  	  	  There	  was	  no	  association	  between	  the	  increased	  NGF	  levels	  and	  the	  severity	  of	   cystitis	   in	   this	   study.	  This	  could	  be	  because	  urinary	  NGF	  may	  be	  a	  poor	  biomarker	  of	  bladder	  inflammation.	  Bladder	  biopsy	  of	  a	  small	  area	  may	  not	  be	  representative	  since	  a	  previous	  study	  did	  not	  find	  any	  correlation	  between	  the	  severity	  of	  cystoscopy	  and	  histology	  
	  	  	  	  
120	  
findings	  (Denson	  et	  al.	  2000).	  Limitations	  of	  this	  study	  include	  lack	  of	  control	  group	  and	  also	  unequal	  numbers	  in	  the	  subgroups	  in	  addition	  to	  those	  discussed	  above.	  The	   significantly	   increased	   NGF	   levels	   in	   the	   symptomatic	   group	  compared	   to	   controls	   could	   be	   explained	   by	   the	   presence	   of	  overactive	  bladder.	  However	  these	  increased	  NGF	  values	  did	  not	  add	  to	   the	  prediction	  of	   severity	   in	  erythema,	   trigonitis	  or	   trabeculation	  on	  cystoscopy	  or	  cystitis	  on	  histology	   therefore	  urinary	  NGF	  should	  not	  be	  considered	  as	  a	  surrogate	  marker	  of	  bladder	  inflammation.	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  
121	  
	  	  	  	  	  	  	  	  	  	  	  	  
CHAPTER	  7	  	  
	  
DO	  URINARY	  NGF	  LEVELS	  ALTER	  IN	  WOMEN	  WHO	  HAVE	  
HAD	  IMPROVEMENT	  IN	  THEIR	  OAB	  SYMPTOMS	  AFTER	  
ANTERIOR	  COLPORRHAPHY	  FOR	  VAGINAL	  PROLAPSE?	  	  	  
	  
Hypothesis:	  NGF	  levels	  do	  not	  change	  in	  women	  who	  have	  had	  an	  	  
improvement	  in	  their	  overactive	  bladder	  symptoms	  after	  anterior	  	  
colporrhaphy.	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CHAPTER	  7:	  DO	  URINARY	  NGF	  LEVELS	  ALTER	  IN	  WOMEN	  
WHO	   HAVE	   HAD	   IMPROVEMENT	   IN	   THEIR	   OAB	  
SYMPTOMS	   AFTER	   ANTERIOR	   COLPORRHAPHY	   FOR	  
VAGINAL	  PROLAPSE?	  
	  
7.1	  Introduction:	  	  	  Urinary	  Nerve	  growth	   factor	  (NGF)	   levels	  are	  significantly	  higher	   in	  patients	  with	  bladder	  outlet	  obstruction	  (BOO)	  compared	  to	  controls	  (Liu	  and	  Kuo	  2008).	  Steers	  et	  al	  demonstrated	  about	  two	  decades	  ago	  that	   bladder	   outlet	   obstruction	   in	   rodents	   was	   associated	   with	  bladder	   hypertrophy	   and	   increased	   urinary	   frequency.	   There	   was	  also	   evidence	   of	   hypertrophy	   of	   dorsal	   root	   ganglia	   that	   provide	  sensory	   afferent	   fibres	   to	   the	   bladder	   and	   increased	   growth	   of	  afferent	   and	   efferent	   neurons.	   Hypertrophied	   bladders	   contained	  significantly	  more	  NGF	  levels	  than	  normal	  bladders.	   	  The	  rise	   in	  the	  NGF	  levels	  occurred	  before	  the	  neuronal	  hypertrophy	  and	  increased	  urinary	   frequency.	   Corroborating	   these	   findings,	   autoimmunity	   to	  NGF	  was	  found	  to	  reduce	  the	  neuronal	  hypertrophy	  (Steers,	  Kolbeck	  et	  al.	  1991).	  	  Chronic	   BOO	   results	   in	   stretching	   of	   the	   urothelium	   and	   smooth	  muscle,	  which	   can	   stimulate	  NGF	   production.	   In	   vitro	   experimental	  models	  on	  rats	  have	  demonstrated	  that	  repetitive	  stretch	  stimulation	  of	   bladder	   smooth	   muscle	   cells,	   which	   mimics	   the	   effects	   of	   outlet	  obstruction,	   resulted	   in	   increased	  expression	  of	   a	   variety	  of	   growth	  factors	   like	  NGF	  (Persson,	  Sando	  et	  al.	  1995,	  Yamaguchi	  2004).	  This	  increased	   NGF	   production	   is	   postulated	   to	   partly	   contribute	   to	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enhanced	  spinal	  reflex	  and	  overactive	  bladder	  [OAB].	  Bladder	  outlet	  obstruction	   is	   uncommon	   in	   women	   however	   anterior	   wall	  prolapse/cystocele	  is	  common	  and	  the	  relationship	  between	  anterior	  vaginal	  wall	  prolapse	  and	  NGF	  levels	  have	  not	  been	  studied	  so	  far.	  	  Women	   with	   anterior	   vaginal	   wall	   prolapse	   frequently	   suffer	   with	  overactive	   bladder	   symptoms.	   Prevalence	   of	   OAB	   in	   patients	   with	  pelvic	  organ	  prolapse	  ranges	  widely	  from	  16%-­‐88%	  and	  prevalence	  of	  detrusor	  overactivity	  ranges	  from	  10-­‐50%	  (de	  Boer,	  Salvatore	  et	  al.	  2010).	   Several	   mechanisms	   are	   thought	   to	   play	   a	   role	   in	   the	  pathophysiology	   of	   OAB	   in	   patients	   with	   prolapse	   including	  obstructive,	  myogenic	  and	  neurogenic	  factors(de	  Boer,	  Salvatore	  et	  al.	  2010,	  Patil	  and	  Duckett	  2010).	  	  Overactive	   bladder	   symptoms	   have	   been	   shown	   to	   improve	  significantly	   after	   anterior	   colporrhaphy.	   Postoperatively	   urinary	  frequency,	  urgency	  and	  urge	  incontinence	  disappeared	  in	  60,	  70	  and	  82%	  of	  women	  respectively	  (p	  value	  <	  0.001).	  Improvement	  of	  OAB	  was	  not	   seen	   in	  all	   cases(Digesu,	  Salvatore	  et	  al.	  2007).	  Similarly	   in	  other	  studies,	  anterior	  repair	  was	  associated	  with	  49%	  reduction	   in	  urgency	   urinary	   incontinence	   (Fletcher,	   Haverkorn	   et	   al.	  2010)resolution	  of	  urgency	   in	  55%	  of	  patients	  and	   improvement	   in	  19%	   of	   patients(Duckett	   and	   Chakani	   2013)	   .A	   recent	   study	   has	  found	  an	   improvement	   in	  urinary	   frequency	  and	  urgency	  as	  high	  as	  85-­‐89%	   in	   patients	   who	   underwent	   apical	   and	   or	   anterior	  repair(Miranne,	  Lopes	  et	  al.	  2013)	  .	  It	  was	  hypothesized	  that	  patients	  with	  anterior	  vaginal	  wall	  prolapse	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have	   increased	   NGF	   levels	   compared	   to	   controls	   since	   BOO	   and	  bladder	  wall	  stretching	  have	  been	  postulated	  as	  causes	  for	  increased	  NGF	   levels.	   It	   was	   also	   postulated	   that	   if	   increased	   NGF	   levels	   are	  contributing	   to	   the	   overactive	   bladder	   symptoms	   then	   NGF	   levels	  should	   decrease	   after	   anterior	   repair	   in	   women	   who	   have	   had	   an	  improvement	  in	  their	  overactive	  bladder	  symptoms.	  	  	  Therefore	  the	  objective	  was	  to	  assess	  whether	  the	  NGF	  levels	  change	  in	   women	   who	   have	   had	   improvement	   in	   their	   overactive	   bladder	  symptoms	  after	  anterior	  colporrhaphy.	  
	  
7.2	  Methods	  Women	   were	   recruited	   following	   ethical	   approval	   (REC	   reference	  number:	  11/LO/1029)	  into	  this	  prospective	  cohort	  study.	  	  	  
7.2.1	  Inclusion	  and	  exclusion	  criteria:	  Women	  over	  the	  age	  of	  18	  years	  who	  underwent	  anterior	  repair	  for	  symptomatic	  anterior	  vaginal	  wall	  prolapse	  were	  recruited	   into	  this	  study.	  	  Women	   with	   history	   of	   neurological	   dysfunction,	   bladder	   pain	  syndrome,	   bladder	   cancer/calculi	   and	   previous	   anterior	   repair	   or	  continence	   surgery	   were	   excluded	   from	   the	   study.	   Women	   with	  urinary	  tract	  infection	  during	  preoperative	  and	  follow	  up	  assessment	  were	  also	  excluded	  from	  the	  study.	  
7.2.2	  Study	  design:	  	  Study	  participants	  were	  seen	  pre	  operatively	  and	  six	  to	  eight	  weeks	  following	  anterior	  repair.	  A	  clean	  catch	  midstream	  specimen	  of	  urine	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(MSU)	  was	  collected	  with	  a	  full	  bladder	  at	  baseline	  and	  at	  follow	  up	  to	   measure	   the	   urinary	   NGF	   levels.	   Assessment	   of	   symptom	  improvement	   was	   done	   using	   validated	   questionnaires	   at	   baseline	  and	   six	   weeks	   after	   surgery.	   	   To	   establish	   normative	   ranges	   MSU	  samples	  were	  also	  obtained	  from	  asymptomatic	  subjects	  who	  did	  not	  suffer	  with	  overactive	  bladder	  symptoms	  or	  vaginal	  prolapse.	  These	  patients	  were	  recruited	  from	  general	  gynaecology	  clinics.	  Either	   one	   of	   the	   two	   consultant	   urogynaecologists	   or	   the	  subspecialist	   trainee	   in	   urogynaecology	   performed	   the	   prolapse	  surgery.	   Urodynamics	   was	   carried	   out	   by	   certified	   urodynamicists.	  The	   researchers	   conducting	   the	   NGF	   assays	   were	   blinded	   to	   the	  patient	  symptoms	  pre	  and	  post	  prolapse	  surgery.	  
	  
7.2.3	  Methods	  of	  assessment:	  	  POP	   Q	   quantification	   system	   was	   used	   for	   assessment	   of	   stage	   of	  prolapse(Bump,	   Mattiasson	   et	   al.	   1996).	   Objective	   and	   subjective	  assessment	   was	   performed	   at	   baseline	   and	   at	   six	   to	   eight	   weeks	  following	   prolapse	   surgery	   using	   a	   three-­‐day	   bladder	   diary,	   King’s	  Health	  Questionnaire	   and	  Patients’	   Perception	  of	  Bladder	  Condition	  questionnaire	  (PPBC)	  (Coyne,	  Matza	  et	  al.	  2006).	  The	  PPBC	   is	  a	  reproducible	  validated	  single	   item	  questionnaire	   that	  assesses	   the	   patients’	   subjective	   impression	   of	   their	   urinary	  problems.	   The	   questionnaire	   has	   a	   six	   point	   scale	   with	   responses	  ranging	   from	   ‘‘no	  problems	  at	  all’’	   to	   ‘‘many	  severe	  problems”.	   	  The	  changes	  in	  PPBC	  score	  from	  baseline	  to	  post	  surgery	  were	  stratified	  into	   four	   groups:	   deterioration	   (difference	   in	   scores	   is	   positive),	   no	  change	  (difference	  in	  scores	  is	  0),	  minor	  improvement	  (difference	  in	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scores	   is	   negative	   in	   magnitude	   of	   1),	   and	   major	   improvement	  (difference	   in	   scores	   is	   negative	   in	   magnitude	   of	   2	   or	   more)	   as	  previously	  described	  by	  Coyne	  et	  al.	  Women	  who	   reported	  moderate	   or	   severe	   urinary	   urgency	  with	   or	  without	   urgency	   urinary	   incontinence	   were	   classified	   as	   having	  overactive	  bladder.	  All	  these	  women	  had	  undergone	  urodynamics	  at	  baseline	  prior	  to	  surgery	  using	  a	  standardised	  protocol	  according	  to	  ICS	  guidelines	  (Haylen,	  de	  Ridder	  et	  al.	  2010)	  	  
7.2.4	  NGF	  assay:	  	  Midstream	  specimens	  of	  urine	  was	  collected	  at	  baseline	  and	  at	  follow	  up	   for	  measurement	   of	   urinary	   NGF	   levels.	   Urine	  was	   immediately	  centrifuged	  at	  3000	  rpm	  at	  4	  0	  C	  for	  10	  minutes.	  About	  3	  ml	  of	  urine	  was	   also	   sent	   to	   measure	   urine	   creatinine.	   The	   centrifuged	  supernatant	  urine	  was	  then	  frozen	  at	  -­‐800	  C	  and	  used	  to	  measure	  the	  urinary	   NGF	   levels	   by	   ELISA	   using	   the	   NGF	   E	   max	   Immuno	   assay	  system	   (Promega	  Madison	  WI)	   as	   described	   in	   chapter	   4.	   The	   total	  urinary	  NGF	   levels	  were	   further	  normalized	   to	   the	   concentration	  of	  urinary	  creatinine	  (NGF/Cr	  level).	  	  
7.2.5	  Statistical	  methods:	  Mann	  Whitney	  U	   test	  was	  used	   to	   compare	   the	  NGF	   levels	  between	  patients	   with	   prolapse	   and	   asymptomatic	   patients.	   Urinary	   NGF	  levels	   were	   compared	   before	   and	   after	   anterior	   repair	   using	  Wilcoxon	   signed	   rank	   test.	   .	   The	   daytime	   frequency,	   nocturia	   and	  PPBC	   scores	   were	   compared	   before	   and	   after	   treatment	   using	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Student’s	   t	   test	   or	   Wilson	   signed	   rank	   test	   as	   appropriate.	   Mann	  Whitney	   U	   test	   was	   used	   to	   compare	   the	   NGF	   levels	   after	   anterior	  repair	   between	   the	   group	   of	   women	   who	   had	   no	   improvement	   in	  their	  PPBC	  scores	  and	  the	  group	  who	  had	  an	  improvement.	  This	  was	  a	  pilot	   study;	  hence	  sample	  size	  calculation	  was	  not	   carried	  out.	  All	  analyses	  were	  carried	  out	  using	  SPSS	  version	  20,	  Chicago,	  IL,	  USA).	  	  
7.3	  Results	  A	  total	  of	  30	  women	  were	  recruited	  into	  the	  study.	  Six	  women	  were	  excluded	  due	  to	  reasons	  summarised	  on	  table	  7.1.	  Four	  patients	  were	  excluded	   due	   to	   active	   infection	   or	   post	   op	   pain,	   which	   might	  influence	  the	  NGF	  levels.	  	  	  Reason	  for	  exclusion	   n	  Vault	  Infection	   1	  Pain	   2	  Lost	  for	  follow	  up/late	  follow	  up	   2	  Urinary	  tract	  infection	   1	  
Table	  7.1:	  Reasons	  for	  exclusion	  from	  study	  	  The	   demographics	   of	   study	   participants	   [n=24]	   at	   baseline	   are	  summarised	   on	   table	   7.2.	   The	   preoperative	   median	   NGF/Cr	   levels	  were	   much	   higher	   than	   found	   in	   asymptomatic	   women	   without	  prolapse	   [26.07ng/g	   [7.63-­‐182.04]	   vs.	   2.05ng/g	   [0.1-­‐11.88]	   p<.	   05].	  Fourteen	   patients	   underwent	   anterior	   and	   posterior	   repair;	   2	  patients	   underwent	   anterior,	   posterior	   repair	   and	   sacrospinous	  fixation	  and	  8	  patients	  underwent	  vaginal	  hysterectomy,	  anterior	  and	  posterior	  repair.	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Mean	  Age	  	   55.37[±11.6]	  *	  Median	  parity	  	   3[2-­‐4]	  #	  Mean	  BMI	   26.3[±1.25]*kg/m2	  POP	  Q	  Stage	  II	  or	  III	  prolapse	   n=23	  POP	  Q	  Stage	  I	  prolapse	   n=1	  Daytime	  frequency	   10.5[±2.45]	  *	  Nocturia	   1.82[±1.28]	  *	  PPBC	  score	   4.0[2.25-­‐4.75]	  #	  Detrusor	  overactivity	  on	  urodynamics	   n=15	  Voiding	  dysfunction	   n=0	  
Table	  7.2:	  Baseline	  demographics	  and	  clinical	  characteristics	  of	  patients	  	  
*Values	  are	  expressed	  as:	  mean	  (standard	  deviation)	  
# 	  Values	  are	  expressed	  as	  median	  (25th-­‐75th	  interquartile	  ranges)	  	  There	   was	   no	   significant	   difference	   in	   the	   median	   NGF/Cr	   levels	  before	  and	  after	  anterior	  repair;	  p	  value	  >	  0.05,Wilcoxon	  signed	  rank	  test	  [Table	  7.3].	  	  	  	  
Table	  7.3:	  Median	  NGF/Cr	  levels	  before	  and	  after	  anterior	  repair	  	  	  Sixty	   six	   per	   cent	   [n=16]	   of	   patients	   had	   either	   minor	   or	   major	  improvement	   in	   their	   OAB	   symptoms	   after	   anterior	   repair	   as	  assessed	   by	   PPBC	   scores.	   There	   was	   a	   statistical	   significant	  improvement	  in	  the	  daytime	  frequency,	  nocturia	  and	  PPBC	  scores	  
	   Median	   [interquartile	   range]	  ng/g	   P	  	  Preoperative	   NGF/Cr	  levels	   26.07[7.63-­‐182.04]	   	  0.14	  Postoperative	   NGF/Cr	  levels	   120.99[17.43-­‐250.71]	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after	  anterior	  repair	   in	  the	  group	  of	  patients	  who	  had	  improvement	  in	   their	   OAB	   symptoms	   [Table	   7.4].	   There	   was	   no	   significant	  difference	  between	  the	  median	  NGF	   levels	   [Table	  7.5]	  after	  anterior	  repair	   between	   the	   group	   of	   women	   who	   had	   no	   improvement	   in	  their	  PPBC	  scores	  and	  the	  group	  who	  did	  [Mann	  Whitney	  U	  test].	  The	  mean	  difference	  in	  the	  NGF	  levels	  before	  and	  after	  surgery	  was	  also	  not	   significantly	  different	  between	  women	  who	  did	  or	  did	  not	  have	  an	   improvement	   in	   their	   overactive	   bladder	   symptoms	   as	   assessed	  by	  PPBC	  [Mann	  Whitney	  U	  test,	  p=0.213].	  	  	  
Table	  7.4.	  OAB	  symptoms	  at	  baseline	  and	  at	  follow	  up	  post	  surgery	  
*Values	  are	  expressed	  as:	  mean	  (standard	  deviation)	  
# 	  Values	  are	  expressed	  as	  median	  (25th-­‐75th	  interquartile	  ranges)	  	  
	  
Table	   7.5:	   Comparison	   of	   postoperative	   Median	   NGF/Cr	   levels	   between	  
groups	  who	  did	  or	  did	  not	  have	  an	  improvement	  in	  their	  OAB	  symptoms	  
	   Pre-­‐op	   Postop	   p	  Daytime	  frequency	   10.5(±2.45)	  *	   5.8(±2.19)*	   <0.001	  Nocturia	   1.82(±1.28)*	   0.85((±0.93)*	   <0.001	  PPBC	  scores	   4.0[2.25-­‐4.75]	  #	   2.0(1.0	  to	  3.0)#	   <0.001	  
	   Median	   [Interquartile	   range]	  ng/g	   P	  	  Group	  who	  had	  improvement	  in	  their	  OAB	  symptoms	  [n=16]	  
152.56[48.68-­‐308.78]	   	  0.17	  
Group	  who	  had	  no	  improvement	  in	  their	  OAB	  symptoms	  [n=8]	  
29.60[11.95-­‐102.89]	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7.4	  Discussion:	  The	  median	  NGF	  levels	  are	  high	  in	  women	  with	  anterior	  vaginal	  wall	  prolapse	  compared	  to	  asymptomatic	  subjects.	  However	  there	  was	  no	  significant	   difference	   between	   preoperative	   and	   postoperative	   NGF	  levels	   after	   the	   anterior	   repair.	   There	   was	   also	   no	   significant	  difference	  in	  the	  NGF	  levels	  between	  the	  groups	  who	  did	  and	  did	  not	  have	   improvement	   of	   their	   overactive	   bladder	   symptoms	   after	   the	  anterior	   repair.	   Contrary	   to	   what	   was	   postulated	   the	   urinary	   NGF	  levels	  were	  high	  after	  the	  anterior	  repair.	  	  High	  urinary	  NGF	  levels	  in	  this	  study	  cohort	  could	  be	  due	  to	  bladder	  wall	  stretching	  as	  found	  in	  animal	  experiments(Persson,	  Sando	  et	  al.	  1995).	   Bladder	   outlet	   obstruction	   led	   to	   morphological	   and	  physiological	   changes,	   which	   includes	   bladder	   and	   neuronal	  hypertrophy	   and	   enhanced	   spinal	   reflexes(Steers,	   Kolbeck	   et	   al.	  1991)	   .This	   was	   associated	   with	   increased	   NGF	   production,	   which	  precedes	   the	   neuronal	   hypertrophy	   suggesting	   a	   link	   between	  NGF	  and	   bladder	   overactivity.	   The	   mechanism	   has	   been	   investigated	  further	   in	   vitro	  models	   by	   applying	  mechanical	   stretch	   to	   cultured	  smooth	   muscle	   cells	   and	   this	   resulted	   in	   increased	   expression	   of	  nerve	  growth	  factor	  and	  other	  specific	  proteins	  (Persson,	  Sando	  et	  al.	  1995,	   Yamaguchi	   2004).	   Stretch-­‐activated	   ion	   channels	   (SACs)	   and	  protein	   kinase	   C	   (PKC)	   act	   as	   sensors	   to	   mechanical	   stretch	  stimulus(Yamaguchi	   2004)	   and	   PKC	   is	   thought	   to	   play	   a	   role	   in	  controlling	   the	   synthesis	   of	   NGF(Persson,	   Sando	   et	   al.	   1995).	  Stretching	  of	  bladder	  wall	   in	  cystocele	  is	  postulated	  to	  stimulate	  the	  stretch	   receptors,	   which	   results	   in	   secretion	   of	   chemical	  mediators	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and	  detrusor	  overactivity	  (de	  Boer,	  Salvatore	  et	  al.	  2010).	  	  We	   postulated	   that	   if	   increased	   NGF	   levels	   occur	   as	   a	   result	   of	  bladder	   wall	   stretching	   and	   probably	   the	   cause	   for	   overactive	  bladder	  then	  the	  levels	  should	  fall	  after	  anterior	  repair	  accompanied	  by	   improvement	   in	   the	   overactive	   bladder	   symptoms.	   However	  contrary	  to	  the	  hypothesis	  the	  urinary	  levels	  were	  high	  at	  6-­‐8	  weeks	  after	  anterior	  repair	  as	  well	  as	  in	  the	  group	  who	  had	  improvement	  in	  their	   OAB	   symptoms,	   which	   could	   be	   explained	   by	   more	   than	   one	  theory.	  Relief	   of	   obstruction	   in	   animal	   studies	  only	   caused	  a	  partial	  reversal	   of	   neuronal	   hypertrophy	   as	  well	   as	   increased	  NGF	   level	   in	  animal	   studies	   in	   spite	   of	   reduction	   in	   urinary	   frequency(Steers,	  Kolbeck	  et	  al.	  1991).	  This	   incomplete	  reversal	  of	  neuronal	  plasticity	  could	   be	   the	   aetiology	   for	   the	   elevated	   levels	   in	   urinary	   NGF	   after	  anterior	   repair	   in	   women	   who	   have	   had	   improvement	   in	   their	  overactive	   bladder	   symptom.	   There	   could	   be	   other	   neurotrophic	  factors	   as	   ciliary	   neurotrophic	   factor;	   brain-­‐derived	   neurotrophic	  factor	   and	   basic	   fibroblast	   growth	   factor	   responsible	   for	   neural	  plasticity	   and	   NGF	   may	   not	   be	   the	   only	   factor	   contributing	   to	  neurotrophic	  changes	  (Steers,	  Kolbeck	  et	  al	  1991).	  	  Although	  there	  was	  no	  significant	  difference	  between	  preop	  and	  post	  op	  values	  the	  post	  op	  NGF	  levels	  were	  high.	  It	  is	  possible	  that	  surgery	  to	  the	  vaginal	  wall	  supporting	  the	  bladder	  might	  itself	  be	  a	  trigger	  for	  production	  of	  NGF	  although	  there	  is	  no	  breech	  to	  bladder	  epithelium	  due	  to	  alteration	  in	  the	  structural	  milieu.	  So	  measuring	  urinary	  NGF	  levels	   post	   surgery	   may	   not	   be	   reliable	   .It	   is	   possible	   that	   NGF	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measurements	   were	   done	   too	   early	   following	   surgery	   and	   the	  optimal	  time	  for	  measuring	  NGF	  levels	  after	  an	  intervention	  needs	  to	  be	  explored	  further.	  	  Improvement	  in	  OAB	  symptoms	  following	  anterior	  repair	  was	  found	  in	   two	   thirds	   of	   this	   study	   population,	   which	   is	   similar	   to	   other	  studies.	   Improvement	  of	  voiding	   function	   is	  postulated	   to	  be	  one	  of	  the	  reasons	  for	  OAB	  resolution	  after	  anterior	  repair,	  but	  none	  of	  the	  study	  cohorts	  had	  voiding	  dysfunction	  on	  pressure	  flow	  studies(Basu	  and	  Duckett	  2009).	  	  	  The	   drawbacks	   of	   this	   study	   include	   small	   numbers	   with	   unequal	  numbers	  in	  the	  subgroups	  .The	  striking	  findings	  of	  the	  study	  results	  are	   the	  wide	   ranges	   in	   the	  NGF	   levels.	   	   These	   prevent	   any	   changes	  being	   statistically	   significant	   and	   would	   also	   mean	   that	   large	  numbers	  are	  required	  in	  any	  interventional	  study	  to	  detect	  a	  change.	  	  The	   study	   has	   added	   some	   valuable	   information	   that	   Urinary	   NGF	  levels	   are	   high	   in	   women	   with	   anterior	   vaginal	   wall	   prolapse	   and	  OAB	   symptoms.	   However	   it	   is	   not	   possible	   to	   attribute	   these	  increased	  NGF	  levels	  to	  either	  bladder	  wall	  stretching	  or	  presence	  of	  OAB.	  Measurement	  of	  urinary	  NGF	  levels	  after	  a	  surgical	  intervention	  or	  presence	  of	  prolapse	  may	  not	  be	  reliable	  and	  has	  to	  be	  interpreted	  with	  caution.	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CHAPTER	  8	  	  	  
CHANGES	  IN	  NGF	  LEVEL	  AND	  SYMPTOM	  SEVERITY	  
FOLLOWING	  ANTIBIOTIC	  TREATMENT	  FOR	  
REFRACTORY	  OAB	  	  	  	  
Hypothesis:	  Urinary	  NGF	  level	  measurement	  does	  not	  change	  in	  
response	  to	  antibiotic	  therapy	  for	  refractory	  OAB	  and	  cannot	  be	  
used	  to	  assess	  treatment	  response.	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CHAPTER	   8:	   CHANGES	   IN	   NGF	   LEVEL	   AND	   SYMPTOM	  
SEVERITY	   FOLLOWING	   ANTIBIOTIC	   TREATMENT	   FOR	  
REFRACTORY	  OAB	  
	  
8.1	  Introduction:	  	  Animal	   studies	   have	   demonstrated	   a	   direct	   link	   between	   increased	  levels	   of	   NGF	   in	   bladder	   tissue	   and	   bladder	   dysfunction(Steers	   and	  Tuttle	   2006)	   especially	   bladder	   overactivity(Chuang	   et	   al.	   2001,	  Zvara	   and	   Vizzard	   2007).	   These	   experimental	   data	   have	   been	  explored	   in	   human	   studies,	   with	   increased	   levels	   of	   urinary	   NGF	  reported	  in	  patients	  with	  overactive	  bladder	  (OAB)	  (Kim	  et	  al.	  2006),	  detrusor	   overactivity	   (DO)	   	   and	   interstitial	   cystitis(Liu	   et	   al.	   2010).	  NGF	   levels	   have	   also	   been	   found	   to	   decrease	   after	   successful	  antimuscarinic	  treatment	  for	  OAB(Cho	  et	  al.	  2012,	  Liu	  et	  al.	  2010).	  In	  the	   light	  of	   these	  data	  some	  authors	  have	  suggested	  that	  NGF	  levels	  could	  be	  considered	  as	  a	  biomarker	  for	  OAB,	  as	  well	  as	  an	  assessment	  of	   therapeutic	  outcome	  in	  patients	  with	  OAB	  or	  DO(Liu	  et	  al.	  2010).	  Interestingly	   NGF	   levels	   are	   higher	   in	   OAB	   patients	   who	   do	   not	  respond	  to	  antimuscarinics	  but	  the	  reasons	  for	  this	  are	  unknown(Liu	  et	  al.	  2011).	  	  	  Patients	   with	   DO	   may	   present	   with	   symptoms	   of	   OAB	   such	   as	  urgency,	   urgency	   urinary	   incontinence,	   frequency	   and	   nocturia.	  Detrusor	   overactivity	   is	   a	   chronic	   condition	   which	   has	   a	   negative	  impact	  on	   life(Banakhar	  et	  al.	  2012)	  and	  recent	  studies	  have	  shown	  that	   up	   to	   88%	   of	   women	   with	   idiopathic	   DO	   have	   persistent	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symptoms	   at	   long-­‐term	   follow	   up(Garnett	   et	   al.	   2009).	   However	  there	   is	   no	   consensus	   on	   the	   definition	   of	   refractory	   overactive	  bladder	   or	   refractory	   DO.	   In	   general	   patients	   who	   have	   not	  responded	   to	   first	   line	   management	   therapies	   such	   as	   behavioural	  modification,	   bladder	   retraining	   and	   anti-­‐muscarinic	   therapy	   are	  considered	  to	  have	  refractory	  overactive	  bladder.	  	  Overactive	   bladder	   and	   detrusor	   overactivity	   have	   a	   multifactorial	  aetiology(Diamond	   et	   al.	   2012).	   An	   interesting	   hypothesis	   has	  recently	  emerged	  linking	  OAB	  symptoms	  and	  sub-­‐clinical	  infection.	  A	  subset	   of	   women	   with	   OAB	   has	   persistent	   pyuria	   and	   low	   count	  bacteriuria(Khasriya	   et	   al.	   2010,	   Walsh	   et	   al.	   2011).	   Underlying	  untreated	  infection	  could	  therefore	  be	  one	  of	  the	  causes	  for	  increased	  NGF	  levels	  in	  women	  with	  refractory	  OAB	  symptoms.	  	  Therefore,	  the	  objective	  of	  the	  present	  study	  was	  to	  assess	  change	  in	  urinary	   NGF	   levels	   following	   antibiotic	   treatment	   and	   measure	  concomitant	  changes	  in	  objective	  and	  subjective	  symptom	  severity	  in	  women	  with	  refractory	  OAB	  symptoms.	  	  	  
8.2	  Materials	  and	  methods:	  	  	  Women	   were	   recruited	   from	   a	   tertiary	   urogynaecology	   referral	  centre	   following	   ethical	   approval	   (REC	   reference	   number:	  11/LO/1029)	  into	  this	  prospective	  six-­‐week	  cohort	  study.	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8.2.1	  Inclusion	  and	  Exclusion	  criteria:	  	  Adult	   women	   with	   overactive	   symptoms,	   and	   with	   an	   urodynamic	  diagnosis	   of	   detrusor	   overactivity,	   who	   had	   failed	   to	   respond	   to	   a	  combination	   of	   lifestyle	   adaptations,	   bladder	   retraining	   and	  antimuscarinics	  were	  included	  in	  the	  study.	  None	  of	  the	  women	  were	  on	   antimuscarinics	   during	   the	   study	   period	   but	   they	   had	   each	  previously	   had	   a	   minimum	   12-­‐week	   trial,	   including	   at	   least	   two	  antimuscarinics.	  	  Women	   were	   excluded	   if	   they	   had	   a	   history	   of	   neurological	  dysfunction,	   bladder	   pain,	   bladder	   cancer,	   bladder	   or	   renal	   calculi,	  previous	   continence	   surgery,	   presence	   of	   voiding	   dysfunction,	  vaginal	   prolapse	   [≥	   Stage	   II	   on	   POPQ],	   urinary	   tract	   infection	   by	  conventional	  microbiological	  criteria	  (colony	  count	  ≥10	  5)	  or	  history	  of	   allergic	   reaction	   or	   side	   effects	   to	   more	   than	   one	   antibiotic	   of	  choice.	  	  
8.2.2	  Study	  design:	  Study	   participants	   were	   seen	   prior	   to	   and	   six	   weeks	   following	  antibiotic	   treatment.	   A	   clean	   catch	   midstream	   specimen	   of	   urine	  (MSU)	  was	  collected	  at	  full	  bladder	  at	  baseline	  and	  after	  six	  weeks	  of	  antibiotic	   treatment	   to	  measure	   the	  urinary	  NGF	   levels.	  Assessment	  of	   symptom	   improvement	  was	   done	   using	   validated	   questionnaires	  at	   baseline	   and	   six	   weeks	   after	   treatment.	   	   To	   establish	   normative	  ranges	  MSU	  samples	  were	  also	  obtained	  from	  asymptomatic	  subjects	  who	  did	  not	  suffer	  with	  overactive	  bladder	  symptoms.	  These	  patients	  were	  recruited	  from	  general	  gynaecology	  clinics.	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8.2.3	  Treatment:	  	  Participants	   were	   treated	   with	   a	   six-­‐week	   course	   of	   rotational	  antibiotics.	   Patient’s	   previous	   sensitivities	   to	   proven	   urinary	   tract	  infection	   and	   drug	   allergies	  were	   taken	   into	   consideration	   prior	   to	  treatment.	   Three	   consecutive	   antibiotics	  were	   given	   for	   two	  weeks	  each;	  ciprofloxacin	  [1gm	  orally	  in	  two	  divided	  doses]	  to	  cover	  gram-­‐positive	  and	  gram-­‐negative	  organisms,	  doxycycline	  [200mg	  orally	  in	  two	   divided	   doses]	   to	   cover	   chlamydia	   trachomatis	   and	   atypical	  organisms	   like	   Mycoplasma	   hominis	   and	   ureaplasma	   urealyticum	  and	   cephalexin	   [1500mg	   orally	   in	   three	   divided	   doses]	   or	   Co-­‐amoxiclav	   [1875	   mg	   orally	   in	   three	   divided	   doses]	   to	   cover	   gram	  positive	  and	  gram-­‐negative	  urinary	  pathogens.	  	  
8.2.4	  Methods	  of	  assessment:	  	  Objective	  and	  subjective	  assessment	  was	  performed	  at	  baseline	  and	  after	  six	  weeks	  of	  antibiotic	  therapy	  using	  a	  three-­‐day	  bladder	  diary,	  Patients’	  Perception	  of	  Intensity	  of	  Urgency	  Scale	  (PPIUS)(Cartwright	  et	  al.	  2011),	  King’s	  Health	  Questionnaire	  and	  Patients’	  Perception	  of	  Bladder	  Condition	  questionnaire	  (PPBC)(Coyne	  et	  al.	  2006).	  	  The	  PPIUS	   is	  a	   tool	  designed	   to	  assess	   the	   intensity	  of	  urinary	  urge	  sensation.	   It	   has	   a	   5-­‐point	   scale	   ranging	   from	  0	   to	   4,	  with	   grades	  3	  and	   4	   representing	   severe	   urgency	   and	   urgency	   incontinence	  respectively.	  The	  PPBC	   is	  a	  reproducible	  validated	  single	   item	  questionnaire	   that	  assesses	   the	   patients’	   subjective	   impression	   of	   their	   urinary	  problems.	   The	   questionnaire	   has	   a	   six	   point	   scale	   with	   responses	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ranging	   from	   ‘‘no	   problems	   at	   all’’	   to	   ‘‘many	   severe	   problems”.	   The	  changes	   in	   PPBC	   score	   from	   baseline	   to	   week	   six	   of	   antibiotic	  treatment	  were	  stratified	  into	  four	  groups:	  deterioration	  (difference	  in	   scores	   is	   positive),	   no	   change	   (difference	   in	   scores	   is	   0),	   minor	  improvement	  (difference	  in	  scores	  is	  negative	  in	  magnitude	  of	  1),	  and	  major	  improvement	  (difference	  in	  scores	  is	  negative	  in	  magnitude	  of	  2	  or	  more)	  as	  previously	  described(Coyne	  et	  al.	  2006).	  	  	  
8.2.5	  NGF	  assay:	  Collected	   urine	   samples	   were	   immediately	   refrigerated	   and	  centrifuged	   at	   3000rpm	  at	   4	   0	  C	   for	   10	  minutes.	   Three	  millilitres	   of	  urine	   were	   also	   sent	   for	   measurement	   of	   urinary	   creatinine.	   The	  centrifuged	   supernatant	   urine	   was	   stored	   at	   -­‐80°0C,	   until	   further	  processing.	   Urinary	   NGF	   levels	   were	   measured	   by	   enzyme	   linked	  immunosorbent	   assay	   (ELISA)	   using	   the	   NGF	   Emax	   Immunoassay	  System	   (Promega,	  Madison,	  WI,	  USA)	   as	  described	   in	   chapter	  4.The	  measured	   urinary	   NGF	   levels	   were	   normalised	   against	   the	  concentration	   of	   the	   urinary	   creatinine	   to	   take	   into	   account	   the	  variation	  in	  urine	  concentration.	  	  	  
8.2.6	  Statistical	  methods:	  Based	  on	  previous	   studies(Liu	   et	   al.	   2010)	   a	   sample	   size	   of	   34	  was	  estimated	   to	   provide	   80%	   power	   	   for	   a	   half	   standard	   deviation	  change	   in	   NGF,	   and	   90%	   power	   for	   a	   60%	   of	   standard	   deviation	  change,	  with	  alpha	  set	  at	  0.05.	  Spearman	  correlation	  test	  was	  used	  to	  assess	  the	  correlation	  between	  the	  baseline	  NGF	  values	  and	  the	  PPBC	  scores.	  Urinary	  NGF	  levels	  were	  compared	  before	  and	  after	  antibiotic	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therapy	   using	   Wilcoxon	   signed	   rank	   test,	   and	   with	   levels	   from	   a	  parallel	  control	  group	  of	  asymptomatic	  women	  using	  Mann	  Whitney	  U	   test.	   The	   daytime	   frequency,	   nocturia,	   urgency	   scores	   and	   PPBC	  scores	  were	   compared	  before	   and	   after	   treatment	  using	   Student’s	   t	  test	  or	  Wilson	  signed	  rank	  test	  as	  appropriate.	  Mann	  Whitney	  U	  test	  was	   used	   to	   compare	   the	   NGF	   levels	   after	   antibiotic	   treatment	  between	  the	  group	  of	  women	  who	  had	  no	  improvement	  in	  their	  PPBC	  scores	   and	   the	   group	  who	  did.	   (SPSS,	   Inc.	   version	  14.0,	   Chicago,	   IL,	  USA)	  	  
8.3	  Results	  	  	  Thirty-­‐nine	   symptomatic	   women	   with	   refractory	   detrusor	  overactivity	  were	  recruited	  who	  reported	  urinary	  urgency	  as	  well	  as	  urgency	   incontinence.	   In	  addition	  MSU	  samples	  were	  collected	  from	  27	   asymptomatic	   women	   who	   served	   as	   controls.	   Four	   patients	  (10.2%)	  were	  excluded	  from	  the	  final	  analysis	  due	  to	  discontinuation	  of	   antibiotics,	   commonly	   due	   to	   gastro	   intestinal	   side	   effects	   [n=3]	  and	  vulvovaginal	  candidiasis	  [n=1].	  	  The	  median	  NGF/Cr	   level	   in	   the	  control	  group	  was	  1.96	  ng/g	   (25th-­‐75th	   interquartile	   range,	   0.1-­‐11.47).	   The	   pre-­‐treatment	   median	  NGF/Cr	   level	   in	   the	   symptomatic	   group	   was	   21.09	   ng/g	   (25th-­‐75th	  interquartile	  range,	  6.82	  –	  100.93).	  There	  was	  a	  significant	  difference	  in	   the	   median	   NGF/Cr	   levels	   between	   the	   control	   and	   the	  symptomatic	  group	  at	  baseline	  (Mann	  Whitney	  test,	  Z	  value	  -­‐3.060;	  p	  value	  <	  0.	  005).	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The	   baseline	   demographics	   and	   the	   clinical	   characteristics	   of	   the	  symptomatic	   group	   (n=35)	   are	   listed	   in	   Table	   8.1.	   There	   was	   a	  statistical	   significant	   difference	   in	   the	   mean	   age	   between	   the	  symptomatic	  and	  asymptomatic	  group	  (Independent	  sample	  T	  test,	  p	  value	   =0.04).	   However	   there	   was	   no	   correlation	   between	   the	   NGF	  values	  and	  age	  (Spearman	  correlation	  test,	  rho	  0.06;	  p	  value	  >0.05).	  There	   was	   a	   significant	   correlation	   between	   the	   baseline	   NGF/Cr	  values	  and	  the	  PPBC	  scores	  (Spearman’s	  rho	  0.34;	  p	  value<	  0.05).	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Table:	  8.1	  Baseline	  demographics	  and	  clinical	  characteristics	  of	  patients.	  	  
*Values	  are	  expressed	  as:	  mean	  (standard	  deviation)	  
# 	  Values	  are	  expressed	  as	  median	  (25th-­‐75th	  interquartile	  ranges)	  	  The	   NGF/Cr	   levels	   decreased	   significantly	   after	   six	   weeks	   of	  antibiotic	  therapy	  as	  shown	  in	  Table	  8.	  2	  (Wilcoxon	  Signed	  rank	  test,	  Z	  value-­‐2.424;p=0.015).	  OAB	  symptoms	  including	  daytime	  frequency,	  nocturia	  and	  urgency	  were	  also	  significantly	   improved	  by	  antibiotic	  therapy	  as	  shown	  in	  Table	  8.3.	  	  
Mean	  Age	   44.8(±14.9)*	  Mean	  duration	  of	  symptoms	  (months)	   22	  (±5.6)*	  Median	  Parity	   2.0(1.0to	  3.5)#	  	  Median	  Number	  of	  antimuscarinics	  tried	  
	  3.0(2.0	  to	  4.0)#	  
	  Mean	  day	  time	  frequency	  	   	  12.8(±3.5)*	  	  Median	  Nocturia	   	  2.0(1.0	  to	  3.0)#	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Table	  8.2.	  Urinary	  NGF/Cr	  levels	  at	  baseline	  and	  six	  weeks	  	  
	  
Table	  8.3.	  OAB	  symptoms	  at	  baseline	  and	  six	  weeks	  after	  antibiotic	  therapy	  
*Values	  are	  expressed	  as:	  mean	  (standard	  deviation)	  
# 	  Values	  are	  expressed	  as	  median	  (25th-­‐75th	  interquartile	  ranges)	  
	  	  	  The	  magnitude	  of	   improvement	   in	  PPBC	  after	   antibiotics	   therapy	   is	  as	  shown	  in	  Table	  8.4.	  Overall	  74%	  of	  women	  found	  a	  minor	  to	  major	  improvement	   in	   their	   symptoms	   after	   antibiotic	   treatment.	   The	  median	  NGF/Cr	  values	  after	  antibiotic	   treatment	  were	   lower	   in	   this	  group	  compared	  to	  that	  of	  women	  who	  had	  no	  improvement	  in	  their	  PPBC	  scores.	  However	  this	  difference	  was	  not	  statistically	  significant	  (17.41	  vs.	  10.61;	  Mann	  Whitney	  U	  test;	  p=0.52).	  	  
	  
	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Baseline	   After	  6	  weeks	  of	  antibiotics	   p	  Median	   25th-­‐75th	  IQR	   Median	   25th-­‐75th	  IQR	  NGF/Cr	  levels	  ng/g	   21.09	   6.82-­‐100.93	   13.33	   2.81-­‐23.62	   .015	  
	   Pre-­‐treatment	   After	  6	  week	  course	  of	  antibiotics	   p	  Day	   time	  frequency	  	   12.8(±3.5)*	   8.7(±2.7)*	   <0.005	  Nocturia	   2.0(1.0	  to3.0)#	   1.0(0	  to	  3.0)#	   <0.050	  PPBC	  scores	   5.0	  (4.0	  to	  6.0)#	   2.0(1.0	  to	  4.0)#	   <0.005	  PPIUS	  scores	   3.0(1.0	  to	  5.0)#	   2.0(1.0	  to	  3.0)#	   <0.005	  










Table	  8.4:	  Magnitude	  of	  improvement	  in	  PPBC	  scores	  
	  
	  
8.4	  Discussion:	  	  Urinary	  NGF/Cr	   levels	  were	  significantly	  higher	   in	   the	  symptomatic	  study	   group	  with	   refractory	  OAB	   symptoms	  when	   compared	   to	   the	  control	   subjects	   at	   baseline,	  which	   is	   in	   keeping	  with	   the	   results	   of	  other	  studies(Kim	  et	  al.	  2006,	  Liu	  et	  al.	  2010).	  Significant	  correlation	  existed	   between	   the	   baseline	   NGF/Cr	   values	   and	   the	   severity	   of	  urinary	   symptoms.	   Antibiotic	   treatment	   in	   women	   with	   refractory	  OAB	  symptoms	  was	  associated	  with	  a	  significant	  decrease	  in	  the	  NGF	  levels	   as	   well	   as	   improvement	   in	   patients’	   symptoms	   and	   PPBC	  (figure	   8.1	   &Table	   8.3).	   Supporting	   this	   data,	   animal	   studies	   have	  shown	   a	   link	   between	   increased	   NGF	   levels	   and	   infection.	  Experimentally	   induced	   bacterial	   cystitis	   in	   animal	   bladders	   was	  found	   to	   result	   in	   increased	  NGF	   levels(Dupont	   et	   al.	   2001).	  NGF	   is	  produced	   by	   the	   urothelium	   and	   detrusor	   in	   the	   bladder	   but	   other	  possible	   sources	   are	   eosinophils	   and	   macrophages	   (Aloe	   et	   al.	  1997).Therefore	   women	   with	   refractory	   OAB	   symptoms	   may	   have	  inflammation	  secondary	  to	  	  infection,	  	  associated	  with	  increased	  NGF	  levels.	  	  
	  
Magnitude	  of	  Improvement	  in	  PPBC	  
	  
Proportio
n	  No	  change	  =	  score	  of	  0	   26%	  Minor	  improvement	  =	  score	  of	  -­‐1	   17%	  Major	  improvement	  =score	  of	  -­‐2	  or	  more	   57%	  




Figure	  8.1:Median	  NGF/Cr	  levels	  before	  and	  after	  antibiotic	  treatment	  
	  
	  The	  diagnosis	  of	  overactive	  bladder	  or	  detrusor	  overactivity	  is	  made	  only	  in	  the	  absence	  of	  urinary	  tract	   infection	  with	  a	  culture	  of	  ≥10	  5	  CFU/ml	  or	  other	  obvious	  pathology(Haylen	  et	  al.	  2010).	  Interestingly	  it	   has	   been	   shown	   that	   the	   likelihood	   of	   having	   asymptomatic	  bacterial	  cystitis	  in	  women	  undergoing	  urodynamics	  is	  6%	  in	  women	  with	   detrusor	   overactivity	   compared	   to	   1%	   in	   women	   with	  urodynamic	  stress	  incontinence(Moore	  et	  al.	  2000)	  and	  women	  who	  develop	  OAB	  in	  later	  life	  are	  more	  likely	  to	  suffer	  from	  urinary	  tract	  infections	  in	  their	  childhood(Salvatore	  et	  al.	  2012)	  	  	  	  In	  a	  study	  in	  women	  with	  lower	  urinary	  tract	  symptoms	  (LUTS)	  the	  incidence	   of	   bacteriuria	   was	   29%	  when	   a	   threshold	   of	   102	  CFU/ml	  was	  chosen,	  compared	  to	  15%	  at	  the	  routinely	  used	  threshold	  of	  10	  5	  CFU/ml(Khasriya	  et	  al.	  2010).	  Similarly,	  in	  a	  study	  using	  a	  threshold	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of	   103CFU/ml,	   28%	   of	   women	   with	   OAB	   were	   found	   to	   have	  bacteriuria(Hessdoerfer	   et	   al.	   2011).	   In	   women	   with	   acute	  exacerbation	  of	  OAB	  symptoms,	  the	  prevalence	  of	  bacteriuria	  on	  MSU	  samples	   at	   low	   count	   of	   ≥103	   was	   39%	   compared	   to	   6	   %	   in	  controls(Walsh	  et	  al.	  2011).	  Concerns	  have	  therefore	  been	  raised	  that	  urinary	  tract	  infections	  may	  be	  missed	  or	  under	  diagnosed	  in	  women	  with	  symptoms	  of	  overactive	  bladder	  if	  a	  threshold	  of	  105	  CFU/ml	  is	  used	  for	  diagnosis.	  	  	  There	   is	   also	   evidence	   to	   suggest	   that	   infection	   caused	   by	   atypical	  organisms	   such	   as	   mycoplasma	   hominis;	   ureaplasma	   urealyticum	  and	   chlamydia	   not	   detected	   by	   routine	   urine	   culture	   methodology	  may	   be	   associated	   with	   overactive	   bladder	   symptoms.	   A	  retrospective	  observational	  study	  in	  patients	  with	  urinary	  symptoms	  showed	   a	   prevalence	   of	   13.7%	   of	   atypical	   organisms(Latthe	   et	   al.	  2008,	  Steers	  and	  Tuttle	  2006,	  Zvara	  and	  Vizzard	  2007)	  	  Based	   on	   the	   available	   data,	   women	   with	   OAB	   seem	   to	   have	   an	  increased	   likelihood	  of	  having	  asymptomatic	  bacterial	   infection	  that	  may	  be	  missed	  due	  to	  usage	  of	  a	  higher	  threshold	  of	  105	  for	  diagnosis	  or	  lack	  of	  specific	  culture	  techniques.	  	  Bacterial	   infection	  has	  been	   shown	   to	   trigger	  neutrophil	   infiltration	  into	  bladder	  mucosa	  and	  also	  production	  of	  cytokine	  IL-­‐6.	  Therefore	  untreated	   infection	   could	   result	   in	   chronic	   cystitis	   and	   non-­‐	  responsiveness	  to	  anti	  muscarinics.	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Inflammation	  has	  been	  postulated	  to	  be	  one	  of	  the	  causative	  factors	  for	   the	   development	   of	   OAB(Hsiao	   et	   al.	   2012,	   Saini	   et	   al.	   2008).	  Bladder	   biopsies	   from	   patients	   with	   detrusor	   overactivity	   before	  intravesical	   botulinum	   toxin	   injection	   revealed	   presence	   of	   chronic	  inflammation	   in	   59%	   of	   cases(Apostolidis	   et	   al.	   2008).	   Animal	   and	  clinical	  studies	  on	  inflammatory	  biomarkers	  have	  provided	  evidence	  for	   the	  role	  of	   cytokines,	  prostaglandins	  and	  nerve	  growth	   factor	   in	  the	   development	   of	   lower	   urinary	   tract	   symptoms(Kim	   et	   al.	   2006,	  Liu	  et	  al.	  2010,	  Steers	  and	  Tuttle	  2006,	  Tyagi	  et	  al.	  2010,	  Zvara	  and	  Vizzard	  2007).	  	  We	   postulated	   that	   bladder	   inflammation	   might	   be	   the	   underlying	  pathogenesis	   for	   their	   refractory	   overactive	   bladder	   symptoms,	  which	   may	   occur	   as	   a	   result	   of	   chronic	   subclinical	   infection.	  Therefore	  we	  treated	  our	  patients	  with	  a	  combination	  of	  antibiotics	  to	  treat	  common	  urinary	  tract	  pathogens	  such	  as	  gram	  negative	  and	  gram-­‐positive	   organisms	   as	   well	   as	   atypical	   organisms	   such	   as	  mycoplasma	   hominis,	   ureaplasma	   urealyticum	   and	   chlamydia.	   The	  main	   limitation	   of	   this	   study	   is	   the	   lack	   of	   evidence	   for	   infective	  aetiology	  in	  the	  treatment	  group.	  However	  treatment	  with	  antibiotics	  in	  women	  with	  refractory	  overactive	  bladder	  significantly	  decreased	  the	  urinary	  NGF	   levels	   (table	   2).	   This	   study	   also	   shows	   a	   statistical	  significant	   improvement	   in	   the	   daytime	   frequency,	   nocturia	   and	  urgency	  and	  PPBC	   scores	   after	   antibiotic	   treatment.	  Twenty-­‐six	  per	  cent	   of	   women	  who	   received	   antibiotic	   treatment	   did	   not	   find	   any	  improvement	   in	   their	   symptoms,	   whereas	   74%	   of	   them	   found	   a	  minor	   to	   major	   improvement	   in	   their	   symptoms	   (Table	   8.4).	   The	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median	  NGF/Cr	  values	  after	  antibiotic	  treatment	  in	  women	  who	  had	  improvement	  in	  their	  PPBC	  scores	  were	  lower	  compared	  to	  those	  of	  women	  who	   had	   no	   improvement.	   However	   this	   difference	   did	   not	  reach	  statistical	  significance,	  which	  could	  be	  due	  to	  small	  numbers	  in	  the	  subgroups.	  	  Antibiotics	   could	   have	   indirect	   immune	   modulatory	   effects	   in	  addition	   to	   antimicrobial	   effects(Tauber	   and	   Nau	   2008).	   There	   is	  evidence	   that	   drugs	   such	   as	   Doxycycline,	   ciprofloxacin;	   cephalexin	  and	  Co-­‐amoxiclav	  exert	  anti-­‐inflammatory	  properties	  (D’Agostino	  et	  al	   1998,Sun	   et	   al	   2000,Miyachi	   et	   al	   1986	   &	   Casellas	   et	   al	   1998).	  Therefore	   it	   is	   possible	   that	   the	   antibiotics	   that	   were	   used	   had	   an	  anti-­‐inflammatory	   effect,	   which	   resulted	   in	   improvement	   of	   the	  overactive	  bladder	  symptoms	  rather	  than	  an	  anti-­‐infective	  effect.	  It	  is	  also	  possible	  that	  the	  treatment	  with	  antibiotics	  had	  a	  placebo	  effect.	  However	   the	   improvement	   in	   the	   PPBC	   scores	   is	   far	   larger	   at	   74%	  than	  most	  placebo	  studies	  where	  improvement	  levels	  of	  only	  40-­‐45%	  have	   been	   reported	   with	   placebo(Van	   Kerrebroeck	   et	   al.	   2009).	  There	   is	   one	   study	   using	   sequential	   antibiotics	   compared	   with	  placebo	   but	   the	   study	   group	  were	   patients	  with	   interstitial	   cystitis,	  which	   showed	   no	   significant	   difference	   between	   the	   two	   treatment	  arms(Warren	  et	  al.	  2000).	  This	  report	  is	  not	  applicable	  to	  the	  present	  study	  due	  to	  the	  differences	  in	  pathology	  as	  the	  patients	  had	  pain	  and	  no	   incontinence.	   	   Therefore	   we	   can	   be	   confident	   this	   is	   the	   first	  report	   of	   sequential	   antibiotic	   treatment	   of	   this	   group	   of	   patients.	  Although	  a	  small	  number	  of	  adverse	  events	  were	  found	  in	  this	  short-­‐term	  study,	  it	  is	  important	  to	  keep	  in	  mind	  that	  microbial	  resistance	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could	  occur	  with	  long-­‐term	  of	  antibiotics	  particularly	  if	  the	  treatment	  is	  repeated	  for	  symptom	  recurrence.	  	  The	  limitations	  of	  this	  study	  are	  inherent	  in	  the	  uncontrolled	  design,	  which	  could	  create	  a	  risk	  of	  biases	  and	   the	  use	  of	  patients	  who	  had	  failed	  first	  line	  therapies	  limits	  the	  generalizability.	  Although	  the	  NGF	  measurements	   were	   performed	   blind,	   limiting	   the	   risk	   of	  experimenter	  bias,	  without	  a	  group	  of	  untreated	  controls	  the	  changes	  observed	  may	  result	  from	  unmeasured	  factors.	  A	  placebo-­‐controlled	  study	   is	   therefore	  required	   to	  quantify	   the	   therapeutic	  effect.	  These	  data	  provide	  a	  convincing	  rationale	  for	  the	  design	  of	  a	  controlled	  trial	  of	  this	  therapy,	  and	  it	  is	  important	  for	  such	  a	  study	  to	  assess	  the	  long	  term	  outcome	  of	  treatment.	  	  	  	  Urinary	   NGF	   levels	   may	   be	   responsive	   to	   antibiotic	   treatment	   in	  women	  with	  refractory	  OAB.	  This	  key	  finding	  provides	  scope	  for	  the	  potential	   use	   of	   urinary	   NGF	   to	   assess	   treatment	   response	   in	   OAB	  patients.	   Furthermore	   targeted	   antibiotic	   treatment	   is	   associated	  with	   subjective	   and	   objective	   improvement	   in	   OAB	   symptoms.	  Antibiotics	   may	   be	   acting	   by	   an	   antibacterial	   or	   anti-­‐inflammatory	  effect.	   	   Antibiotic	   treatment	   could	   be	   considered	   in	   women	   with	  refractory	  OAB	  symptoms	  before	  invasive	  treatment	  modalities	  such	  as	  botulinum	  toxin,	  neuromodulation	  and	  bladder	  augmentation.	  The	  use	   of	   NGF	   as	   a	   predictor	   of	   antibiotic	   treatment	   response	   merits	  testing	  in	  a	  blinded	  randomized	  trial.	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CHAPTER	  9:	  CONCLUSION	  	  	  	  An	  ideal	  biomarker	  should	  be	  easily	  measurable,	  reliable	  and	  valid	  .It	  should	  have	  either	  superior	  performance	  to	  existing	  tests	  or	  provide	  new	   information	   and	   improve	   existing	   tests.	   Most	   importantly	   it	  should	  help	  the	  clinician	  to	  manage	  the	  patients	  better.	  	  	  There	  are	  few	  advantages	  of	  using	  urinary	  NGF	  as	  a	  biomarker	  in	  the	  assessment	   of	   patients	   with	   LUTD.	   Urine	   is	   easily	   accessible	   and	  obtaining	   a	   urine	   sample	   for	   NGF	   assay	  would	   be	  more	   acceptable	  from	   a	   patient’s	   perspective	   since	   it	   is	   less	   invasive	   especially	   on	  comparison	  with	  urodynamics.	  Although	   cost	   analysis	   has	  not	   been	  done,	  NGF	  assays	  are	  not	  expensive	  since	  the	  cost	  of	  ELISA	  analysis	  is	  £4	   per	   urine	   sample	   excluding	   lab	   consumables.	   Therefore	   urinary	  NGF	  assay	   can	  be	   less	   expensive	   and	  non-­‐invasive	  on	   comparing	   to	  urodynamic	   assessment	   and	   more	   objective	   and	   less	   biased	   on	  comparing	  to	  patient	  reported	  outcomes.	  	  	  However	   there	   are	   certain	   limitations	   with	   urinary	   NGF	  quantification.	  The	  assays	  are	  done	   in	  batches	  and	  there	   is	  no	  rapid	  turn	  over	  which	  affects	  its	  practicality	  in	  clinical	  practice.	  	  Interindividual	   and	   intraindividual	   variability	   is	   a	   major	   concern	  with	   biomarkers	   and	   the	   latter	   is	   mainly	   due	   to	   lab	   errors	   or	  conditions	   specific	   to	   the	   individual	   (Mayeux	   2004).The	   test-­‐retest	  reliability	   of	   currently	   available	   urinary	   NGF	   assays	   by	   ELISA	   has	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been	  reported	  for	  the	  first	  time	  in	  chapter	  4.	  It	  is	  a	  reliable	  test	  with	  an	   ICC	   of	   0.889	   with	   almost	   perfect	   agreement.	   Test-­‐retest	  assessments	   were	   done	   within	   a	   short	   time	   interval	   of	   four	   weeks	  and	   these	   measurements	   represent	   the	   reproducibility	   only	   within	  this	  particular	  time	  interval.	  	  The	   criterion	   validity	   of	   measuring	   urinary	   NGF	   levels	   has	   been	  evaluated	   thoroughly	   with	   ROC	   analysis	   and	   sensitivity,	   specificity,	  PPV	  and	  NPV	  has	  been	  reported	  in	  chapter	  5.The	  urinary	  NGF	  levels	  are	   significantly	   increased	   in	   patients	   with	   LUTS	   and	   different	  symptomatic	   groups	   such	   as	   OAB,	   SUI	   and	   BPS	   on	   comparing	  with	  controls.	  On	  ROC	  analysis,	  NGF	  levels	  demonstrate	  poor	  discriminant	  ability	   in	   differentiating	   different	   symptomatic	   and	   urodynamic	  groups	   [AUC	   <0.6]	   except	   for	   the	   OAB	   and	   non	   OAB	   group	  [AUC=0.66].	   Using	   13.0	   ng/g	   as	   a	   cut	   off	   for	   urinary	   NGF/Cr	  concentration	  the	  test	  provides	  a	  sensitivity	  of	  80.7%	  and	  specificity	  of	  only	  39.4%,	  PPV	  of	  53.33%	  and	  NPV	  of	  70.42%	  in	  diagnosing	  OAB	  among	  patients	  with	  LUTS.	  NGF	  was	  also	  a	  good	  predictor	  of	  patients	  having	  OAB	  when	  multivariate	   logistic	  regression	  was	  performed	  to	  assess	   the	   effects	   of	   age	   and	  NGF	  on	  predicting	   participants	   having	  OAB	  with	  an	  adjusted	  odds	  ratio	  of	  1.006;	  p=.	  047.	  	  	  	  Urodynamics	   was	   used	   as	   the	   reference	   standard	   to	   evaluate	   the	  diagnostic	   accuracy	   of	   NGF	   levels	   and	   there	   was	   no	   significant	  difference	   in	   the	   NGF	   levels	   between	   the	   different	   urodynamic	  groups	  such	  as	  DO,	  USI	  and	  MUI.	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All	   the	   focus	   has	   been	   on	   OAB	   and	   IC/BPS	   but	   this	   study	   has	  demonstrated	   increased	   urinary	   NGF	   levels	   in	   stress	   urinary	  incontinence	   contrary	   to	   the	   results	   from	   Liu	   and	   co-­‐workers.	   This	  finding	   supports	   the	   results	   from	   animal	   study	   with	   experimental	  urethrolysis	  and	  questions	  the	  specificity	  of	  urinary	  NGF	  levels	  since	  it	  is	  increased	  in	  various	  conditions	  of	  LUTD.	  	  	  These	   results	   show	   that	   although	   Urinary	   NGF/Cr	   concentration	   is	  certainly	  increased	  in	  patients	  with	  LUTS	  especially	  in	  OAB,	  it	  cannot	  be	   used	   as	   a	   discriminatory	   tool.	   The	   limitations	   of	   urinary	   NGF	  assays	   seem	   to	  be	   low	   specificity,	   lack	  of	   discrimination	  power	   and	  wide	  standard	  deviations.	  It	  is	  difficult	  to	  establish	  normal	  ranges	  for	  NGF	  because	  NGF	  levels	  can	  be	  undetectable	  in	  OAB	  patients.	  	  The	  link	  between	  NGF	  and	  inflammation	  was	  explored	  further	  in	  the	  study	  detailed	  on	  chapter	  6.There	  was	  no	  relationship	  between	  NGF	  levels	   in	   OAB	   patients	   and	   the	   severity	   of	   trigonitis,	   erythema	   or	  trabeculation	  on	   cystoscopy	  or	   cystitis	   on	  histology.	  NGF	   cannot	   be	  the	   sole	   mediator	   of	   inflammation	   and	   there	   are	   several	  neurotransmitters	   and	   mediators	   of	   inflammation,	   which	   are	  involved	   in	   the	   pathology	   of	   bladder	   inflammation	   and	   OAB.	  Cystoscopy	   findings	   itself	   may	   be	   a	   poor	   indicator	   of	   bladder	  inflammation	   however	   the	   lack	   of	   association	   between	   NGF	   levels	  and	   severity	   of	   cystoscopic	   findings	   suggest	   either	   that	  NGF	   should	  not	   be	   used	   as	   surrogate	   markers	   of	   bladder	   inflammation	   or	  cystoscopic	   findings	   are	   not	   valuable	   in	   classifying	   degrees	   of	  inflammation.	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  We	  speculated	  that	  NGF	  levels	  should	  decrease	  after	  anterior	  repair	  in	  women	  who	  have	  had	  an	  improvement	  in	  their	  overactive	  bladder	  symptoms	   and	   this	   was	   explored	   further.	   [Chapter7].	   However	  contrary	   to	   our	   speculation	   the	   urinary	   NGF	   levels	  were	   high	   after	  the	   anterior	   repair	   in	   women	   who	   had	   improvement	   of	   their	  overactive	  bladder	   symptoms.	  Although	   it	   is	   a	  pilot	   study	   the	   study	  has	   added	   some	   valuable	   information	   that	  measurement	   of	   urinary	  NGF	  levels	  after	  a	  surgical	  intervention	  or	  presence	  of	  prolapse	  may	  not	  be	  reliable	  and	  has	  to	  be	  interpreted	  with	  caution.	  A	  future	  study	  needs	  a	  larger	  study	  group	  and	  with	  a	  longer	  follow	  up	  of	  six	  months	  to	  ensure	  that	  surgical	  inflammation	  has	  settled.	  	  	  To	   explore	   the	   role	   of	   NGF	   as	   a	   biomarker	   to	   assess	   therapeutic	  outcome,	   NGF	   levels	   were	   measured	   before	   and	   after	   antibiotic	  treatment	   for	   refractory	   OAB	   in	   the	   study	   described	   on	   chapter	   8.	  About	  74%	  of	  women	  found	  a	  minor	  to	  major	  improvement	  in	  their	  symptoms	   after	   antibiotic	   treatment	   and	   NGF	   levels	  were	   found	   to	  decrease	  significantly	  after	  six	  weeks	  of	  antibiotic	  therapy.	  Although	  the	   NGF	   measurements	   were	   performed	   blind,	   limiting	   the	   risk	   of	  experimenter	  bias,	  without	  a	  group	  of	  untreated	  controls	  the	  changes	  observed	   may	   result	   from	   unmeasured	   factors.	   The	   improvement	  after	   treatment	   could	   be	   due	   to	   variation	   in	   the	   measurement	   of	  biomarker.	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CHAPTER	   10:	   RECOMMENDATIONS	   FOR	   FUTURE	  
RESEARCH	  	  	  	  The	  results	  from	  this	  study	  have	  added	  new	  information	  with	  regards	  to	  the	  criterion	  validity	  of	  urinary	  NGF	  measurement,	  which	  helps	  in	  bridging	  the	  gaps	  in	  the	  evaluation	  of	  urinary	  NGF	  as	  a	  biomarker	  as	  well	   as	   corroborating	   and	   refuting	   some	   of	   the	   available	   evidence.	  However	   the	   role	   of	   urinary	   NGF	   as	   a	   diagnostic	   biomarker	   needs	  further	   evaluation	   and	   the	   following	   recommendations	   are	   put	  forward.	  	  There	   are	   pitfalls	   with	   the	   NGF	   assay	   itself	   and	   this	   needs	   to	   be	  improved	   by	   standardizing	   the	   sample	   collection	   and	   the	   ELISA	  assays.	  All	   the	  reported	  studies	   in	  the	   literature	  have	  used	  Promega	  ELISA	  kits	  and	  the	  antibodies	  used	  are	  prepared	  from	  animal	  species	  but	   marketed	   for	   research	   studies	   to	   measure	   NGF	   levels	   only	   in	  tissue	   culture	   supernatants	  or	   tissue	  extracts.	  There	  are	  NGF	  ELISA	  kits	   prepared	  with	   human	   antibodies	   but	   these	   kits	   have	   not	   been	  employed	  to	  measure	  urinary	  NGF	  levels.	  The	  commercially	  available	  NGF	  ELISA	  kits	  need	  to	  be	  validated	  for	  measuring	  urinary	  NGF	  levels	  in	  human.	  The	  assays	  need	  to	  be	  developed	  to	  improve	  the	  detection	  of	   NGF	   in	   urine.	   Assays	   need	   to	   be	   quicker	   and	   simpler	   since	   the	  currently	  available	  assays	  are	  laborious	  and	  involve	  a	  3	  day	  process.	  	  Measurements	   can	   be	   affected	   by	   prolonged	   intervals	   due	   to	  uncontrolled	   variables	   such	   as	   degeneration	   of	   protein.	   Further	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studies	  with	  large	  numbers	  need	  to	  be	  done	  at	  various	  time	  intervals	  to	   account	   for	   variations	   in	   the	   assays.	   In	   this	   study	   only	   intra	  observer	  reliability	  after	  an	  interval	  of	  four	  weeks	  has	  been	  assessed	  and	  it	   is	   important	  to	  also	  test	   for	   interobserver	  reliability	   in	   future	  studies.	  	  There	  are	  certain	  inherent	  problems	  with	  NGF	  quantification	  in	  urine	  sample.	   The	   urine	   NGF	   levels	  may	   not	   be	   exclusively	   derived	   from	  bladder.	   The	   only	   evidence	   is	   from	   a	   small	   experimental	   study	   by	  Steer	   et	   al.	   Tissue	   levels	   of	  NGF	  were	   assayed	   in	   organs	   other	   than	  the	  urinary	  bladder	  from	  normal	  and	  obstructed	  animals	  to	  ascertain	  whether	   the	   increases	   in	  bladder	  NGF	  were	   specific	   for	   the	  urinary	  tract.	   No	   significant	   increases	   were	   seen	   in	   NGF	   content	   in	   other	  tissue	   specimens(Steers	   and	  Tuttle	  2006).	  More	  evidence	   is	  needed	  for	  the	  bladder	  specificity	  of	  urinary	  NGF	  levels	   .It	   is	  also	   important	  to	  assess	  the	  correlation	  between	  urinary	  and	  bladder	  NGF	  levels.	  	  Urinary	  NGF	   levels	   can	  be	   influenced	  by	  various	  systemic	  disorders	  in	   which	   serum	   NGF	   levels	   are	   raised.	   This	   can	   result	   in	   false	  positives	   .In	   order	   to	   reduce	   the	   false	   positives	   the	   effect	   of	   raised	  serum	  NGF	   levels	   on	   urinary	   secretion	   need	   to	   be	   investigated	   and	  accounted	  for	  in	  future	  assays.	  	  	  It	  is	  also	  possible	  that	  certain	  drugs	  can	  affect	  the	  levels	  of	  NGF	  such	  as	   progesterone(Choi	   et	   al.	   2010)	   psychotropic	   drugs(Hassanzadeh	  and	   Rahimpour	   2011),	   steroids	   (Schaper	   et	   al.	   2009),	   anti-­‐inflammatory	   drugs(Jang	   et	   al.	   2006)	   (Hochstrasser	   et	   al.)	   ,	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isoprenaline	  ,	  phenylephrine(Persson	  et	  al.	  1997)among	  many.	  These	  confounding	  factors	  need	  to	  taken	  into	  account	  and	  evaluated	  further	  in	  order	  to	  avoid	  bias.	  	  	  Patient	  recruitment	  criteria	  need	  to	  be	  standardized	  in	  future	  studies	  that	   evaluate	   the	   role	   of	   urinary	   NGF	   as	   a	   diagnostic	   biomarker	   in	  LUTD.	  Larger	  studies	  are	  needed	  to	  assess	  the	  relationship	  between	  urinary	   NGF	   levels	   and	   anterior	   vaginal	   wall	   prolapse,	   BMI	   and	  ethnicity.	   There	   is	   a	   need	   for	   larger	   samples	   with	   age	   matched	  controls	   to	   evaluate	   and	   determine	   the	   accuracy,	   reliability,	  interpretability,	   and	   feasibility	   of	   NGF	   assays	   before	   we	   draw	   any	  conclusion.	   To	   implement	   urinary	   NGF	   as	   a	   biomarker	   in	   clinical	  practice	   the	   limitations	   in	  NGF	  quantification	  need	   to	   be	   addressed	  first.	  	  Technical	  advances	  allow	  simultaneous	  measurement	  of	  biomarkers	  using	   multiplex	   technology.	   LUTD	   is	   multifactorial	   therefore	   NGF	  alone	  may	   be	   insufficient	   to	   act	   as	   a	   sole	   urinary	  marker	   for	   OAB.	  Measurement	   of	   polypeptides	   and	   other	   neurotrophic	   factors	   apart	  from	  NGF	  such	  as	  BDNF,	  which	  are	  implicated	  in	  the	  pathophysiology	  of	   bladder	   dysfunction,	   need	   to	   be	   evaluated.	   This	   may	   provide	   a	  scope	   for	   introducing	   a	   series	   of	   multiple	   biomarkers,	   which	   may	  serve	  as	  non-­‐invasive	  diagnostic	  tools	  in	  assessment	  of	  patients	  with	  LUTD.	   Such	   biomarkers	   may	   be	   used	   alone	   or	   in	   combination	   to	  screen	   and	   diagnose	   various	   LUTD	   and	   may	   complement	   existing	  diagnostic	   tools	   such	   as	   frequency	   volume	   chart,	   bladder	   wall	  thickness,	   urodynamics	   etc.	   They	   may	   also	   be	   valuable	   in	   clinical	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